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Abstract
DEPOSITIONOF INHALED PARTICLES IN A SYMPTOMATIC ASTHMATIC HUMAN
RESPIRATORYTRACT
John N. DiFlorio
Advisor: Dr. Risa J. Robinson
Inhalation medicinal aerosol and biological aerosol risk assessment are the current
motivation for deposition models to be developed. Inhalation aerosols have been around for
many years for the treatment of asthma and other respiratory ailments in which the aerosols
targeted the upper airways. Current research is focused to target the alveolar sacs due to their
vast surface area for drug and gene delivery. Targeting the alveolar sacs Corkery (2000)
requires a slow and deep breathing pattern for maximum deposition at the alveolar units.
Also the particles must be fairly small (1-3 urn) to avoid deposition by impaction. Gautam et
al. (2003), states that aerosol inhalation therapy has the following advantages: a greater
surface area to absorb and sediment drugs and genes, the absorption is immediate, there is
low systemic toxicity, and the delivery of the drug is a non-invasive procedure. The authors'
foresee inhalation medicine coming into practice in the near future. A proven and effective
case is the delivery of insulin formulation via an inhalation device. Through inhalation of
insulin, patients will not have to tolerate the constant injection of insulin thus improving their
obedience in taking their insulin devotedly.
Biological aerosol risk assessment is another topic that warrants deposition modeling
in the lung. According to Douwes et al. (2003), the occupational environment is producing
potent bio-aerosols that lead to infectious diseases, acute toxic effects, allergies and cancer
within people exposed to these aerosols. The authors cite examples of industries that are
producing these bio-aerosols, such as the cotton industry, farming, waste and compost
industry, and the automotive industry, etc. The main focus is to assess these industries and
the bio-aerosols that they produce in a quantitative way. The
authors'
note that these
assessments of bio-aerosols have mainly been qualitative or semi-quantitative at best in
research and stress that there needs to be more quantitative analysis on the bio-aerosol
production and risk assessment, so that proper care and caution can be taken in the future.
There are significant gaps in information completeness concerning modeling
particulate deposition in diseased lungs. The gaps in information stem from inaccurate or
vague results in quantification of the geometric and dynamic parameters that deviate
respiratory ailments from a normal individual, also, there is lack of computer models that
describe the different respiratory ailments. This former idea is a necessity for advancement
of a particular problem. Computermodels reflect a compilation of knowledge on a particular
subject that produces an end result that can be verified readily by field tests.
The goal of this research was two-fold. First objective were to perform a literature
search that summarized the current literature on experimental deposition data, pulmonary
function test data, and airway modifications due to asthma and COPD. Second, the separate
modules of the computer routine will predict deposition of inhaled particles of varying sizes
in a symptomatic asthmatic case (COPD data from literature did not yield enough
quantitative data to make modifications). The inputs consist of breathing patterns, lung
geometry, and particle concentration and distribution. The inputs are then used in
conservation equations and deposition mechanisms to describe how the particles will move
n
throughout the region. Outputs are in the form of mass deposition fraction [%], deposition
efficiency, and average deposition per generation.
Overall the model was successful in predicting the intuition one would have in
comparing deposition amounts in asthma versus healthy cases. There was more total
deposition of particles for every particle size in the symptomatic asthma cases relative to the
normal case specifically as particle size increased. The increased deposition was primarily
due to the impaction deposition mechanism for larger particles sizes, specifically 5 urn and
10 urn particle sizes.
This work was supported by a grant from the Phillip Morris External Research
Foundation.
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Chapter 1 - Background on Aerosol
Mechanics in the Human Respiratory Tract
Our lungs provide us with the means to acquire air from our environment for fueling
metabolic processes and more importantly sustentation of life. Oxygen is extracted from the
inhaled air while carbon dioxide, from the waste processes of the cells, is exhaled to the
environment. The surface area of the lungs is the only internal part of our bodies that is
exposed to the outside environment, which is composed of particulate (dusts, pollen, animal
dander, cigarette smoke particles, automobile exhaust etc.). The respiratory system serves to
filter and clear the particulates that are inhaled daily while providing effective gas-exchange
for the body to function.
1.1 Characteristics ofLung Anatomy
The air that is inspired passes through 4 regions before coming into contact with the
bloodstream. Those regions are the oral and nasal cavity, pharynx, larynx, and the
tracheobronchial (TB) tree, shown in Figure 1.1. The oral cavity is just one of the entrances
to the respiratory system; it really is more appreciated for mechanical breakup and the taste
of food, but still retains its stature as one of the ways for airflow to enter the body. The nasal
cavity is the second way air can enter the body; it has functions of sensing smell and filtering
foreign particulate by means of sticky mucous and torturous paths before the air travels any
further in the body. Next the air enters the pharynx region, which is composed of 2 parts:
nasopharynx and oropharynx. If the airflow is coming from the nasal cavity it will precede
first to the nasopharynx region, then the oropharynx; whereas, if the airflow is coming from
11
the oral cavity, then the airflow will proceed to the oropharynx. The nasopharynx is home to
the eustachian tube, which functions to balance middle ear pressure with the outside
environment; other than the eustachian tube, it serves as just another passageway. After the
oropharynx the airflow will advance to the larynx. The larynx's important constituents are
the epiglottis and the vocal cords. The epiglottis is a plate of flexible cartilage that acts to
direct food to the esophagus or air into the trachea, while the vocal cords are used to produce
sound. Once the airflow is past the vocal cords it enters the tracheobronchial region.
Anterior
Nasal Passao*
Posterior
Nasal Passage
Prmry^/NasalPart
VOratPait
Mam Bronchi
Bronchioles
Extrathoracic
Thoracic
Bronchial
BroneHoiar
Alveolar Interstitial
Bronchioles
Terminal Bronchlotse
Respiratory Bronchioles
Alveolar Duct +
Alveoli
Figure 1.1 - Respiratory system, (International Commission on Radiological Protection, 1994)
The TB is a series of airways that increase in number and decrease in caliber as the
airflow progresses to the site of gas exchange. The TB airways can be classified by either
12
consisting of cartilage or not. Typical components of the airway are depicted in Figure 1.2
with cartilage being present in cartilagionous airways only. The main difference between
cartilaginous and non-cartilaginous airways is that the cartilaginous mainly serve to transport
the airflow to the respiratory zone, where the non-cartilaginous have respiratory surfaces as
well as transporting the air to the alveoli.
The cartilaginous airways are the trachea, main bronchi, and bronchi from Figure 1.1.
The non-cartilaginous airways refer to the bronchiole and terminal bronchioles. Bronchioles
are differentiated from bronchi by the lack of connective tissue surrounding the airway. This
lack of connective, or supportive tissue, makes the bronchioles expand and contract when
there is differences in pressure or size of the lung. Terminal bronchioles are the site where
the conducting zone ends and the respiratory zone begins.
NERVE
BLOOD VESSEL
SMOOTH MUSCLE
CARTILAGE
Figure 1.2 - Cross-section of large bronchus, Crystal et al. (1997)
The respiratory zone is comprised of respiratory bronchioles, alveolar duct, and
alveolar sacs known as alveoli, see Figure 1.1. Alveoli are present in all of these structures
and function to promote gas exchange. The alveoli expand due to inhalation of air, thus their
walls, which are surrounded by capillaries, get thinner; this promotes gas transfer by
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diffusion. The estimated area of gas exchange is 140 m2, which is about the size of a tennis
court.
An important factor in research of respiratory disease is to completely describe these
airway dimensions. This is an arduous task because there is an approximate of
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paths in
the lung. A very renowned researcher in morphology, Weibel (1963), studied 5 autopsied
lungs of normal individuals of varying age; he meticulously measured and approximated the
dimensions of the lung. The lung dimensions that he provided are based on a symmetric lung
and are represented in Table 1.1.
Table 1.1 - Weibel dimensions of the tracheobronchial tree, adapted fromWeibel (1963)
Accumul. Volume
Number of
Generation
z
airways per
generation
n(z)
Diameter
d(z)
cm
Length
l(z)
cm
Total Cross-section
cm2
Total VolumeV(z)
cm3 iva)
1=0
cm3
0 1 1.8 12.0 2.54 30.50 30.5
1 2 1.22 4.76 2.33 11.25 41.8
2 4 0.83 1.90 2.13 3.97 45.8
3 8 0.56 0.76 2.00 1.52 47.2
4 16 0.45 1.27 2.48 3.46 50.7
5 32 0.35 1.07 3.11 3.30 54.0
6 64 0.28 0.90 3.96 3.53 57.5
7 128 0.23 0.76 5.10 3.85 61.4
8 256 0.186 0.64 6.95 4.45 65.8
9 512 0.154 0.54 9.56 5.17 71.0
10 1,024 0.130 0.46 13.4 6.21 77.2
11 2,048 0.109 0.39 19.6 7.56 84.8
12 4,096 0.095 0.33 28.8 9.82 94.6
13 8,192 0.082 0.27 44.5 12.45 106.0
14 16,384 0.074 0.23 69.4 16.40 123.4
15 32,768 0.066 0.20 113.0 21.70 145.1
16 65,536 0.060 0.165 180.0 29.70 174.8
17 131,072 0.054 0.141 300.0 41.80 216.6
18 262,144 0.050 0.117 534.0 61.10 277.7
19 524,288 0.047 0.099 944.0 93.20 370.9
20 1,048,576 0.045 0.083 1,600.0 139.50 510.4
21 2,097,152 0.043 0.070 3,220.0 224.30 734.7
22 4,194,304 0.041 0.059 5,880.0 350.00 1,084.7
23 8,388,608 0.041 0.050 11,800.0 591.00 1,675.0
In reality, the lung is asymmetric and different ventilation is present depending on the
individual, but the Weibel data has provided accurate results in healthy deposition models
(Robinson & Yu, 1998). Below are two adapted pictures from Crystal et al. (1997), showing
the description of the generations and representative quantitative data. The paper of Crystal
et al. (1997), with Weibel as one of the authors, presented new values for the airway
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generations, specifically concerning modifications to the respiratory region. The data is
presented in Table 1.2.
j= \^
Figure 1.3 - Left: Weibel organization of airways in human lung, Crystal et al. (1997), Right: Increase in
cross-sectional area as generations proceed, Crystal et al. (1997)
Table 1.2 - Weibel dimensions of the tracheobronchial tree, Crystal et al. (1997)
Generation, z
Number of airways
per generation, n(z)
Airway segment
diameter, d(z) (cm)
Length, l(z) (cm)
Distance from
carina to end of
generation (cm)
Total airway cross-
section, (cm2)
0 1 1.8 12.0 - 2.54
1 2 1.22 4.76 4.76 2.33
2 4 .83 1.90 6.66 2.13
3 8 .56 0.76 7.42 2.00
4 16 45 1.27 8.69 2.48
5 32 .35 1.07 9.76 3.11
6 64 .28 0.90 10.66 3.96
7 128 .23 0.76 11.42 5.10
8 256 .186 0.64 12.06 6.95
9 512 .154 0.54 12.60 9.56
10 1,024 .130 0.46 13.06 13.4
11 2,048 .109 0.39 13.45 19.6
12 4,096 .095 0.33 13.78 28.8
13 8,192 .082 0.27 14.05 44.5
14 16,384 .074 0.16 14.21 69.4
15 32,768 .050 0.133 14.34 117.0
16 65,536 .049 0.112 14.46 225.0
17 131,072 .040 0.093 14.55 300.0
18 262,144 .038 0.083 14.63 543.0
19 524,288 .036 0.070 14.70 978.0
20 1,048,576 .034 0.070 14.77 1,743.0
21 2,097,152 .031 0.070 14.84 2,733.0
22 4,194,304 .029 0.067 14.91 5,070.0
23 8,388,608 .025 0.075 14.98 7,530.0
The dimensions that Weibel published in 1963 have been the standard for many
models of deposition and referred to in many journal articles. Subsequent researchers, such
as Horsfield et al. (1971), Raabe et al. (1976), and Yeh & Schum (1980), have proposed
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different dimensions for the airways and have even developed asymmetric data. Although
asymmetric data is a closer representation to the actual TB airways, the current scope of this
study was to extend the computer code of Robinson & Yu, (1998), to one that encompasses
disease alterations, using deposition physics and the Weibel (1963) model.
1.2 Breathing Function and Terminology
Airways are the necessary conduits for gas-exchange, but the body relies on muscles to pull
air into the lung and to push air out of the lung. Airflow results from a pressure difference
(gradient) between atmospheric pressure and pressure in the alveoli. The pressure gradient is
created by the muscles of inspiration (intercostals, abdominal, and diaphragm), which
function to enlarge the volume of the lung, see Figure 1.4, and act in accordance to Boyle's
law. Boyle's law states that when temperature is constant, PV=const, meaning an increase in
pressure (P) directly relates to a decrease in volume (V), or visa versa. Three pressures are
used to describe the creation of airflow within the lung: alveolar, intrapleural, and transmural,
see Figure 1.4. Alveolar pressure is the pressure within the alveoli; at inhalation this pressure
is sub-atmospheric. Intrapleural is the pressure in the region between the chest wall and
lung; this space usually carries a negative value. Transmural pressure is simply the alveolar
minus the intrapleural pressure. The volume enlargement mentioned above will, according to
Boyle's Law, decrease the pressure within the lung as long as the temperature remains the
same. With the expansion of the chest, the intrapleural pressure decreases and the transmural
pressure gradient increases. The transmural pressure gradient causes the alveoli to expand in
accordance to the compliance curves of the individual alveoli. The alveolar pressure is
decreased now since the volume has increased, and airflow will enter as long as the pressure
gradient is strong enough to prevail over the resistance of the airways.
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Figure 1.4 - Interaction of the lung and chest wall upon inspiration, (Levitsky, 1999)
1.3 Lung Volumes
The classification of lung volumes is as important as the description of breathing
function of the respiratory system. The examination of lung volume is one of the simplest
ways to qualitatively and quantitatively show abnormalities within a respiratory system.
Figure 1.5 shows the break up of the different volumes into the proper terminology used
throughout the academic and medical communities. The individual used in this example
figure was a healthy 70 kg adult. Figure 1.5 starts out with the individual maximally
exhaling and then maximally inhaling. The individual then returns to the normal breathing
cycle and the test is stopped. During this cycle the data is collected via spirometry, which
will be described in Section 1.4.1, but serves to record the volume as a function of time.
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Figure 1.5 - Volumes of the lung (normal 70 kg adult), modified from Levitsky (1999)
The following volumes are defined:
Tidal Volume, Vj is the volume of air inhaled during normal breathing (eupnoea)
Inspiratory Reserve Volume, IRV is the amount of air that a person can inhale
above normal VT inhalation
Expiratory Reserve Volume, ERV is the amount of air that a person can maximally
exhale, that does not include reserve volume
Reserve Volume, RV is the volume that is beyond maximum exhale, it is the volume
which keeps a person's lung in an inflated state. If this volume is depleted, the lungs
are in a collapsed state.
Vital Capacity, VC is the amount of air from full inspiration to full expiration
Inspiratory Capacity, IC is the total amount of air that a person can inhale
Functional Residual Capacity, FRC is the maximal amount of air that a person can
exhale plus the reserve volume
Total Lung Capacity, TLC is the amount of air represented by maximally inhaling
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Some examples of pulmonary function tests are given in the following pages
pertaining to lung volumes and airflow. Pulmonary function tests that analyze gas exchange
are not included because they lie outside the scope of this research.
1.4 Pulmonary Function Tests
Pulmonary Function Tests (PFT) are performed as a way to distinguish between a normal
person and one suffering from a particular (or multiple) respiratory disorders. The output
always consists of graphs, which can be interpreted qualitatively or quantitatively, and are
used to monitor, or diagnose certain ailments. PFT's can provide information on airflow,
lung volumes/capacities, and/or gas exchange.
1.4.1 Spirometry
Spirometry is a clinical test that results in a graph, or trace, of a patient's inspiration and
expiration. The patient can be instructed to breathe a variety of breathing patterns and the
spirometer will collect the data which will be exported to a tabulated graph. The lung
volumes that a spirometer can capture from an individual are the following (Levitzky, 1999):
VT, IRV, ERV, IC, and VC. Volumes that spirometry cannot measure are RV, FRC, and
TLC because the spirometry cannot fully measure the lung in a collapsed state. Additional
parameters that can be collected with spirometry are forced volumes, such as forced
expiratory volume in 1 second (FEVO, forced vital capacity (FVC), and forced (Mid)
expiratory flow rate (FEF2s-75%). Some examples of typical evaluations in spirometry are that
a normal person should be able to expel ~4 liters to FVC in 3 seconds and -3.2 liters in 1
second. The difference in these two statements is that the volume gets harder to expel when
you drive formaximally exhaled volume.
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A useful relationship attained from the spirometer is the flow/volume loop shown in
Figure 1.6. The positive portion of the graph indicates a maximal expiratory flow-volume
(MEFV), whereas the negative portion is a maximal inspiratory flow-volume (MEFV). As
noted by Farzan & Farzan (1997), the first 1/3 of MEFV is directly related to the pressure
from within the cavity of the chest, while the remaining 2/3 of the MEFV is indicative of the
mechanical characteristics of the airways. For the MEFV, the relationship is essentially
always symmetric and non-normal patterns show obstruction in the central or upper airways.
12 r
PHFR
-10 lr
Figure 1.6 - Flow/volume curve,Madama (1997), FIF = forced inspiratory flow , FEF = forced expiratory
flow, PIFR = peak inspiratory flow rate, PEFR = peak expiratory flow rate
In Figure 1.7 there are a series of flow/volume curves relating to lungs that are normal and
with particular respiratory ailments. The normal case is the outline of the flow/volume curve
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in the following curves beside the normal case, while the shaded is the performance of the
respiratory ailment.
Normal
Fixed
Intrathoracic
Variable
Extrathoracic
Variable
Restrictive
Disorder
Small
Airway
Obstruction
large
Airway
Obstruction
Large
Airway
Obstruction
Large
Airway
Obstruction
VOLUME
Figure 1.7 - Flow/volume curves of different disorders, adapted fromMadama (1997)
1.4.2 Esophageal Balloon
The esophageal balloon measures the intrapleural pressure within the body. The balloon is
passed through the nose to the lower third of the esophagus with the aid of an anesthetic
which is given to alleviate the urge to gag or vomit. Changes in intrapleural pressure are
accounted for due to the esophagus, lung, and heart all sharing the pleural space. The
balloon is very loose and flabby, and has hardly any air in it, as is the case with the
esophagus also. For that reason, intrapleural pressure changes are directly related to changes
of balloon pressure, and this is detected by a pressure transducer outside the body.
1.4.3 Body Plethysmography and Pneumotachometer
In body plethysmography, the patient sits in a sealed, air-tight box where his or her nose is
clipped with their mouth attached to a mouthpiece, fitted with a one-way valve and
pneumotachograph for breathing pattern analysis, see Figure 1.8. Once the breathing pattern
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is established, the technician will shut the one-way valve after the patient has exhaled the
normal tidal volume. The patient will try to inhale, but the valve is closed. Although the
patient will try to breathe against a closed valve, the chest will still expand.
Plethysmography determines thoracic gas volume, which is the volume of air within the chest
at any time and any alveolar pressure, and airway resistance, Raw-
Flow (vi
Mouth pressure
(Pmouth)
Figure 1.8 - Obtaining Ra from plethysmography and pneumotachometer, adapted from Ruppel (1998).
A. Set-up, B. Plot of pressure vs. flowrate
The plethysmography is based on Boyle's Law. When the patient's chest expands
there is a decrease of volume within the box that increases the pressure of the box. This
pressure increase is known through the use of a pressure transducer mounted to the box; the
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pressure of the patient's volume is also measured by a pressure transducer connected to the
mouthpiece. The following describes the process mathematically. From Boyle's law,
Pbi VBi = PB2 VB2 = PB2 (VBi + AV)
where P is pressure, V is volume, and subscripts B refer to box values and 1 and 2 are initial
and final values, respectively. Then the change in volume, AV is given by,
Ay = v*l(Pgl~Pfi2) (l.i)
1 B2
which can be calculated because all the values on the right hand side are known from
measurement. For the patient this AV is utilized in the following expression:
Ppi Vpi = Pp2 VP2 = PP2 (VP] + AV)
So that Vpi is
rPl rP2
where the subscript P now refers to patient values and VPj, is the FRC, the volume before
taking a breath.
Raw is expressed by alveolar pressure, Pa, divided by volumetric airflow,V . Ruppel
(1998), describes the method of obtaining Raw within a subject using body plethysmography
and the use of a pneumotachometer. Alveolar pressure is collected by the body
plethysmography, while pressure at the mouth is obtained by the pneumotachometer. Figure
1.8 shows the arrangement of the body plethysmography and the pneumotachometer. This
setup collects plethysmograph pressure as a function of airflow, and the characteristic plot is
shown in the lower portion of Figure 1.8. The 1 refers to the pressure scale in units of
cmH20. The slope of the relationship between pressure and volume flow rate is the main
parameter used in calculation of Raw-
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With more detail than above, the plethysmography maneuver is accomplished twice
to obtain a value of Raw. First, the patient breathes freely through the mouthpiece within the
box with a small tidal volume of approximately 2-3 breaths per second. The apparatus
collects the airflow and pressure of the box, therefore the first slope obtained is v/PB . The
second maneuver shuts the mouthpiece valve while the person is breathing freely. The
subject is still breathing; but, since the mouthpiece is closed, pressure at the mouth is equal to
alveolar pressure due to no airflow passing in or out of the lungs. Concurrently, PB and
pressure at the mouth are being collected and another slope is gathered, Pa/PB- Therefore,
very simply, the equation depicted in Equation 1.3 is setup and Raw is solved for.
^.MomhCal
m
V/PB FlowCal
Pb cancels and the equation simplifies to the fundamental definition of Raw, Pa/V . The
calibration factors (mouth cal and flow cal) are added to this equation due to different
collection sensors being used in the experiment which require calibration.
Raw is usually expressed in the units of cmFkO-s/L or kPa-s/L. Other parameters that
are often collected are Gaw, SRaw, and SGaw. Gaw is the airway conductance and is the inverse
of Raw; it is the degree of flow that is generated from the available AP. SRaw and SGaw
(specific airway resistance or conductance) are Raw and Gaw values divided by a unit lung
volume, which is captured by body plethysmography. These parameters allow for
compatibility and standardization among tests. Some typical values of resistance parameters
are given in Table 1.3, and the effect that different severities of obstruction influence
resistance are represented in Table 1.4.
24
Table 1.3 -Normal values associated with resistance of airways, (Madama, 1998)
Normal Values
ofResistance Value, unit
tCaw 0.6-2.8, cmH20/L/s
oKaw 0.190-0.667, cmH20/L/s/L
vJaw 0.36-1.70, L/s/cmH20
^^-Jaw 0.114-0.404, L/s/cmH20/L
Table 1.4 - Degrees of severity of resistance, (Madama, 1998)
Severity of Raw Raw? cmlhO/L/s
Mild 2.8-4.5
Moderate 4.5-8.0
Severe >8.0
Madama, 1998, states that overall resistance to a person breathing is split into two
descriptions: elastic resistance and non-elastic resistance. It is estimated that elastic
resistance accounts for 65% of the total resistance of breathing, while 35% is non-elastic
related. Raw is a non-elastic resistance and accounts for 80% of non-elastic resistance (28%
of overall resistance). Sharing that category is tissue resistance, which is a measly 7% of
non-elastic resistance. The major source of Raw in a normal individual comes from the
large/central airways due to their small cross-sectional area as compared to the airways less
then 2 mm in diameter.
As noted above, elastic resistance is the major contributor towards work of breathing
(WOB). The total elastic resistance result is accomplished through measurements of alveolar
elastic recoil pressure, compliance, and dynamic compliance.
The alveolar elastic recoil pressure represents the transmural pressure (Pl) needed to
produce a maximum inspiratory volume. Transmural pressure is PL = Pa - PPi and was
mentioned in Section 1.1, where Pa is alveolar pressure and Ppi is intrapleural pressure. In the
measurement of elastic recoil pressure, Pa is zero because there is no flow entering or leaving
the lung due to the plethysmograph shutter being closed; therefore, recorded changes in Ppi
are directly related to changes in transmural pressure. Elastic recoil pressure is recorded as
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the intrapleural pressure upon the patient maximally inspiring to the TLC volume. This Ppl is
obtained through the use of an esophageal balloon snaked through the nose to the lower third
of the esophagus. Pressure changes in the lower third of the esophagus are nearly
approximate to the pressure changes of Ppi.
Compliance is, according to Madama (1998), the change of transmural pressure (APL)
necessary to produce a change in lung volume (AV,), which is elastic resistance (Re] or 1/Qt)
to ventilation. There are two components in determination of Rd, lung compliance (CO and
thoracic compliance (Ct). The relationship is analogous to electrical resistances in series:
-L--U-L (1.4)
C C c*-lt *"/ *-
where Q and Qt can be measured while Ct must be calculated fromQ and Qt.
Ci is the slope of the static volume versus pressure curve from FRC to FRC + 0.5(L),
shown in Figure 1.9, and is calculated from
AV^ (1.5)
APpl PplFRC0.5-PplFRC
where AVi is change in lung volume and APpi is change in intrapleural pressure. The FRC
increase of 0.5 is the standard increment to record the slope Q. Ppi is taken by esophageal
balloon on an exhalation maneuver from TLC to FRC or RV, but the majority of the test
utilizes the pneumotachometer and body plethysmography. The pneumotachometer shutter
is closed at various times and corresponding values of Ppi are recorded at no flow conditions.
As noted before changes in Ppi are related to changes in Pl.
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Figure 1.9 - TLC and transpulmonary pressure for disease state, (Madama, 1998), note CL above is Q in
the document
Cu is the transthoracic/pulmonary pressure necessary for a change in lung volume.
The expression is as follows:
AV,
C, =
AP7
(1.6)
TL
where APtl is the change in transthoracic/pulmonary pressure. Ptl is the difference between
atmospheric pressure and alveolar pressure (PA). According to Madama (1998), obtaining Cu
is greatly based upon the measurements of Ptl when the ventilatory muscles are completely
relaxed. Commonly utilizing the shutting of the shutter on the pneumotachometer of the
body plethysmograph at various known interval lung volumes will accomplish the relaxation
of the ventilatory muscles. When the shutter is shut, and the muscles are relaxed, the
pressure at the mouth is taken due to this pressure approximating alveolar pressure (Pa) at
stagnant flow conditions. Once the value ofmouth pressure is taken relative to Patm (gauge),
this is essentially the Ptl, therefore Qt is achieved. In addition, with the values ofQ and Cu,
Ct can now be calculated by Equation 1.4.
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Dynamic compliance, Cdyn, is a collective result of which encompasses elastic (Rd)
and non-elastic resistance. Cdyn is the largest impediment to the WOB. Cdyn is found by the
following expression:
c_-i
'dyn
AP,
VT
P - P
pl_insp p/_exp
(1-7)
where Ppi_insP is end-inspiratory intrapleural pressure and Ppi_exP is end-expiratory intrapleural
pressure. Table 1.5 shows typical elastic resistance factors for a normal adult
Table 1.5 - Elastic resistance factors of a normal adult, (Madama, 1998)
Normal Adult Values for Elastic Resistance Factors
Elastic recoil pressure 34 (cmH20)
c, 0.2 (L/cmH20)
ct 0.2 (L/cmH20)
Cu 0.1 (L/cmH20)
SClt 0.05-0.06 (L/cmH20/L)
^--dyn 0.09-0.07 (L/cmH20) at a flow of 0.5 L/sec
1.4.4 Bronchoscope
The bronchoscope is a flexible tube that is inserted into your mouth or nose to view the
bronchial airways and provides a direct look at the situation. The tube is long and thin, and
equipped with a camera. Other instruments can be inserted through the bronchoscope to
either collect cells or mucous, or to perform a biopsy. Again, patients are usually given a
local anesthetic to reduce the response of gagging or coughing due to the bronchoscope. The
bronchoscope is usually ordered after a chest x-ray to assess or collect information on the
tissue of the airway if a lung disease is present. An ultra-fine bronchoscope usually has a
range that extends to the small airways of the lung.
1.4.5 Computed Tomography
Computed tomography (CT) is a specific x-ray related procedure that produces scans of the
cross-section of the body at different planes. CT is not really a pulmonary function test but is
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correlated with a specific test that can show inhaled particles within the lung; it is the test of
choice of some medical journal articles discussed later in the text. The backbone of this
procedure is the computer, which compiles the tissues of different density to yield the final
cross-sectional image. CT is very useful in detecting cancer because it can scan for abnormal
density masses and output the specific location, size, and shape of the cancerous mass. The
time required for this procedure is roughly 20 minutes and is painless. CT provides a much
more clear-cut output than a conventional chest x-ray. Figure 1.10 shows a CT scan, the
black regions are the right and left lungs, note the white matter within the right lung is a
cancerous region.
Figure 1.10 - CT scan of lung cancer, A&B depict a growing cancerous mass, C&D show how
chemotherapy eliminates the majority of the mass, Naidich et al. (1991)
1.5 Mechanics ofDeposition
Deposition is the capturing of particles within a system. For this research the concern is how
particles of different size are captured within the respiratory systems of healthy and diseased
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individuals. The following two sections will provide some background on aerosol
characteristics and deposition mechanisms.
1.5.1 Aerosol Characteristics
An aerosol is a solid or liquid particle that is suspended in a gas. Aerosols can be formed
from a variety of ways such as combustion, nucleation, condensation, etc. The size of
aerosol particles usually range from
10"3
pm to
102
pm (see Figure 1.11). The criteria for a
particle to be an aerosol are: low settling velocity, Brownian motion is significant, Reynolds
number is less than 1, and the surface area/volume ratio is high. There are three main shapes
of aerosols: isometric - all dimensions are relatively the same, platelet - 2 large dimensions
with small
3rd dimension, and fibrous - 1 long dimension and 2 small dimensions.
There are a variety of physical and dynamical diameters for classifying the physical
effects of the aerosol (see Figure 1.12). The three physical diameters are: Farads, Martin, and
projected area diameter. Farads diameter is the maximum distance from edge to edge of the
aerosol. Martins diameter is the length of a line that separates the particle into two equal
volumes. And the projected area diameter is the diameter of the circle having the same
projected area of the particle.
There are three dynamical diameters: aerodynamic, Stokes, and diffusion diameters.
Aerodynamic diameter is the diameter of a unit density sphere having the same settling
velocity as the particle. Stokes diameter is the diameter of a sphere having the same density
and settling velocity as the particle. Diffusion diameter is the diameter of the sphere having
the same diffusion coefficient as the particle.
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Figure 1.11 - Typical sizes of different particles, adapted from Hinds (1999)
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Figure 1.12 - Left: Three particle diameters, Reist (1992), Right: equivalent spheres of an irregular
particle, Hinds (1999)
1.5.2 Aerosol Deposition
On an average day a person will pass roughly 10,000 liters of air through their lungs. This
volume of air is most likely not filtered; therefore, along with the air that we take in, are the
aerosols of our environment. Our respiratory system, as described before, tries to filter and
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destroy any foreign aerosols that come into our system using mucous, torturous paths, or
micro-organisms that engulf the matter. The three main ways that particles will deposit
within the respiratory system are: impaction, sedimentation, and diffusion. Impaction mainly
occurs to the larger sized particles (>5 pm) that were inhaled, and have trouble due to their
size and weight turning the tight corners of the rigorous system. The particles either impact
on the mucous covered nasal cavity, pharynx, or bifurcations. Medium particles (1-5 pm) are
deposited by sedimentation and eventually settle in the small airways of the lungs. Small
particles (<0. 1 pm) deposit by diffusion, which is a random movement of particles, in the
alveoli. Note that not all particles will demonstrate these concrete deposition mechanisms in
specific regions.
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Chapter 2 - Characteristics of the Diseased
Lung
There are a variety of different lung ailments that affect people. A concise outline follows
that aids to filter through common respiratory problems. Respiratory diseases and/or
complications seriously diminish the quality of life of the individual affected. Symptoms
range from coughing up blood to having to use mechanical ventilation for acquiring oxygen.
2.1 Overview ofLung Disease Categories
An overview of lung diseases was provided by West (1998), in which he presents four
categories for describing lung disease: obstructive, restrictive, vascular, and environmental.
Upon reviewing other literature, specifically Farzan & Farzan (1997), two other groups may
be added for clarity, neoplastic and infectious diseases of the lungs to provide a deeper scope.
The following are the six main branches that can distinguish most of the respiratory ailments:
Obstructive diseases are characterized by increased resistance to flow in and out of
the lung airways. The obstruction is caused by mucus decreasing the diameter of the
lumen, inflammation or contraction of the airway wall, or degeneration of cells
outside the airway wall thus reducing the diameter of the airway.
Restrictive diseases are distinguished by the reduction in capability of lung
expansion. This hindrance is due to either changes in the lung parenchyma or disease
in the pleura, chest wall, or neuromuscular components. Unlike obstructive diseases
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the airway resistance is not increased, but volumes vital capacity and resting lung
volume are diminished.
Vascular diseases involve the vascular system which closely intertwines the heart
with the lungs in both an anatomic and physiological sense. Blood is utilized in two
ways: to transport gases and provide nourishment to lung tissue. Gas exchange (02-
C02) occurs in the pulmonary capillaries in which the capillaries closely hug the
alveolar sac and actively exchange C02 for 02 with low resistance. The capillaries
are controlled by the automatic nervous system, and can expand and adjust to larger
flow conditions without a corresponding pressure change. They also sense acidosis,
vasoactive substances, and changes in alveolar oxygen tension and adjust
correspondingly. Additionally, bronchial arteries supply the tracheobronchial airways
with arterial blood. Defects and deformity in the lung, blood vessels, and or heart of
various causes affect pulmonary circulation. Injury by the disease process or
deviations in blood gases affect the vascular system; while blood clots and/or
abnormal particle circulating in the blood complicate flow in pulmonary blood
vessels. Both halves of the heart have an impact on pulmonary circulation and
disease. The right side of the heart, if affected, will limit functioning of gas
exchange; a defect in the left side of the heart will essentially reduce the circulatory
capabilities.
Environmental factors such as dusts, and atmospheric pollutants such as byproducts
of occupational or industrial processes, can be responsible for most respiratory
diseases.
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Neoplastic diseases of the lungs refer to abnormal growth of lung tissue with no
particular function (lung cancer).
Finally, Infectious diseases of the lung are complications that are caused by
bacterium, fungus, mycoplasmas, and/or viruses that enter the TB through inhalation.
A flow chart of each of the 6 disease classifications is shown in Figure 2.1
(obstructive and restrictive), Figure 2.2 (vascular and environmental), and Figure 2.3
(infectious and neoplastic). The following sections provide more detail on each of the
disease types. The information was combined and summarized fromWest (1998) and Farzan
& Farzan (1997).
35
Figure 2.1 - Disease tree, restrictive and
obstructive branches
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Figure 2.2 - Disease tree,
environmental and vascular
branches
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Figure 23 - Disease tree, infectious and
neoplastic branches
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2.2 Obstructive Diseases
2.2.1 Chronic Obstructive Pulmonary Disease (COPD)
COPD is a lumped term to describe conditions of emphysema, chronic bronchitis or a
combination of both. Conditions include dypsnea, reduced exercise capability, large lung
volume, diminished air flow rate, and continual cough.
2.2.1.1 Emphysema
Emphysema (E) is the term that describes destruction of cells of parenchyma that are distal to
the terminal bronchiole. The region, known as the acinus, exhibits loss of alveolar walls and
capillary beds, which provides C02-02 gas exchange as well as damaging small airways of
less than 2 mm in diameter. There are two types of emphysema, as shown in Figure 2.4,
centriacinar and panacinar. Centriacinar deals with the destruction concentrated in the
central portion of the lobule, while panacinar is concerned with overall destruction of the
lobule respectively.
Normal
TB RB
Centriacinar
TB RB
Panacinar
TB RB
Figure 2.4 - Types of emphysema,West (1998)
Centriacinar emphysema is more prone to be the type that smokers will develop, showing
most common destruction in the upper lobes of the lung, (Saetta et al., 1985). However,
people with panacinar usually developed emphysema at a young age and the disease disturbs
the lower lung lobes. Compliance is decreased in emphysema due to scar tissue that
surrounds the alveolar sacs; this scar tissue has poor elastic behavior.
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2.2.1.2 Chronic Bronchitis
Chronic bronchitis (CB) is described by an excessive amount of mucus and semi-solid
blockages in the airways because the mucus glands are swollen and enlarged within the walls
of the airways. The mucus serves normally as a medium that will trap foreign bodies in the
airflow; then these trapped foreign bodies are transported up the TB by mucocilliary
transport. The clinical definition of chronic bronchitis is expectoration (coughing or spitting
mucus) on most days, for at least 3 months in the year, for at least 2 successive years.
Cigarette smoking and pollution are the main reasons for this condition.
2.2.2 Asthma
Asthma (A) is a condition which affects a person who is irritated by a stimulant of varying
aerosols, allergies, cold air, exercise, smoke, etc. In response to the stimuli, the airways
smooth muscle contracts and releases thick mucus into the airways, this further diminishes
the airflow rate and blood gas exchange. Asthma occurs most in children but can also be
present in people of all ages. COPD and asthma obstructive characteristics are similar, but
distinction can be found in terms of asthma being reversible, while COPD symptoms are
irreversible.
2.2.3 Suppurative Diseases
Suppurative diseases are diseases that cause pus to discharge to various organs or lumens of
the body and include bronchiectosis and cystic fibrosis.
2.2.3.1 Bronchiectasis
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Bronchiectasis is a recurrent disease of the bronchioles and bronchi that is typified by
swelling and damage to their walls and permanent expansion of the lumen. With the
associated dilation of the lumen, the mucociliary transport is hindered and mucus secretion
builds, becomes stagnant, and thus leads to infection. The expectoration in Bronchiectasis is
green or yellow and may have an associated foul odor. There are five different geometrical
configurations the swelling may result in: cystic or saccular, varicose or fusiform, and
cylindrical. Pulmonary function tests for the mild to moderate cases of Bronchiectasis will
not show deviation from normal patients, but severe cases demonstrate both obstructive and
restrictive disease similarities with pulmonary function tests. Severe cases show variation
from normal patients in lung volumes, ventilatory mechanics, distribution of ventilation, and
gas exchange. Finger clubbing, where the nail part of the finger looks swollen, is an exterior
indication of severe cases.
2.2.3.2 Cystic Fibrosis
Cystic fibrosis (CF) causes several organs within the body to become obstructed by thick
mucus, therefore collecting and harboring infectious agents. Ciliary activity is impaired thus
providing a good chance of infection. The organs that this abnormality affects are the lungs,
liver, pancreas, small intestine, and reproductive tract. Most of the deaths from cystic
fibrosis are due to the clogging of airways. Generally this disease affects children up to
people in their twenties and is more prominent in Caucasians. Respiratory symptoms include
expectorant cough, chronic chest infections, and limited exercise capability. Salty skin and
finger clubbing are external notifications of the disease. Pulmonary function tests show
increased unbalanced distribution of ventilation, decreases in FEV1 and FEF25-75%, increase
in RV and FRC, and loss of elastic recoil.
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2.2.3.3 Localized airway obstruction
Localized airway obstruction is an obstruction in the tracheal region (trachea) or bronchial
region (bronchi).
2.3 Restrictive Diseases
2.3.1 Diseases ofLung Parenchyma
Lung parenchyma refers to the alveolar tissue of the lung. Diseases associated with the
function of parenchyma are described below.
2.3.1.1 Diffuse Interstitial Pulmonary Fibrosis
Diffuse interstitial pulmonary fibrosis, also known as idiopathic pulmonary fibrosis,
interstitial pneumonia, and cryptogenic fibrosing alveolitis, is described by scarring of the
alveolar wall tissue. Thickening of the walls is from scar tissues that have air-filled cystic
spaces due to a dilated state of the airway. This characteristic is often called a honeycomb
lung. The patient may present a case of shallow fast breathing with dypsnea in clinic. In
more advanced stages there will also be noticeable finger clubbing. Pulmonary function tests
show all lung volumes are reduced, untypical large pressures are needed to distend the lung,
and flow rate and diameter of the airways are increased.
2.3.1.2 Sarcoidosis
Sarcoidosis deals with lesions that can be present in a variety of organs inside and outside the
body such as liver, lungs, skin, eyes, etc. Pulmonary function tests and symptoms are
essentially the same as the diffuse interstitial pulmonary fibrosis, both having low lung
volume and compliance. This inflammation usually occurs in people 20-40 years of age,
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with a larger probability in the African American community. In normal cases, the body
heals itself or the doctor may prescribe medication.
2.3.1.3 Other diseases of the lungparenchyma
Hypersensitivity Pneumonitis
Interstitial Disease caused byDrugs, Poisons, or Radiation
Collagen Diseases
Lymphangitis Carcinomatosa
2.3.2 Diseases of Pleura
There are two sacs, parietal and visceral pleura, which surround the lung. These two sacs
have a small fluid-filled space between them that aids in preventing friction in breathing
mechanics. Diseases associated with the pleura including pneumothroax, pleural effusion,
and pleural thickening are described below.
2.3.2.1 Pneumothroax
Pneumothroax is the condition when air or some other gas enters the intrapleural space. A
gas can be introduced to this space by a variety of ways. Trauma, microorganisms, excessive
exercise, COPD, asthma, cigarette smoking, scuba diving, and even the tube that assists
people in breathing can produce a gas in this space which results in pneumothroax. Signs of
pneumothroax are chest pain while breathing and dypsnea, though there may be no signs if
the pneumothroax is small. Bluish lips, fingernails, and swollen neck veins are apparent if a
large amount of tissue is affected. Pulmonary function tests are not that useful in evaluating
pneumothroax, but FEV1 and FVC both decrease. A more useful too in determining this
43
disease is the radiograph, which shows that the lung is collapsed and the rib cage is extended
out.
2.3.2.2 Pleural Effusion
Pleural effusion refers to fluid (pus, blood, lymph, etc) in the intrapleural space rather than
gas. Pleural fluid is normally produced in specific amounts to lubricate the pleura. Pleural
effusion is an abnormal collection of this lubrication caused by congestive heart failure or
disease.
2.3.2.3 Pleural Thickening
Pleural thickening is a long-term result of pleural effusion where the pleura is fibrotic and
essentially prevents the lung from expanding.
2.4 Vascular Diseases
2.4.1 Pulmonary Edema
Pulmonary edema stems from a malfunction of the heart, where backpressures in the lung
veins cause an accumulation of fluid in the lungs. The accumulation of fluid in the alveoli
essentially destroys the lungs capability for gas exchange. The malfunction of the heart can
be due to a heart attack, valve disease (mitral or aortic), cardiomyopathy, etc. Symptoms
include extreme dypsnea, grunting sounds while breathing, inability to lie down, coughing up
blood, pale skin, anxiety, wheezing, rales, and nasal flaring. This condition is serious but a
direct result of a cardiac problem; therefore, preventing a cardiac problem is the only way to
thwart pulmonary edema. A chest x-ray is useful for detecting fluid in the lung, as well as
listening for abnormal lung or heart sounds with a stethoscope.
2.4.2. Pulmonary Embolism
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Pulmonary embolism is a blood clot (or globule of fat, an air bubble, mass of bacteria, etc)
usually formed in the legs, it then travels up to an artery in the lung and becomes immovable.
This causes a resistance, if not complete blockage, and eventual infection or death.
Symptoms include dypsnea, chest pain, bloody cough sputum, sweating, tachycardia,
lightheadedness, clammy-bluish skin, and wheezing. Some key terms in blood clots include
the thrombus and embolus. Thrombus is a clot that forms and remains in the vein; embolus
is a clot that travels to another part of the body. Blood clots occur for a number of reasons
such as a long period of inactivity, cancer that causes an increasing level of clotting factors in
the blood, injury to veins in surgical procedures, and cardiovascular disease.
2.4.3. Pulmonary Hypertension
Pulmonary hypertension, with exception of diseases of the heart or lung, is characterized by
abnormally high blood pressure in the arteries of the lung. The small arteries of the lung
narrow throughout the lung; this narrowing results in hypertension. The right side of the
heart becomes enlarged due to the added workload from the hypertension. Heart failure is
the eventual product of this condition. Symptoms are similar to pulmonary embolism with
physical signs of distended neck veins, heart murmur, and liver enlargement.
2.4.4. Pulmonary Arteriovenous Fistula
Pulmonary arteriovenous fistula describes bypassed blood from artery to vein-to-vein causing
a decreased gas exchange for the person. These arteriovenous fistulas and stem from the
uncharacteristic growth of the blood vessels of various organs in particular the lung and are
congenital. There may be no symptoms or symptoms of the prior vascular diseases.
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2.5 Environmental
Dusts and atmospheric pollutants as byproducts ofmany occupational or industrial processes
can be responsible for most respiratory diseases. Various environmental diseases of the lung
are listed below:
Diseases caused by atmospheric pollutants
Carbon Monoxide
Nitrogen Oxides
Sulfur Oxides
Hydrocarbons
Particulate Matter
Photochemical Oxidants
Cigarette Smoke
Asbestos-related Diseases
Diffuse Interstitial Fibrosis
Bronchial Carcinoma
Pleural Disease
Coal Workers' Pneumoconiosis
Other Pneumoconiosis
Byssinosis
Occupational Asthma
2.6 Neoplastic Diseases of the Lung
Neoplastic diseases are those which defect the normal lifespan of cells; lung cancer is an
example. Normal cells will be created and die in a regulated fashion. Cancerous cells are
when cells do not readily die but multiply. When they multiply, they can either stay as a
mass (tumor) in one location or spread throughout the body, triggering mass growth and
replacement of normal cells. According to the American Lung Association, lung cancer is
the top cancer killer in both sexes. Cancer can be broken down into non-small cell lung
cancer and small cell lung cancer, as described below.
2.6.1. Non-Small Cell Lung Cancer
2.6.1.1 Squamous Cell Carcinoma
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Squamous cell carcinoma is a condition that is described by malignant tumors that are
located in squamous cells. It is estimated that 25%-30% of cancer is of squamous cell
carcinoma type. The location of this type is usually found near a bronchus of central
location. The main cause of this type of cancer is cigarette smoking.
2.6.1.2Ademocarcinoma
Adenocarcinoma deals with the cancer affecting the peripheral of the lung. There is an
estimate that this type of cancer accounts for 40% of the cancer population. It is noted that
this is a mild form of cancer, meaning the prospects are better for the person than any other
type of cancer.
2.6.1.3 Large Cell Carcinoma
Large cell carcinoma, estimated 10%-15% of the cancer cases, is characteristic of large
growth and fast dispersion. It usually affects the middle to peripheral of the lung, and is
usually diagnosed when squamous cell and ademocarcinoma have been excluded.
2.6.2 Small Cell Lung Cancer (Oat Cell Cancer)
Small cell lung cancer is approximated to be about 20% of the cases of cancer. This type of
cancer has a high dispersion rate and tends to grow rapidly once placed. The American
Cancer Society states that it is very rare for this type of cancer to be associated with any
cause other than cigarette smoking.
2.7 Infectious Diseases of the Lung
Infectious diseases including acute lower respiratory tract infections, pulmonary tuberculosis,
fungal infection of the lung, and pulmonary complications with FflV are described in further
detail below.
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2.7.1 Acute Lower Respiratory Tract Infections
2.7.1.1 Pneumonia
Pneumonia is an intense inflammation of the respiratory bronchioles, alveolar ducts and sacs,
and alveoli caused by various microorganisms. Pneumonia is predominantly active when
there is a weakening of the normal respiratory defense actions. This weakening can happen
through a recent viral infection, obstructing airway lesions, COPD, alcoholism, malnutrition,
major surgical operations and/or defective cellular immunity, etc. The influx of
microorganisms stimulates a tissue reaction, which brings about exudates and cells of
inflammatory response. The alveolar components, in result, are filled with these cells of
exudates. White blood cells phagocytize organisms; thus, releasing enzymes which further
inflammation and inflammation cells. A certain point in the tissue reaction the inflammatory
cells and exudates will firm up. This consolidation is where the bacteria can necrotize the
lung tissue, eventually enter the blood stream and invade the whole body. The way to
determine if pneumonia is present is from a radiograph, where regions of thick-density -
consolidation are present. Physical and mental condition is also a notification that the person
is experiencing pneumonia. Malaise, disorientation, fever, chills, sweating, and bluish lips
and nails are all involved states for the patient.
2.7.1.2 LungAbscess
A lung abscess is a pus-emitting lesion that is localized and will cause necrosis of the lung
tissue when left alone. This can be a result of other diseases and/or infections, but this
singular case is presented when it forms without connection to any other diseases or
infections. The cause of the lesion is from bacteria, mainly anaerobic bacteria. Usually the
onset is pneumonitis, with a concurrent formation of the lesion in 2 weeks after foreign body
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inhalation. Symptoms range from dry to fruitful cough that is usually foul smelling, weight
loss, fever, rapid heart rate, and clubbed fingers and toes may be present. Again, a
radiograph is useful in finding spots of high density, but a sputum collection will also show
tissue damaging materials and pus cells.
2.7.2 Pulmonary Tuberculosis
Pulmonary tuberculosis (PT) is a communicable bacterial infection that is mainly concerned
with the lungs but also could spread to other organs. The lung tissues that are affected have
granulomas or granular tumors at the site. People are susceptible to the disease if: they
haven't received the primary infection, exposed to a large number of people who have poor
environment and nutrition, weak immune system such as HTV sufferers, or come into contact
with drug resistant strains of PT. PT has symptoms of dyspnea, extreme sweating, chest
pain, minor cough with possibility of blood, and fever. Pulmonary function tests are not used
to diagnose this condition; rather a stethoscope is used in sensing any crackles in the patient,
observation of swollen lymph nodes in the neck, physical examination of clubbed fingers or
toes, and testing for pleural effusion. Permanent lung damage can occur if PT is left
untouched.
2.7.3 Fungal Infection of the Lung
Fungi are essentially everywhere around us, therefore preventing inhalation of fungi is
virtually impossible. It is when people are weakened or there is an extreme amount of this
fungi present that people contract the infection. Essentially, four of the most common fungal
infections are discussed below in detail.
2.7.3.1 Histoplasmosis
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Histoplasmosis (agent H capsulatum) are common fungus that are found in the soil of
particular regions of the continent and are enhanced by various bird droppings; examples
include chickens, bats, pigeons, etc. It is common around the river valleys of the United
States. Histoplasmosis can be in two different forms based on temperature; at room
temperature it is mold while in the tissue 37 C it is yeast. A primary infection can serve as
immunity for this infection. In fact in states like Tennessee and Kentucky, 90% of the people
test positive by a histoplasmin skin test for infection. For the most part, the symptoms are
unrecognizable if someone has the primary infection, but for people that have been exposed
to a large dose the symptoms of the flu are most likely. It seems that once you recover from
the first infection the chance of contracting another infection are slight, except if you have a
weakened immune condition like HTV.
2.7.3.2 Coccidioidomycosis
Coocidioidomycosis is a fungal disease that chiefly affects the lungs but also could spread to
numerous other organs; the main agent of infection is C immitis in mycelial form. It seems
the origin is in the southwestern United States and has origins again from the soil. A person,
who has the initial infection, or an injection of the infection, can develop positive immunity
from this disease. If there is no immunity present the infection will produce problems for a
variety of organs. Again, there may not be any symptoms present but more severe cases will
generally be flu-like symptoms, desert fever, and lesions.
2.7.3.3 Blastomycosis
An Eastern North American chronic infection from thick-walled spherical yeast,
blastomycosis is often found in soil of barns, chicken coops, and cattle crossing.
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Blastomycosis is characterized by the common suppurative lesions in and out of the body.
People, mostly, can recover from this infection with or without treatment. People in a
weakened state will be more susceptible to this infection.
2.7.3.4Aspergillosis
Aspergillosis (aspergillus) is a mold that grows everywhere, so to prevent contact with it is
virtually impossible. Despite this, only some people are susceptible to it under certain
circumstances. There are several different types of aspergillosis that affect people: one
causes an allergic reaction for people with asthma; another can create a fungus ball
(aspergilloma) where growth and colonization occurs on an old healed tissue from prior
diseases. Finally, the third type can be an all-encompassing infection that is spread through
the bloodstream and is most harmful for people with weak immune systems. There are
typical symptoms of this infection such as dypsnea, weight loss, malaise, etc; diagnosis can
be found by using the sputum test and chest x-ray.
2.7.4 Pulmonary Complications with HIV
The pulmonary complications with HTV are listed below:
Pneumocystis carinii Pneumonia
Tuberculosis
Atypical Mycobacterial Disease
Viral Pneumonia
PulmonaryMycoses
Bacterial Pneumonia
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Chapter 3 - Literature Survey
3.1 Experimental Deposition in Human Subjects with Lung Diseases
A collaboration of fifteen different journal articles all presented experimental deposition data
of disease showing a variety of breathing patterns and particle sizes. These journal articles,
located in Appendix A, show deposition results between normal patients with asthma, CF,
and/or COPD conditions. Explanations of these journals with experimental deposition data
are as follows.
Lippmann et al. (1971) looked at regional deposition measurements in patients of
varying conditions. Deposition was examined in the head, tracheal and alveolar regions, also
whole lung and exhaled aerosol deposition were accounted for. The study consisted of 65
patients: 14 normal, 29 cigarette smokers, 6 with bronchitis, and 1 asthmatic. The particles
ranged from 1-14 pm in diameter. The results of this report had a lot of variability in the
deposition plots; therefore, an estimate of the relationships was made to communicate the
details, see Table 3.1.
Table 3.1 - Deposition data table from Lippmann et al. (1971), where PS is particle size
Non-smokers Bronchitic Asthmatic
Head Deposition
PS: < -3-4 (im
Deposition (%): <20
PS: < -2-3 urn
Deposition (%): <20
For the data available, values were
under a D% of 10
PS: -3-4 to 12 Mm
Deposition (%): 20-80
Linearly increasing with
increasing PS
PS: -2-3 to 5 Mm
Deposition (%): 10-75
Linearly increasing with
increasing PS
Tracheal
Deposition
PS: < -3-4 nm
Deposition (%): <10
PS: 1.2-5 um
Deposition (%): -0-30
Scattered data points
PS: 1.4-2 Mm
Deposition (%): <8
PS: -3-4 to 12 (jm
Deposition (%): -0-45
Linearly increasing with
increasing PS
TB Deposition
PS: 2.5-13 Mm
Deposition (%): 20-96
Linearly increasing with
increasing PS
PS: 1.2-6 Mm
Deposition (%): 73-97
Cloud-like data with one end up
PS: 1.45-4.2 Mm
Deposition (%): 35-84
Linearly increasing with increasing PS
Alveolar
Deposition
PS: 2-10 Mm
Deposition (%): 3-70
Linearly decreasing with
increasing PS
PS: 1.8-8.5 Mm
Deposition (%): 2-28
Linearly decreasing with
increasing PS
PS: 1.8-4.8 Mm
Deposition (%): 12-50
Linearly decreasing with increasing PS
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D% = -3.72 FEF50_15% + 25.07
Love andMuir (1976) studied deposition of 1 pm particles (GSD 1.13) in coal miners
as a function of PFT parameters. A total of 57 coal miners were examined: 8 Nonsmokers, 7
Ex-smokers, and 42 Smokers. The lung function parameters that were hypothesized to have
a relationship with deposition were: FEV-, FEVi/FVC, FEF50-75%, and RV/TLC. The most
significant correlation with deposition was with forced expiratory flow in the third quarter of
FRC (FEF50-75%) in which the regression equation was the following:
(3.1)
Deposition percent was calculated by 1 minus the concentration of exhaled particles divided
by the concentration of inhaled particles. The patients were examined in the sitting position
and while exercising, with flow conditions of 15 breaths per minute. The tidal volume of 1.6
L was used to normalize between patients due to the linear relationship of tidal volume to
deposition. The Table 3.2 shows the results of the research. Love and Muir's study showed
that the highest deposition and most reduced ventilation capacity were in the smokers group.
The authors believe that the strong correlation between deposition and FEF5o-75%may be due
to abnormalities in the peripheral airways less than 2 mm in diameter.
Table 3.2 - Deposition data and correlation (PFT to D%) from Love & Muir (1976), where SD is
standard deviation
Group No. ofSubjects D%, (SD) FEV, FEVj/FVC FEF5o.75% RV/TLC
Non-smokers 8 18.5(4.1) 2.75 (0.67) 70.5 (12.9) 1.73 (0.94) 38.8(10.1)
Ex-smokers 7 19.9 (3.0) 2.54 (0.38) 71.6(4.2) 1.07 (0.37) 39.0 (4.2)
Smokers 42 21.6(3.3) 2.62 (0.63) 67.1(10.0) 0.98 (0.48) 39.9 (7.6)
Ilowite, J. S. et al. (1987) performed an analysis of aerosol antibiotics, which
involved 13 patients with CF. The antibiotic was Gentamicin and was aerosolized toMMAD
of 1.1 pm. As stated before, CF is a disease that causes several organs of the body to over-
secrete thick mucus which results in inflammation and/or infection. The mucus affects the
airways of the lungs by constricting the flow rate thus hindering gas exchange. The use of
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aerosol antibiotics results in smaller dosage of antibiotic and targeted distribution to the site
of infection. On average approximately 7.7% of the original Gentamicin amount was
deposited. The report also contained comparisons of 133Xe scans of central and peripheral
deposition of the antibiotic in terms of a ratio central to peripheral, C/P. This ratio was
compared to FEVi and sputum levels; it showed an inverse exponential relationship with
FEVi implying that increased obstruction means increased central deposition. The sputum
and C/P ratio had a linear correlation meaning that the higher the sputum level the higher the
deposition.
Anderson, P. J. et al. (1989) studied the inspired and expired boluses of 11 patients
with cystic fibrosis and 1 1 normal patients. The inspired particles were 1 0. 1 pm in size
and consisted of boluses of 70 cm3in volume. The tidal volume for the patients was kept at 1
L. The deposition fraction for both normal and cystic fibrosis cases was graphed with respect
to volumetric lung depth, Vd, 100-700 cm3. Results of this relationship concluded that the
deposition fractions for both cases were both linear increasing with similar slopes, implying
that deposition increases with increasing lung penetration up to 700 cm . The difference was
that cystic fibrosis data points were greater in magnitude for every point. Estimated
equations for the relationship are for CF: D% - 3/49 Vd + 20 ; and for N:
D% = 18/400 -Vd -8, concluding that deposition percent (D%) was larger in the diseased
cases in comparison to the healthy patients.
Anderson, P. J. et al. (1990) is one of the first articles (for that time) to present
quantitative total deposition for ultrafine particles within normal, obstructive, and restrictive
diseases. Non-hygroscopic particles ranging from 0.02-0.24 pm were inhaled by 10 normal,
5 with obstructive disease, and 3 with restrictive disease patients. An electric aerosol
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analyzer was used to detect the concentration difference of inhaled and exhaled air of the
patients. Table 3.3 provides the results of the deposition fraction as a function of particle size
for all three sets of patients. This study shows that the deposition fraction is increased for the
obstructive patients when compared to the normal patients, and that the restrictive disease
does not have that significant of a change from normal patients in respect to deposition. As
the particle size gets larger, so does the factor comparing obstructive to normal.
Table 3.3 - Deposition data fromAnderson et al. (1990), SD is standard deviation, and f is factor from
Normal (healthy) subject data
Size, pm Normal, (SD) Obstructive, (SD) Restrictive, (SD)
0.02 0.47 (0.03) 0.54 (0.02), f= 1.2 0.45 (0.02), f= -1.0
0.04 0.38 (0.02) 0.46 (0.02), f= 1.2 0.38 (0.01), f= 1.0
0.08 0.33 (0.03) 0.45 (0.02), f= 1.4 0.35 (0.01), f= 1.1
0.13 0.24 (0.02) 0.40 (0.02), f= 1.7 0.29 (0.01), f= 1.2
0.24 0.17 (0.03) 0.39 (0.03), f = 2.3 0.25 (0.01), f= 1.5
Svartengren et al. (1990) provides deposition results pertaining of 3.6 0.3 /xm particles in
people with asthma. The sample was composed of 10 asthmatics, of which 5 were ex-
smokers and the other 5 never smoked. This data was compared to Svartengren et al.
(1989b) data on deposition within a healthy sample. The 3.6 /xm particles were inhaled to the
maximum volume 8-12 times at a flow rate of 0.5 L/s and also included a pause of 1-2
seconds. The study was performed analyzing particle retention, which was measured at 0, 6,
24, and 48 hours. The results presented in the article are given below in Table 3.4. Clearly
the results indicate a greater deposition in the asthmatic patients but not within the margin of
error. In addition, the author verified that regional deposition could be measured using lung
retention in at least 6 hours after inhalation within the patients.
Table 3.4 - Svartengren et al. (1990) deposition data, where SD is standard deviation
Condition
Healthy
Asthma
Deposition % SD
73 15 %
83 12 %
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Olseni et al. (1994) analyzed different aerosol deposition patterns to determine if any
correlation existed that would separate people with chronic bronchitis from healthy people.
The particles were 4.9 pm MMAD with a GSD of 1.9. Some of the parameters they
investigated were VC, FEVi, FEVi/VC (FEV%) and penetration index (PI). All parameters
showed relatively good correlation between aerosol deposition and FEVi, but the authors
concluded that this should not be employed in a clinical setting due to the small gain in
detection of airway disease over current clinical methods. An interesting analysis in this
journal article is the penetration index (peripheral/central deposition). The images showed
that in the obstructed patients most deposition is in the central region; whereas, the healthy
cases have a more uniform distribution between the two regions. Values of PI obtained were:
1.69 0.22 for normal subjects and 0.96 0.41 for subjects with CB, which reinforce that
there is more peripheral deposition in patients with CB.
Siekmeier et al. (1994) deals with convective gas transport of asthmatic patients
compared with a control group of normal patients. A total of 25 patients were in the group:
15 healthy and 10 asthma; and 0.8 pm monodisperse aerosol particles were inhaled to
different volumetric depths (0-1000 cm3). Data was collected through the standard
pulmonary function tests, PFT, as well as aerosol pulse dispersion parameters. Raw, SRaw,
FRC and TLC were obtained through body plethysmography; and IVC, FVC, FEVi,
FEVi/TVC, MEFV75, MEFV50, and MEFV25 were obtained through spirometry, see Section
1.4.3 and Section 1.4.1, respectively.
The graph of interest included in the article by Siekmeier is the deposition percentage
versus volumetric lung depth. Data points for the graph are given in Table 3.5, which shows
the starting and ending points for the relationship. So, as the lung depth goes from 150-800
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cm3, D% gets larger, as with asthma D% compared to normal. In summary, the data
suggested that the symptoms of asthma do present an obstacle for breathing mechanics,
which directly results in more total deposition percentage in asthma patients.
Table 3.5 - Siekmeier et al. (1994) deposition at volumetric lung depth
Volumetric Lung
Depth, cm3
150
800
Normal,
Deposition (%)
28
Asthma,
Deposition (%)
11
30
Roy M. et al. (1994) studied the deposition of particles of size 1.2, 2.3, and 3.3 pm
(aerodynamic diameter) within healthy subjects and patients of restrictive and obstructive
disease. This study focused on the total deposition through inhaled and exhaled
concentrations with use of laser velocimetry. The flow conditions were regulated for all the
participants in the study with tidal volume being 0.5 L and an inspiratory time of 1.5 s.
Deposition (D) was calculated using the following equation:
r\ 1 aero_\
-C
aero
_ insp )
V. c
insp aero_\
(3.2)
where Vj is the aerosol flow rate before inspiration (L min"1), V. is the flow rate during
inspiration (L min"1), caewlis the aerosol concentration before inspiration (particle number
ml"1), and caerojnspis the aerosol concentration during respiration (particle number ml"1). D
was expressed as D% shown in Table 3.6:
Table 3.6i - Deposition data from Roy et al. (1994)
Deposition Percentage (%)
Sample 1.2 pm 2.3 pm 3.3 pm
Healthy non-smoker 26.1 34.2 45.2
Restrictive 37.7 46.3 56.6
Obstructive 39.2 47.7 56.7
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O'Riordan, T. G. et al. (1995) were interested in the deposition patterns in patients of
different respiratory ailments for further advancement in aerosolized drug delivery. The drug
that was utilized was cyclosporine A, a drug that has proven to be effective in prolonging the
life of lung allograft recipients. The allograft patients had the following disorders: primary
pulmonary hypertension (vascular disease), sarcoid (restrictive disease), lymphangio-
myomatosis (restrictive disease), cystic fibrosis (obstructive disease), and emphysema
(obstructive disease). The nebulizer generated aerosol of mass median aerodynamic diameter
(MMAD) 1.2 pm and a geometric standard deviation (GSD) of 2.1. A mass balance
technique was employed to measure the total deposition. The data in Table 3.7 was obtained.
Notice the asymmetry in the lung dose and the large amount of deposition in emphysema.
The results from this study conclude that aerosol targeting is very complicated due to the
asymmetry in left/right lung that disease conditions bring about.
Table 3.7 - Deposition data from O'Riordan et al. (1995)
Primary Disease mgInhaled
mg
Deposited
Deposition
Fraction, DF
Lung Dose (mg)
Left/Right
Primary Pulmonary
Hypertension
69.8 34.9 0.50 9.5/25.4
Sarcoid (Restrictive) 44.8 24.2 0.54 6.9/15.8
Lymphangio-
myomatosis (Restrictive)
53 35 0.66 20.5/12.3
Cystic Fibrosis 41.7 20.4 0.49 9.4/11.0
Emphysema 61.2 52.6 0.86 6.0/48.6
Svartengren, K et al. (1996) studied the deposition and clearance in the airways of
patients with chronic bronchitis. 16 subjects with chronic bronchitis and 10 healthy
individuals inhaled particles of aerodynamic diameter 6 pm at a slow and normal flow rate of
0.05 and 0.5 L/s. Deposition fraction was calculated from radioactive aerosol scanning and
is presented in Table 3.8 was obtained from radioactive aerosol scanning. Conclusions, for
CB, showed that the slower flow rate proved to have more retention of particles than the
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normal flow rate. CB for 0.05 L/s flow rate was larger than the normal subjects and for 0.5
L/s healthy subjects had a larger deposition percentage.
Table 3.8 - Deposition data from Svartengren et al. (1996)
Chronic Bronchitis Ret 24 % Ret 48 % Ret 72 %
0.05 Us 61 14 57 12 51 12
0.5 L/s 31 17 26 17 23 16
Healthy Subjects Ret 24 % Ret 48 % Ret 72 %
0.05 L/s 526 447 397
0.5 L/s 51 10 49 10 49 10
i
Schiller-Scotland, Ch. F. et al. (1996) hypothesized that the deposition would be
different between healthy and COPD patients due to lung irregularities. The study involved
deposition of aerosol particles of size 1, 2, and 3 pm in 30 people (15 normal and 15 with
COPD). Each particle size had three breathing patterns associated with it as shown in Table
3.9. The results are summarized in Table 3.10 by particle size and deposition fraction. In
spontaneous and controlled breathing no pause conditions there was more deposition percent
in the COPD case, where there was hardly a difference in deposition percent for controlled
breathing with the 6 second pause.
Table 3.9 - Breathing patterns for Schiller-Scotland et al. (1996)
Breathing Pattern
Spontaneous
Controlled Breathing
(No Pause)
Controlled Breathing
(6 Second Pause)
Flow Rate
= 0.310 L/s COPD and
0.380 L/s Normal
VT = 1 L, V = 0.25 L-s"1
VT = 2L,
Vv
=
0.50Ls"1
Table 3.10 - Deposition results ofSchiller-Scotland et al. (1996)
Particle
Size, /xm
Spontaneous Controlled Breathing,
No Pause
Controlled Breathing,
6 Second Pause
Healthy COPD Healthy COPD Healthy COPD
1 11% 35% 24% 44% 55% 65%
2 29% 50% 44% 62% 88% 87%
3 45% 63% 66% 72% 90% 90%
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Bennett, W. et al. (1997) determined the deposition of 2 pm monodisperse particles
within COPD and normal samples. These two populations were studied at their normal
breathing patterns rather than a controlled breathing. The results are shown in Table 3.11.
Notice that the deposition in COPD sample is approximately twice the fraction of the
normals, also VT, and minute ventilation,V^, are increased and breathing period is
decreased for COPD patients. Minute ventilation is a measure of the total volume leaving the
lung each minute, Vt f =V^ , f is breathing frequency, and Ttot is total time for a breathing
cycle.
Table 3.11 - Deposition and breathing pattern data from Bennett et al. (1997), where SD is standard
deviation
COPD (SD) Normal (SD)
Deposition Fraction 0.40(0.16) 0.26 (0.06)
f (breaths/min) 20 16.4
Vr(mL) 541 (150) 436 (144)
Tot (s) 2.98 (0.70) 3.66 (0.89)
Ve (L/min) 11.2(3.0) 7.4 (2.7)
Kim, C. S. and Kang, T. C. (1997) present deposition data as a function of FVC,
FEVi, FEVi/FVC, FRC, FEF25-75%, and SRaw. The study consisted of 45 people - 10 Normal,
10 smokers, 10 small airways disease, 5 asthmatics, and 10 with COPD. The particles that
were inhaled were 1 [im in diameter from a volume of 0.5 L, hence tidal volume was 1 L.
Concentration of particles used in the test was
104
particles per cm3. The patients took 15
breaths at a rate of 30 breaths per minute for the testing. Lung deposition fraction was
computed by Equation 3.3 and the results of this analysis are presented in Table 3.12. It is
clear from Table 3.12 that a respiratory condition will enhance deposition of particles within
the airways of the lung.
D%,-D%.
DF =
D%,
(3.3)
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Table 3.12 - Deposition data from Kim & Kang (1997)
Condition Deposition Percentage
Normal 14 2 %
Smokers 16 2 %
Small Airways Disease 21 5 %
Asthma 22 2 %
COPD 28 3 %
Brand, P. et al. (2002) performed two methods to obtain total and alveolar deposition
of 3, 4, and 5 pm monodisperse particles in 12 patients with ai -antitrypsin deficiency and
symptoms of mild-severe COPD. The two methods were clearance derived regional
deposition (CRD) and single breath regional deposition (SBRD). The flow rate was slow,
V = 200 cm3/s and SBRD measurement involved breathholds of 0 and 2 seconds, while CRD
was 1 inhalation with a 2 second breathhold. The results of this study are shown in Table
3.13 with the deposition in terms of a fraction. It is clear that the two methods of CRD and
SBRD produced close results to each other and are accurate in gathering the deposition
fractions.
Table 3.13 - Deposition data table Brand et al. (2002)
Parameter CRD SBRD
Da (2 pm) 0.46 0.09 0.50 0.04
Da (3 pm) 0.53 0.07 0.53 0.06
Da (4 pm) 0.41 0.13 0.49 0.07
D (2 pm) 0.75 0.04 0.71 0.04
D (3 pm) 0.87 0.03 0.85 0.02
D (4 pm) 0.91 0.03 0.88 0.02
3.2 DepositionModels for Disease Lungs
Deposition models for the diseased lung are quite few in number due to the scarcity and/or
vagueness of data on diseased lung geometry. Four computational disease deposition models
results have been published in literature: Goldberg, I. S. and Lourengo, R. V. (1973) and
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Svartengren, K. et al. (1996) for obstructed lung, Martonen, T. B., et al. (1997) for cystic
fibrosis lung and Segal, R. A., et al. (2002) for COPD lung.
Goldberg, I. S. and Lourenco, R. V. (1973) presented the comparison of deposition of
2.4 pm particles, with constant inspiratory flow of 30 L/min. The deposition physics used
were from the equations of Landahl (1950) that deal with sedimentation and impaction at
bifurcations. The modification that Goldberg and Lourenco used to simulate deposition
within an obstructed lung was an unvarying decrease in diameter along all 23 generations
which corresponded to a factor of 4 increase in resistance for the obstructed case. In Figure
3.1 are the published deposition percent results. The summaries for the results are shown in
Figure 3.1. First, impaction (I) deposition percentage is notably increased in the obstructive
case in generations 0-16. Second, sedimentation (S) deposition is larger in the normal case
for generations 10-23. Finally, cumulative (C) deposition fraction is increased to a higher
deposition percentage quicker due to the large percentage gain in impaction deposition.
Overall there is a slight gain in the amount of deposited particles.
Normal Obstruction
0 4 8 12 16 20
Airway Generation No. Airway Generation No.
Figure 3.1 - Goldberg and Lourenco (1973) calculated deposition results
Svartengren, K. et al. (1996) produced a theoretical deposition model for 6 pm
aerodynamic diameter particles utilizing the Task Group on Lung Dynamics equations for
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sedimentation, diffusion, and impaction and also the Weibel Model generations. Parameters
that may be altered in the model are airway dimensions, tidal volume, inspiratory flow, post-
inspiratory pause, expiratory time, geometric diameter of the particle and particle density.
Modifications used to simulate the comparison of normal and chronic bronchitis conditions
were a general scaling down of the diameters of the airways of generations 4 to 23 by a
uniform factor and resistance measurements of normal and chronic bronchitis patients
obtained from experiments at the circumstance of a tidal volume of 1800 cm3, inspiratory
flow rates of 50 and 500 cm3/s, and a pause of 2 seconds. Also a value of 0.5 cmH2Os/L
was included to represent the airway resistance of the nasopharynx region. Results are
shown in Figure 3.2. The 'G' in the figure represents generations 17-23. For a faster flow
and CB constricted airways, it is apparent that there is more inertial impaction in the lower
generations as compared to the 0.05 L/s plots on the right of Figure 3.2.
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Figure 3.2 - Svartengren et al. calculated deposition results, Svartengren et al. (1996)
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Martonen, T. B., et al. (1997) deals with the modeling of drug delivery for the genetic
inherited abnormality cystic fibrosis. Cystic fibrosis causes several organs within the body to
become obstructed by thick mucus, therefore collecting and harboring infectious agents. The
organs that this abnormality affects are the lungs, liver, pancreas, small intestine, and
reproductive tract. Most deaths from cystic fibrosis are due to the clogging of airways.
Martonen points out that with cystic fibrosis the patient will most likely develop a chronic
obstructive lung disease, which makes this model especially important for insight on the
factors he used to describe this obstruction quantitatively. The respiratory conditions that he
bases his inspiration flow rate on in the model are given in Table 3.14. Results of deposition
for various regions of the lung (TB: generations 0-16 and pulmonary: generations 17-23) and
different inspiratory conditions (10 or 30 L/min) are given in Tables 3.15. AC stands for
airway coefficient, a parameter that Martonen et al. (1997) uses to scale the airways to
account for disease or not. However, it is not clear how the value was obtained. Figure 3.3
shows 4 graphs made of model results of deposition fraction versus airway generation for
different cases.
Summarizing, the graphs show a greater deposition fraction for both GSD of 1.5 and
2.0 disease at the beginning of TB and pulmonary region compared to the normal group at
both inspiratory flow rates 10 and 30 L/min which is most likely due to a significant portion
of the deposition due to inertial impaction. Inertial impaction deposition is very effective in
constricted airways with substantial airflow velocity. Unfortunately this article does not go
into depth on how he accounts for the mucus affecting the airway. Martonen et al. (1997)
utilizes an airway coefficient, which possibly will alter the whole generation's airways by a
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cumulative factor. Another pitfall to this model is that it is not compared with any
experimental deposition.
Table 3.14 - Respiratory conditions for Martonen et aL (1997)Model
Physical Activity Tidal Volume,
VT(ml)
Breathing Frequency,
f (breaths/min)
Sedentary 14 500
Low 12.6 793
Light 15.5 1,291
Heavy 24.5 2,449
Maximal 40 3,050
Table 3.15 - Compartmental deposition patterns of aerosolized drugs in control (AC = 1.0) and diseased
(AC = 0.7) lungs. The aerosolMMAD is 3 urn with a GSD of 1.5 or 2.0. The inspiratory flow rate is 10
and 30 L/min, Martonen, T.B. et al. (1997)
GSD =1.5 GSD = 2.0
10 L/min Total TB P Total TB P
Control (AC = 1.0) 0.42 0.25 0.17 0.44 0.29 0.15
Diseased (AC = 0.7) 0.56 0.27 0.29 0.56 0.32 0.24
GSD = 1.5 GSD = 2.0
30 L/min Total TB P Total TB P
Control (AC =1.0) 0.45 0.21 0.24 0.48 0.26 0.22
Diseased (AC = 0.7) 0.58 0.35 0.23 0.59 0.41 0.18
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Figure 3.3 - Calculated deposition results, fromMartonen et al. (1997), A. Flow rate = 10 L/min, B. Flow
rate = 30 L/min
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Segal, R.A., et al. (2002) who includes Martonen as one of the co-workers, is most
likely the only model, currently available, that has predicted deposition of particulate matter
within a COPD lung. COPD, which is previously defined, consists mainly of chronic
bronchitis and emphysema. Chronic bronchitis is a narrowing of the airways due to
obsessive mucus and inflammation that is a lasting condition as compared to asthma, which
is reversible in nature. Coupled with chronic bronchitis is emphysema. Emphysema is a
degenerating and distending condition that affects the alveolar sacs. The alveolar sacs
increase in volume and lose their elasticity. Segal employs a deposition model from
Martonen that is based upon Weibel' s "Model A" analysis of the lung geometry. Breathing
conditions are essentially 500 mL/s tidal volume with no pause, but this volume was actually
tailored to the group of subjects that were involved with the study. The particles were non-
hygroscopic, 1 pm in size, and had a density of 0.91 g/cm3.
The model incorporates the following modifications: alveolar degeneration (%),
scaling factor based on functional residual capacity (FRC), and a scaling factor based on
resistance of the airway (Raw)- Alveolar degeneration was modeled as 10-30% increase in
alveolar volume. The range was due to variability within patient's disease parameters, but no
actual systematic clinical data was used to validate these percentages. Secondly, a scaling
factor for airway diameters was created using FRC volume for obtaining the total lung
volume. FRC scaling is applied to generations 17-23, because there is a fairly small volume
in the TB region 0-16. One-half the tidal volume plus FRC is the average lung size. Weibel
(1963) states this as 4800 ml. FRC values for the subjects used had a great deal of variability
(1850 - 6820 ml) therefore the scaling factor was either greater than or less than 1. If the
total lung volume was greater than
Weibel'
s value, the FRC factor would be greater than 1,
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and if the total lung volume was less than Weibel's, than the FRC factor would be less than
1.
Lastly, the model takes into consideration the increased airway resistance that is
present within a COPD patient. The information is taken from a variable for airway
resistance, Raw, commonly tested among patients suffering from airway complications.
Chronic bronchitis is the only disease of COPD that mostly contributes to the airway
diameter decrease, asthma is along the same lines as CB. Nevertheless, the current model
scales the diameter uniformly for the generations 0-16 to achieve the Raw values of COPD
patients whose airway resistance was measured. Generations 17-23 are not scaled using
resistance due to there being minute flow resistance in the pulmonary region. To further
refine the airway narrowing the following assessment was made. Generations 0-7 are not as
affected by narrowing as generations 8-16 because of cartilaginous rings. Therefore the
uniform scaling factor for generations 0-16 was modified by applying a 10% reduction for
the scaling factor applied to generations 0-7, then adjusted the remaining diameters of
generations 8-16 to match the same Raw value as the COPD patients. An additional note is
that the COPD patients Raw is modified for the model. Raw consists of two values: Resistance
of the upper airways Ruaw (oropharynx and the larynx) and resistance of the lower airways
RiaW (tracheobronchial and pulmonary airways). Ruaw is not affected in COPD patients and
can therefore assume the resistance of a normal patient. Raw of a normal patient is 1.5
cmH20/(L/s) and the model assumes that RuaW = Riaw = !/2 Raw therefore since the model only
deals with resistance of the lower airways, 0.75 is subtracted from the value obtained from
the patients Raw.
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Table 3.16 gives the different cases that were modeled and the algorithm
implemented to represent each case. Results for Lung A-E are given in Figures 3.4-3.9, and
serve to classify the different modification cases.
The following is the scaling code for the different cases for this model:
A. Alveolar scaling factor, which is essentially 10-30% increase in total alveolar volume
B. Uniform airway scaling factor; airways are scaled by the same factor to obtain a
certain lung volume, the lung volume is FRC + Vi Tidal Volume
C. Total airway resistance (Raw) calculation
D. Computation for a, the chronic bronchitis scaling factor; in generations 0-16 the
diameter is narrowed uniformly to obtain a certain airway resistance
E. Modify previous chronic bronchitis scaling factor by a 10% reduction in generation 0-
7 then recalculate the generations 8-16 with uniform airway constriction to obtain the
certain airway resistance.
F. In each generation calculate the final volume, then import into main program.
Table 3.16 - Modification table for Segal et al. (2002) deposition program
Focus Case Scaling Algorithm
Implemented
Lung A. Normal (Control) Total lung volume (TLV) only 2,6
Lung B. Chronic Bronchitis
(CB)
TLV and Uniform airway
reduction
2-4,6
Lung C. Chronic Bronchitis
TLV and Non-uniform airway
reduction
2-6
Lung D. Emphysema (E)
TLV and Alveolar
degeneration
1,2,6
Lung E. CB and E
Non-uniform airway reduction
and Alveolar degeneration
1-6
The most useful summary graph presented is the deposition fraction versus generation
plot (Figure 3.4). In this graph all of the deposition data for each morphological case are
plotted. The shapes of the data plots are very similar to the data plots in the cystic fibrosis
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model, a concave-down followed by a concave-up and completed by a concave-down. As
expected the non-uniform airway reduction and combined cases (Lung E) had the greatest
deposition fraction, followed by the uniform airway reduction case (Lung B) and the least
deposition fraction was the normal and alveolar degeneration cases (Lung A and D).
Deposition fraction as a function of airway generation for the deposition mechanisms
impaction, sedimentation, and diffusion are depicted in Figures 3.5-3.9, for lungs A-E,
respectively.
0.018
0.016
c
0.014 H
% 0.012 H
2
u. 0.010
c
5 0.008
a
a. 0.006
a
0.004
X Lung A
?LungB
aLungC
A Lung D
XLungE
* ? ? H
i
? B
?
llfi
0002:1Aft****i*ftft*ft*
0.000?^
? 558 g
- r-
5
i
10 20 2515
Generation
Figure 3.4 - Particle deposition fractions for lung models A, B, C, D, and E, Segal et al. (2002)
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Figure 3.5 -Deposition mechanisms deposition fractions for Lung A, Segal et al. (2002)
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Figure 3.7 -Deposition mechanisms deposition fractions for Lung C, Segal et al. (2002)
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Figure 3.8 -Deposition mechanisms deposition fractions for Lung D, Segal et al. (2002)
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Figure 3.9 -Deposition mechanisms deposition fractions for Lung E, Segal et al. (2002)
General conclusions of this deposition model are that Lung C and Lung E, which both
have chronic bronchitis, have more deposition of particles within the lung compared to
emphysema and that compared to normal patients. The single most irrefutable conclusion is
that there is more deposition occurring if the TB airways (generations 0-16) are narrowed.
3.3 Breathing Parameters for Patients with Lung Disease
The parameters compiled in breathing pattern analysis are typically f, VT, inhale time (TO,
exhale time (Te), Ttot, and minute ventilation,!^,. Table 3.17 represents a collection of
breathing parameter data from various journal articles.
Garrard et al. (1979) presented ventilation data from 12 patients who suffered from
severe airflow obstruction. Parameters collected were Ti, Te, FEVi, FVC, FRC, TLC, and
Raw. The authors noticed a diminished tidal volume and an enlarged FRC volume as well as
a lengthened expiratory time.
Bradley et al. (1979) compared 20 patients with COPD and hypoxemia with 17
patients of COPD. Hypoxemia is where there is a deficit of oxygen in the blood. The results
show that minute ventilation, essentially stayed the same in both groups where frequency was
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higher in the hypoxemia group. Other results of tidal volume, VT and inspiration time, T;,
were lower and shorter, respectively.
Table 3.17a - Compiled breathing pattern data
Study Condition
f
(breaths/min) VT(L) T,(s) Te(8) Ttot (s)
min
(L/min)
Garrard et
al. (1979)
COPD 17.2 0.86 1.35 2.13 3.48 -
Bradley et
al. (1979)
COPD 17.5 0.75 1.30 3.82 5.12 11.7
Hypox -
COPD
21.6 0.58 1.06 3.12 4.18 11.4
Tobin et
al. (1983),
a&b
Normal 16.7 0.38 1.64 2.27 3.91 5.97
Sym.
Asthma
(Supine)
16.3 0.53 1.59 2.44 4.03 15.52
COPD 21.9 0.46 1.11 2.10 3.21 9.37
Sanchis et
al. (1990)
Normal 14.8 0.62 1.61 2.65 4.35 8.91
COPD 15.8 0.57 1.70 2.37 4.60 8.81
Bloch et
al. (1997)
Normal 14.5 0.43 1.60 2.70 4.30 5.90
Emphysema 17.4 0.52 1.20 2.40 3.60 8.78
Bennett et
al. (1997)
Normal 16.4 0.44 - - 3.66 7.4
COPD 20.1 0.54 - - 2.98 11.2
Vitacca et
al. (1999)
COPD 20.0 0.38 - - 3.00 7.2
Ritz et al.
(2000)
Normal 12.6 0.60 - - 4.76 7.26
Asym.
Asthma
13.9 0.51 - - 4.32 6.96
Breathing rates among asthmatics of asymptomatic (presenting no symptoms of
disease) and symptomatic manner were evaluated, among other conditions, in comparison to
normal subjects in Tobin et al. (1983). Out of 32 asthmatic patients 17 had asymptomatic
asthma while the remaining 15 had symptomatic asthma. The patients were tested in a
supine (lying down) position. Usual pulmonary function testing (PFT) components were
taken, such as VC, FRC, TLC, FEVi, and Raw and compared with the normal subjects PFT's.
Breathing parameters collected were frequency, f, (breaths/min), tidal volume, VT, (ml),
minute ventilation, V^, (L/min), inspiratory time, Ti; (s), fractional inspiratory time,
T/Ttot, mean inspiratory flow, VT/VT, (ml/s), the percentage of rib cage contribution to tidal
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volume, %RC/VT, and the ratio of the maximum compartmental amplitude to tidal volume,
MCA/VT. Data was taken and logged with a respiratory inductive plethysmograph.
Results for the asymptomatic asthma patients were virtually the same as the data
collected for normal subjects as seen in Table 3.17 whereas there are differences with
symptomatic asthmatics. Raw, VT and V^ are all increased in symptomatic asthmatics as
compared with normal subjects. The author states that these differences may be used to
distinguish asthma from COPD, ie. due to enlarged tidal volume and faster breathing.
The PFT values for COPD were quite standard for COPD PFT results compared to
normal, which included decreased VC and FEVi, and increased TLC and Raw. In COPD
patients there is an increase in frequency of breaths as compared to normals and asthmatics,
also a tidal volume that is larger than that of the normals but smaller than the asthmatics.
Another interesting and puzzling change is that the inspiratory time decreased. The authors
note that ambiguity in this result is that the decrease in inspiratory time would mean that
there is a decrease in compliance of the respiratory mechanics, meaning larger elastic recoil
of the lung that is typical of a patient with restrictive disease. Note, typically in COPD
alveolar elastic recoil pressure is diminished. Also the increase in Vt/Ti is usually the
phenomena when patients are performing the tests with amouthpiece.
Sanchis et al. (1990) analyzed breathing patterns in 14 patients with mild to moderate
upper airway obstruction and compared data with 28 normals. The breathing parameters^,
Ti; Te, and f were collected. Results are that tidal volume; expiratory time and minute
ventilation are all larger in normals than the obstructed cases. Frequency and inspiratory
time were greater in the obstructed.
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Bloch et al. (1997) presented data of ventilation in patients with severe emphysema
before and after lung volume reduction surgery. Breathing parametersV^ , Ttot, Tj, Te, and f
were collected in the supine position and the 60 head up position. Though surgery made
slight improvements in pulmonary function, values of ventilation did not deviate in before
and after cases.
Bennett et al. (1997) provided deposition data of inhaled particulate in COPD patients
breathing at normal resting conditions. Bennett et al. (1997) tested 13 COPD patients and 11
normals and collectedV^, Ttot, and VT. The results showed an increased tidal volume,
minute ventilation in COPD patients, and decreased total time for inhale and exhale.
Vitacca et al. (1999) presented data of tidal volume and minute ventilation in COPD
patients recovering from acute exacerbation. V^ , Ttot, Ti; Te, and f were collected. The
results for the COPD breathing parameters correspond well with other COPD data.
Ritz et al. (2000) set out to determine whether stress and emotion trigger asthma.
There were 24 asthmatics and 24 normals in the study. Patients viewed short films and
underwent two stressful tests. The short films were created to arouse sensations of anger,
depression, anxiety, happiness, contentment and the stressful tests were viewing of medical
slides and mental arithmetic challenges. Overall there was positive evidence that stress and
emotions could be triggers of asthma. In terms of ventilation, tidal volume and minute
ventilation were greater in non-asthmatics while frequency of breaths was larger in
asthmatics.
The different volumes of the lung, variance in breathing patterns, and resistance of
the airways will deviate with different disorders. Below in the following Figures 3.10a-f, the
parameters VT, FRC, Ti? Te, f and Raw, respectively, are compared for healthy normals,
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asthma, COPD and emphysema cases. PFT data is usually collected before any study to
assess and verify the condition of each subject in the study. Factor, F, in the figures is the
average factor of the disease compared to normal subjects. Error bars indicate the data
scatter from the different studies. Studies used to compile the data for VT, Ti; Te, and f are
listed in Table 3.17a along with the reported data. Studies listed in Table 3.17b and 3.17c
were used to compile data for FRC and Raw, respectively.
Table 3.17b - Articles of Functional Reserve Capacity
Functional Reserve Volume, FRC
Healthy Asthmatic COPD Emphysema
Tobin etal. (1983a) Kim and Kang (1997) Kim etal. (1988) Anderson etal. (1990)
Lourenco etal (1971) Colebatch etal (1973) Kim and Kang (1997) Roy etal. (1994)
Kim etal. (1988) Tobin et al. (1983b) Anderson et al. (1990) Tobin etal. (1983b)
Kim and Kang (1997) Roy etal. (1994)
Roy etal. (1994) Bosken etal. (1990)
Bosken etal. (1990) Colebatch etal (1973)
Colebatch etal (1973) Macklem andWilson (1965)
Smaldone etal. (1993) Tobin etal. (1983b)
Pelinkovic etal. (1997) Smaldone et al. (1993)
Green etal. (1989)
Table 3.17c - Articles of resistance of the airways
Resistance of the Airways, Ravi
Healthy Asthmatic COPD Emphysema
Kim etal. (1988) Siekmeier etal. (1994) Kim etal. (1988) Kohlhaufl etal (1999)
Siekmeier et al. (1994) Tobin et al. (1983b) Schiller-Scotland et al. (1996) Kohlhaufl et al. (2000)
Schiller-Scotland et al. (1996) Svartengren et al. (1996)
Kohlhaufl et al. (2000) Brand et al. (2002)
Bennett etal. (1997) Bennett etal. (1997)
Tobin etal. (1983a) Macklem andWilson (1965)
Hogg etal. (1968) Tobin etal. (1983b)
Hogg etal. (1968)
Moller et al., (2001)
Green etal. (1989)
Kohlhaufl et al (1999)
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3.4 Morphological Changes in Lung Disease - Airway Narrowing
3.4.1 Asthma Studies
The literature survey aimed at acquiring quantitative data on the amount of airway narrowing
in asthma and where it affects the airways. Seven articles presented an assessment of the
disease and also the regions that were studied.
The location of the area, in which the article's content dealt with, is labeled with
numbers on Figure 3.11. The following list shows the author and areas that they covered
within their article. As a reference, Figure 1.2 shows a cross-section of an airway which
further clarifies the measurements that were taken.
Article
Dunnill et al. (1969)
Hossain (1973)
Sabonya(1984)
James etal. (1989)
Ebina et al. (1990)
Saetta etal. (1991)
Kuwano etal. (1993)
Regions
mainly
-
OO
o
o
Generations, z
2-3
2-3
0-23
0-14
2-14
4-15
4-14
Figure 3.11 - Asthma articles organization of the airways, modified from Crystal et al. (1997)
Dunnill et al. (1969), studied distinctions of the bronchial wall components of
necropsied lungs (mucous glands, muscle, connective tissue, and cartilage, see Figure 1.2)
within a sample consisting of conditions of asthma, chronic bronchitis, and emphysema, and
compared that to a control group. Dunnill et al. (1969) stated the importance that bronchi
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with the same cross-sectional area of cartilage be used to compare the bronchi, rather than
internal diameter, due to the noticeable fact that cartilage cross-sectional area was a relatively
constant feature between the various cases. The results shown in Table 3.18 indicate that
muscle and mucous gland enlargement are the chief contributors for airway restriction. In
asthma there is both an increase in mucus glands and muscle percentage by factors of 1.84
and 2.59. In CB and E there is only an increase in mucus glands with corresponding factors
of 2.19 and 1.54 respectively, compared to the control.
Table 3.18 - Mean value percentages for components in bronchial wall in the four groups of cases,
modified fromDunnill et al. (1969), where SD is standard deviation
Normal (SD) Asthma (SD) CB (SD) E(SD)
Mucus Glands % 12.7 (2.7) 23.4 (5.4) 27.8 (8.7) 19.6 (6.1)
Muscle % 4.6 (2.2) 11.9(3.4) 5.8 (2.9) 5.5 (2.0)
Connective Tissue % 55.8 (5.2) 42.6 (4.0) 42.5 (8.4) 50.6 (9.8)
Cartilage % 26.9 (5.0) 22.1 (5.8) 23.9 (4.7) 24.4 (9.5)
Hossain (1973) created sections 10 pm thick along the airway, to see the extent that
muscle was increased in asthma. The airways involved were essentially the bronchus to the
basal segment and also posterior to that section, results are shown in Table 3.19. Hossain
(1973) found that in both cases BI (bronchus to basal segments) and B2 (bronchus to the
posterior basal segment) that the cross-sectional areas of the bronchial muscle of both male
and female groups were increased by factors of BI: 3.1 (M), 5.3 (F) and B2: 1.3 (M), 1.5 (F)
compared to the control. Hossain (1973) concludes that there is strong evidence that
narrowing of the large airways is due to contraction of the bronchial muscle.
Table 3.19 - Values for mean area of bronchial muscle in normal subjects and patients with Asthma,
Hossain (1973)
Male (M),
mm2 Female (F),
mmz
Bronchus Normal Asthmatic Normal Asthmatic
BI 0.50 1.54 0.66 0.84
B2 0.10 0.53 0.29 0.42
Sabonya (1984) studied autopsied lungs of patients who died of asthma. Bronchial
glands (%), bronchial muscle (%), area of bronchial muscle (mm2), and basement membrane
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thickness (pm) were all accounted for in the large bronchi. Sabonya (1984) expressed that
bronchial glands, muscle, area of bronchial muscle, and basement membrane all increased in
asthma, with the largest fraction being basement membrane thickness. Increase fractions
were 1.4, 1.4, 1.5, and 1.6, respectively. Sabonya (1984) believes that basement membrane
thickness is the sole parameter that differentiates asthma from the control.
James et al. (1989) examined the airways of autopsied lungs consisting of 18 patients
with asthma and compared them with 23 healthy lungs. The airways were split up into 4
categories based on internal perimeter: membranous < 2 mm and > 2 mm and cartilaginous:
<10 mm and >10 mm. This corresponds to essentially the trachea to the terminal/transitional
bronchiole. Raw data is shown in Table 3.20a and factors increased are shown in Table
3.20b. From the data, every category was enhanced by asthma except for the membranous
airways less than 2 mm in internal diameter, where the value stayed approximately the same,
thus implying that peripheral airway components are not affected in asthma.
Table 3.20a - Data of area (mm2) of epithelium, submucosa, and muscle in the airway walls, James et al.
(1989), A = asthmatic, N = normal
Airway Size (internal perimeter, mm)
Membranous Cartilaginous
< 2 mm > 2 mm <10mm >10mm
Epithelium
A 0.030mm2 0.156mm2 0.46mm2 0.88mm2
N 0.018mm2 0.069mm2 0.18mm2 0.56mm2
Submucosa
A 0.020mm2 0.135 mm2 0.73mm2 1.35mm2
N 0.010mm2 0.049mm2 0.20mm2 0.71mm2
Muscle
A 0.015mm2 0.152mm2 0.67mm2 1.57mm2
N 0.014mm2 0.051mm2 0.14mm2 0.46mm2
Table 3.20b - Factors that area (mm ) of epithelium, submucosa, and muscle in the airway walls were
increased, modified from James et al. (1989)
Membranous Cartilia i>inous
<2 mm >2mm < 10 mm > 10 mm
Epithelium sl.67 = 2.26 = 2.55 = 1.57
Submucosa = 2 = 2.75 = 3.65 = 1.9
Muscle = same = 3 = 4.75 = 3.5
Ebina et al. (1990) studied the whereabouts and reason of muscular hypertrophy
(exaggerated growth) within the TB. Autopsied lungs of 16 people who died of asthma and
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13 people with COPD were morphometrically studied. The results of their study concluded
that there were two types of asthma defined by where the hypertrophy was acting. Asthma I
was defined as hypertrophy of the larger bronchi while asthma II involved the patients total
airways affected by hypertrophy. Table 3.21 describes the raw data that thickness
distribution of airway smooth muscles are increased in asthma compared to the control. As
the table indicates there is a significant factor that muscle thickness is increased compared to
normals. Asthma muscular thickness is dominant among COPD, CB, and normals.
Table 3.21 - Muscular thickness distribution of airway smooth muscles, from Ebina et al. (1990)
Large Bronchi Membranous Bronchioles
D(um)
D =Muscular thickness
D(pm)
D =Muscular thickness
Control 12.4 5.6
Asthma Total 44.1, f= 3.6 9.2, f= 1.6
Type I 64.6, f= 5.2 5.6, f= 1.0
Type II 32.8, f= 2.6 11.5, f=2.1
COPD 26.8, f= 2.2 6.6, f= 1.2
CB 25.6, f= 2.1 7.2, f= 1.3
Saetta et al. (1991) studied the peripheral airway region (non-cartilage and non
respiratory bronchioles) for changes in airway lumen. The lungs involved in this study were
not pressurized due to the airway internal perimeter being relatively constant despite changes
in smooth muscle tone and lung volume, which was researched by James et al. (1988).
Results that Saetta et al. (1991) observed were an approximate 3.5 factor increase in lumen
occlusion in the airways of the asthma patients, with lumen occlusion representing the
fraction of the luminal space that is blocked by mucus and inflammation, etc. From Table
3.22 the data seems ambiguous noting the lumen occlusion being significant, while the
internal diameter of asthma and the control are very similar. Wall thickness and muscle
percentages deal with percentages of the cross-sectional wall area of the airway.
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Table 3.22 - Results of Saetta et al. (1991) survey of the peripheral airways
Internal
Diameter
(mm)
Internal
Perimeter (mm)
Lumen
Occlusion
(%)
Wall
Thickness
(%)
Wall
Muscle (%)
Asthma, X 0.56 3.01 55 15 62
Normal, X 0.53 2.80 16 9 18
As in Saetta et al. (1991), Kuwano et al. (1993) also inspected the peripheral airways
(non-respiratory and cartilage containing airways) of subjects with asthmatics (non-fatal and
fatal), and mild COPD in comparison to normals. For their analysis they used a technique
proposed by Feldman et al. (1988), which deals with a weighted averaging approach to
produce a mean relationship to compare parameters with. Kuwano et al. (1993) states that
the order in which the membranous airway wall thickness is greatest to least occurs in fatal
asthma > non fatal asthma > COPD > control, and that diminution in the airway diameter
may be a result of an increase in submucosal vascular volume. No quantitative data was
given in the article.
3.4.2 COPD Studies
Ten articles presented an assessment of the disease and also the region that they were
studying. Again Figure 3.12 shows one complete path within the TB. The location of the
areas in which the article's content dealt with, are labeled with numbers on the figure.
Dunnill et al. (1969) and Ebina et al. (1990) results for emphysema and chronic bronchitis
were presented in Table 3.18 and 3.21 of the previous section 3.4.1. Qualitative results for
Kuwano et al. (1993) are also presented at the end of section 3.4.1.
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Article
Anderson & Foraker (1962)
Macklem et al. (1965)
Hogg et al. (1968)
Dunnill et al. (1969)
Macklem (1971)
Depierre et al. (1972)
Ebina et al. (1990)
Bosken et al. (1990)
Kuwano etal. (1993)
Kikawada et al. (2000)
Regions
o
o
o
-
G
-
-
Generations, z
-11 -14
0-23
4-14
2-3
see section 3.4.1
4-14
4-14
2-14
see section 3.4.1
3-14
4-14
see section 3.4.1
4-14
Figure 3.12 - COPD articles organization of the airways, modified from Crystal et al. (1997)
In order to clarify the resistance of the airways in emphysema, Anderson & Foraker
(1962) performed strict measurements on the area of bronchial wall components specifically
at the end of the peripheral region - terminal bronchiole - of the conducting tubes, in
autopsied lungs of normal (N) subjects and emphysema (E) patients. On average
parenchymal space was enlarged in the emphysema patient's lungs, which is what should be
found due to the classic definition that emphysema involves an enlargement of the distal
airspaces with degenerated partitions between the airspaces. The degree of enlargement was
not fully appreciated and the author notes that there was excessive inconsistency among the
size ranges. The values of mean cross sectional areas of individual parenchymal space were
5.71E+4 pm2for E compared to 3.45E+4
pm2for normals (factor of 1.7). Terminal bronchial
lumen cross-sectional area proved to be significantly occluded compared to the normals, the
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values were 5.18E+4 pm2 vs. 31.78E+4 pm2 (factor of 6.1). Terminal bronchioles in the TB
are the maximum site of resistance in the conducting airways due to having the smallest
diameter. As the numbers show this diameter was decreased by a factor of ~ 2.5, hence
resistance in the terminal bronchiole, according to Poiseuille's law, Equation 3.4
*~=^ (3-4)
nr
would be increased by a factor of 37. Bronchiolar wall area/bronchiolar lumen area ratio was
calculated by the authors, in which they concluded that the excessive increase in bronchiolar
wall area collapsed the airway therefore constricting the lumen, the values were (E: 3.41 vs.
N: 0.60). Supporting ratio for the collapsed airway was alveolar attachment/bronchiole, this
as expected was also decreased (E: 10.42 vs. N: 16.41).
Macklem et al. (1965) examined 9 patients with mainly emphysema to figure out the
characteristics of how the disease affects the airways. The authors gathered information of
bronchial pressures concurrently with esophagel pressure, lung volume, and flow at the
mouth, to locate airway obstruction. Two graphs were analyzed: bronchial pressure versus
flow-resistive pressure and flow versus flow-resistive pressure. 3 sections of the airways
were represented in the graphs: alveolus to segmental bronchus, segmental bronchus to main-
stem bronchus, and main-stem bronchus to mouth. Bronchial pressure versus flow-resistive
pressure shows the pressure drops between the 3 sections based off of a line of identity.
Flow versus flow-resistive pressure demonstrated an index of peak flow. The patient's
relationships given by the graphs fell into three categories, obstruction of the small airways,
obstruction in the large airways, and obstruction in both small and large airways. Through
their analysis of bronchial pressures the authors concluded that the large and small airways
both experienced changes that result in an obstruction in the airway. The small airways had a
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relatively fixed resistance in inspiration and expiration, and were not a function of change in
lung volume, while the large airways obstruction was sporadic, only apparent on expiration,
and did have a relationship with change in lung volume. No quantitative data for
morphometry measurements were given.
Hogg et al. (1968) performed measurements of resistance (central, peripheral, and
total) in autopsied lungs of normals and COPD persons. They utilized a catheter (through the
bronchial wall, parenchyma and pleural surface) that was lodged into the small bronchus
airways that have a dimension of 2 to 3 mm in internal diameter. With the catheter in place
resistance was found by the following equations:
P -P P -P"o ct n _ * ct
V
'
V
Rc= a\y ,Rp = rr.r (3.2)
where Rc and Rp are the central and peripheral resistance, respectively, V is flow-rate, Pao is
pressure at airway opening, Pct is pressure at the catheter tip, and Pa is alveolar pressure. As
Table 3.23 shows, the peripheral resistance is a factor of 14 larger than the normal cases.
This was attributed to mucous plugs and diminished number of airways in the peripheral
region. No quantitative data for morphometry measurements were given.
Table 3.23 - Results of total, peripheral, and central resistance at 5 cmH2Q, Hogg et al. (1968)
Total Peripheral (<2-mm
internal diameter)
Central (>2-mm internal
diameter)
Normal 0.69 0.18 0.51
COPD 3.03 2.52 0.51
Factor 4.4 14 0
Macklem et al. (1971), studied case histories and autopsied lungs of seven COPD
persons. Upon their examination the only conclusion was that in all of the cases, the
peripheral airways (smallest bronchi and bronchioles) were inflamed or blocked with mucous
plugs, therefore hindering gas exchange. This study was mainly qualitative, but reiterates the
on-going conclusion that the small airways are a main factor in COPD.
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Also dealing with the peripheral or membranous bronchioles was Depierre et al.
(1972). They examined 42 autopsied lungs of panlobular, centrilobular, minimal, and
miscellaneous emphysema in search of a quantitative description of the changes in internal
diameter of bronchioles that various cases of emphysema bring about.
The way the authors assessed, quantitatively, the extent of narrowing within these
lungs was through the variable Br<350 pm (%), which means percentage of bronchioles with
internal diameter less than 350 pm. The results show that the percentage of bronchioles with
internal diameter less than 350 pm is increased across the board for different cases of
emphysema. Factors compared to normal are: panlobular ~ 2.0, centrilobular ~ 3.2, minimal
~ 2.9, and miscellaneous ~ 2.3. Concluding remarks by the authors reiterate much of the
qualitative research pertaining to characterizing emphysema/COPD cases. The decreased
lumen diameter is due to a markedly increase in mucus plugs and inflammation of the airway
wall coupled with stenosis of the lumen, as seen in Figure 3.13, therefore resulting in gas
trapping in the alveolar duct.
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Figure 3.13 - Stenosis of the lumen, Depierre et al. (1972)
Bosken et al. (1990) studied 60 patients lungs for the dimensions and to quantify
airway wall components. The measured parameters were wall area, mm , perimeter, mm,
and diameter, mm. Calculated from those parameters were relaxed luminal diameter, mm,
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and wall thickness, mm. The numbers collected from this experiment conclude that luminal
diameters were decreased, airway narrowness was increased, and wall components were all
slightly increased within the obstructed patients. Measured luminal diameter for the
membranous airways only, was decreased with values of 0.61 mm compared to the controls
of 0.74 mm. Degree of narrowing, which is the luminal area/calculated luminal area was
0.39 for obstructed vs. 0.34 for normal. Inner and outer wall thicknesses were both increased
somewhat with the inner values being obstructive: 0.068 mm vs. control: 0.056 mm and outer
values being obstructive: 0.064 mm vs. control: 0.050 mm. Wall thickness and airway size
were also calculated as shown in Table 3.24:
Table 3.24 - Airway characteristics for control and obstructed, from Bosken et al. (1990)
Control Obstructed
Measured luminal diameter, mm 0.81 0.70
Measured luminal diameter, mm -
membranous airways only
0.74 0.61
Perimeter, mm 3.77 3.47
Degree of narrowing 0.34 0.39
Inner wall thickness, mm 0.056 0.068
Outer wall thickness, mm 0.050 0.064
Kikawada et al. (2000) used an ultra-thin bronchoscope to detail the airway
composition and characteristics of people who were normal, had chronic bronchitis, and had
emphysema. The bronchoscope had an outer diameter of 1.8 mm, which was able to
penetrate down to the 11th or
12th
branching or generation of airways (non-Weibel generation
representation). This was a refreshing article due to the authors being able to physically see
the deviations, in vivo, from the normal airways; the only downfall is that the bronchoscope
would not be able to travel the whole distance to the alveolar sac. Along the bronchoscopes
travel, the authors noted color of the bronchial mucosa, morphological changes, and
existence of secretions and obstruction. The notable results were in chronic bronchitic
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patients. Sporadic secretions were prevalent in the central airways while in the
S^*
branches of the peripheral to the end branch that the bronchoscope could probe, there was a
constant layer of secretions. In emphysema, the central airways were comparable to normal
while the peripheral airway walls revealed a
"net-like"
manifestation. Obstruction was seen
at the 1 1th and 12th branching.
3.4.3 Asthma and COPD Summary
Compilation of respiratory ailment data from Sections 3.4.1 and 3.4.2 is shown in Table 3.25.
The summarized data from the disease modification articles are in terms of factors of normal.
For example, in Bosken et al. (1990), wall thickness in generations 1-14 in a COPD patient is
increased by a factor of 1.2 compared to the healthy control sample. Only articles that
provided quantitative data were included in Table 3.25.
Table 3.25 - Summary of geometry modification articles results
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3.5 Morphological Changes in Lung Disease - Alveolar Degeneration
3.5.1 Overview ofADAM
Aerosol-derived airway morphometry (ADAM), summarized by Blanchard (1996), is a
current technique used to find the relative calibers of airways and acini using the
gravitational settling of particles for given breath hold. ADAM does not require an invasive
procedure to examine patient's peripheral lung regions and it is relatively straightforward to
practice. The procedure involves mono-disperse particles that are inhaled and settle on
different surfaces at various lung volume depths. The particles used in this method are
frequently of larger size, 0.8-1.0 pm, so that the deposition of particles will not exhibit
diffusion mechanisms. Particle recovery is taken into account concurrently and is expressed
as the ratio of exhaled/inhaled particles by number or by concentration. A relationship of
particle loss to breath hold time is acquired and a derivative of the relationship gives the rate
of particle loss for the maneuver. Fundamental theory of ADAM is that the rate of particle
loss is inversely proportional to the relative size of the airway, thus, the smaller the airway
the larger rate of particle loss.
According to Blanchard (1996), there are two theoretical models for determining
effective airspace dimensions, EAD, those being the tube model and chordlength model.
Tube model is basically modeled by a set of random oriented cylindrical tubes in which
particles deposit, while in the chordlength model particles settle along pathlines defined by
dimensions of acini. Both models depend on particle sedimentation length, the product of
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particle settling velocity and breath holding time. The following 6 articles used the technique
of ADAM to predict the extent to which the airspaces in the peripheral of the lung were
increased.
3.5.2 COPD, Asthma, and other studies
Beinert et al. (1995) performed ADAM on 25 patients of COPD and 36 healthy subjects to
gauge the dimensions of the peripheral airways of the lung. They also analyzed a subset of
the patients with computed tomography another method that is used to assess lung condition.
The EAD region the authors were most interested in was at 800 ml volumetric lung depth,
which is representative of generations 21 - 23 in theWeibel model. The EAD measurements
showed that the dimension of the airspace is increased by a factor of 2 in a patient with
COPD, (N: 0.39 0.05 mm, COPD: 0.82 0.33 mm)
Bennett et al. (1997) studied the deposition of fine particles within patients ofmild to
severe COPD and normals. As one of the ways to assess the differences in COPD and
normals, EAD results from the alveolar section of the lung were collected. The results of the
EAD technique were that COPD patients had an EAD of 0.73 (0.24) mm while the normals
had 0.44 (0.10) mm, where the number in the parenthesis is the standard deviation. The
results of the COPD EAD data was that deposition is actually reduced with increasing
effective airspace in the alveolar region, thus proving that in COPD most of the deposition
comes from the CB affected airways.
Kohlhaufl et al. (1998) presented EAD data in normals, and CB patients with and
without E. CB and E are essentially defined as COPD. The EAD data was taken at a lung
depth of approximately 819 95 mL which corresponds to the peripheral airways
(pulmonary region). The results show that normals EAD was 0.34 0.05mm, CB was 0.37
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0.02, and CB+E was 0.86 0.07 which indicates that EAD is accurate in distinguishing if a
patient has E with CB due to enlargement in EAD.
Zeman et al. (1999) utilized EAD measurements to examine the transitional
bronchiole region (D (see Figure 3.12) in healthy children, adults, and older adults, and also
older adult COPD patients. The authors obtained graphs of EAD (mm) vs. % relative
volumetric lung depth (VLD/VO, where Vj is lung volume. When there is a sharp change in
the slope of the relationship, it relates to the terminal bronchiole, the point of the peripheral
airways where there is different branching patterns, see Figure 3.14. The results are shown in
Table 3.26. Lung volume depth (Vd) and corresponding generation were decreased while
EAD was increased by a factor of =1.98.
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Figure 3.14 - EAD vs. % relative volumetric lung depth, Zeman et al. (1999), noteVLD is Vd
Table 3.26 - Transitional bronchioles VLD, EAD, and generation, from Zeman et al. (1999)
Normal Adults COPD Patients
VLDtrans, ml 345 83 21664
BAD,,,,, Him 0.42 0.07 0.83 0.40
Generation 19.0 0.6 15 1.8
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Kohlhaufl et al. (1999) compared the method of CT to ADAM and aerosol bolus
dispersion on patients of emphysema and a mixed bunch of conditions (chronic bronchitis,
lung fibrosis, bronchiectasis, asthma, and pneumonia). EAD measurements were taken at Vd
of approximately 830 ml that corresponds to essentially the peripheral pulmonary airways.
Values of EAD for both cases were as follows: Emphysema patients had an EAD of 0.84
0.53 mm compared to 0.33 0.10 mm of subjects with other respiratory disorders.
Kohlhaufl et al. (2000) was again involved in producing EAD measurements, this
time they investigated patients of emphysema (E) and pulmonary fibrosis with emphysema
(FE). Vd was approximately the same as the other articles around 755 ml. Obtained EAD
values were: N: 0.28 0.05 mm, E: 0.63 0.20 mm, and FE: 0.60 0.27 mm. A summary
of all the EAD results collected is given in Table 3.27.
Table 3.27 Summary ofEAD geometry modification articles results
Anatomic Location
Wiebel
Generations
EAD (Factor
increase over
normal)
Patient
Diagnosis
Beinert etal. (1995) Beyond conducting airways at 800 ml depth 21-23 2.10 COPD
Bennett etal. (1997) Alveolar ducts, sacs and alveoli 17-23 1.66 COPD
Kohlhaufl etal. (1998) 819 ml depth 17-23 2.53 COPD
Kohlhaufl etal. (1998) 819 ml depth 17-23 1.08 CB
Zeman etal. (1999) Transitional bronchial ~200ml 15 1.98 COPD
Kohlhaufl etal. (1999) 830 ml 17-23 2.55 E
Kohlhaufl et al. (2000) At 755 ml depth 17-23 2.25 E
Kohlhaufl et al. (2000) At 755 ml depth 17-23 2.14 FE
3.6 Physiological Changes in Lung Disease - Elasticity
The analysis of elasticity (or inversely, compliance) is usually attained from laborious plots
of lung volume versus transpulmonary pressure. Lung volumes are accomplished by
spirometry and transpulmonary pressure is by esophageal balloon. Percentage of predicted
TLC is sometimes used rather than lung volume for reduction of inconsistency among
subjects. Static lung compliance can be obtained from the slope of this graph. Simply,
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compliance is the ease at which the alveolar sac can expand. Elasticity is the inverse of
compliance, which is a measure of how much resistance that material or object has to being
stretched or expanded. The relationship between percentage of predicted TLC and
transpulmonary pressure is approximately a linear relationship. A graph of emphysema
compared to normals will show a greater slope and a shift to the left, while asthma will
essentially have the same slope as the normals relationship but will be increased in volume
and shifted to the left during an attack, refer to Figure 1.9.
Greaves and Colebatch (1980) studied the elastic behavior between emphysema and
normal states. They used an exponential function to describe a pressure-volume curve rather
than a linear function. Compliance is normally extracted from the PV curve by taking a
slope from the graph, but the authors state that there is error in this method due to the
relationship being non-linear. They fit a relationship ofV = A -
Be'KP
which expresses the
graph relationship. A, B, and K are constants, P is static recoil pressure, and Vi is the lung
volume. They state that K is a measure of the elasticity and that it is closely related to a
measurement of mean alveolar size. K quantifies the shape of the pressure-volume (PV)
curve independently of lung volume. The resulting equations 3.3 and 3.4 show the
relationship between elastic behavior and structure:
K (cm H2O1) = 0.8995 Lm (mm) - 0.0259 (3.3)
K (cm H2O1) = 3.196
10"3 %E + 0.2531 (3.4)
where Lm is the mean interalveolar distances and %E is the amount of emphysema present.
In this study, K for of the subset of emphysematics proved to be a factor of 2.2 times the non-
emphysematous sample.
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In Baldi et al. (2001), the authors investigated whether there was any correlation
between the amount of emphysema and lung mechanics using CT. Though they did not find
any usefulness in the correlations, they did find that the value ofK, a measure of elasticity,
was 258 116% ofpredicted value. Their needs to be more work in gathering articles on the
subject ofelasticity.
3.7 Models of Physiological Changes in Lung Disease
A subset of the literature on airway narrowing and/or resistance from disease dealt with
simulating airway constriction by exploring various theories or known facts to produce a
computational model that outputs a corrected constricted diameter and the corresponding
change in resistance. The following is an overview of the equations and parameters that were
discussed and presented in each of the articles. An accompanying Figure 3.15 was made to
clarify terms and locations ofvariables.
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Figure 3.15 - Schematic of airway cross-section for modification model articles, picture inspired by James
et al. (1988) andWiggs et al. (1990) and created by E. M. DiFlorio
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Moreno et al. (1986) researched and modeled airway narrowing based on airway
smooth muscle (ASM) shortening and changes in airway structure. Details for full
generation airway narrowing were not a goal of this article. The scope was more
fundamental, laying the groundwork for analyzing what happens to an airway upon an attack.
Based on experimental irritant challenge tests the authors propose that a main factor in
airway narrowing is ASM. Moreno et al. (1986) set up a flow chart for the sequence of
airway narrowing based upon a response from a foreign particulate, see Figure 3.16. Upon
stimulus (foreign body inhalation) the ASM is triggered based upon a dose-response curve
and subsequently shortened. The dose-response curve is essentially the relationship of the
irritant dose to diameter of the airway decrease due to the irritant.
Stimulus
<0
>. Agonist receptor
interaction
ASM Activation
& <P
ASM Shortening
Length-tension load,
amount of ASM
contractility, Dose
Response Curves
&
i1Airway Lumen
Proportion of
^ muscle in the airway
circumference
<0 <P
^External Diameter
Wall thickness
secretions
^> C11 Flow regime
*R.
Figure 3.16 - Sequence of airway narrowing,Moreno et al. (1986)
The different parameters that effect ASM are proportion of muscle in the airway
circumference (PMC), proportion of the airway cross-section that is wall area (PW), and
excessive mucus secretions within the airway. All of theses effects decrease airway lumen
and external diameter of the airway, while increasing the resistance of the airway.
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Moreno et al. (1986) presents several trends that establish the methodology for
narrowing an airway. The first trend established the relationship of ASM, PMC, and percent
decrease in external diameter. The result is that as PMC increases, external diameter
decreases linearly for a given ASM shortening percentage. The relationships shown within
the article have different value isopleths of PMC that range from (0.2-1). The axis's of the
graph with the PMC isopleths are % decrease in external diameter (0-80) versus % AMS
shortening (0-80). An isopleth is basically a curve on a graph represented by two variables.
The result of this first trend is intuitive. The more muscle that is present in an airway wall
upon ASM, the smaller the external diameter due to the contraction of the muscle, thus
creating a small lumen space.
The second trend was a relationship between PW, ARaw, and % decrease in external
diameter. The isopleths are PW and have values of 0 to 0.4. The y-axis is ARaw (0-1000)
while the x-axis is % decrease in external diameter (0-80). Essentially the greater the
difference in Raw the more percentage decrease in external diameter there is. The
relationship is exponential and the isopleths of PW show that the larger the value of PW the
closer to the y-axis (shifting to the left) they get. Again the trend is intuitive; the more
resistance in the airway is associated with an increasingly contracting airway. The PW
shifting to the left is counter-intuitive. The larger the proportion that wall area takes up of
the whole airway cross-section, the less percentage decrease in external diameter is present.
Moreno et al. (1986) states an additional conclusion that upon airway contraction the wall
area that is present stays the same value upon external diameter contraction. There is no
reference for this conclusion, but they use it to produce their conclusions within the
mathematics.
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Moreno et al. (1986) start out with the relaxed airway, which can be assumed
concentric circles of external radius (Rer) and internal radius (Rir). From geometry the
perimeter of the airway will be
Per = 2*Rer (3.7)
Next since proportion of ASM (PMS) and PMC both affect % decrease in external diameter
of the airway they are multiplied with Per to reflect a decrease in external perimeter of the
airway
Contraction effect = PMS x PMC xPer (3.8)
Therefore the contracted perimeter would be
Pec = 2nRec = 27iRer - PMS x PMCx Per (3.9)
or solving for the contracted external radius (Rec)
Rec = Rer ~ Rer X PMS * PMC (3.10)
The mucosal area, wall area, is calculated next which Moreno et al. (1986) describes as the
proportion of the airway cross-section that is airway wall
Mucosal Area (WallArea) = 7fo]T x PW (3.11)
Therefore the lumen area of the airway in a contracted state (A,c) is calculated straightforward
by
Aic=nRl-nR*rxPW (3.12)
Finally the internal radius of the contracted airway can be found since,
4=^=<-<xpw
solving for RiC gives,
Ric=4Rl-R>pw (313>
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or using Equation 3.10 substituted into Equation 3.13 for Rec gives,
Ric = RerJ{l - PMS x
PMC)1
- PW (3.14)
James et al. (1988) followed up on Moreno et al. (1986) by proving that throughout
various airway smooth muscle (AMS) shortening conditions, internal perimeter of the airway
and wall area within the airway cross-section are equal in the relaxed and contracted states.
Autopsied lungs of 3 smokers were used in the analysis. The airways were examined in each
of the 3 specimens by use of a microscope fitted with a camera in which the image was
scanned into a computer. From the computer screen, measurements were made of internal
perimeter (Pi), internal area (Aj), external perimeter (Pe), and external area (Ae). The internal
area boundary was the luminal surface of the epithelium while external area boundary was
outer edge of the smooth muscle layer. From the measurements wall area (WA) was
calculated from
WA = At-Ai (3.15)
The relationship of square-root ofWA versus Pj was made to justify that indeed the wall area
remained constant. The author notes that the square-root was used to make the relationship
linear.
James et al. (1988) used 2 methods to estimate the amount of smooth muscle
shortening within an airway. The first method was based on geometric calculations. The
obtained quantities stated before were Pi; A, Pe, and Ae. The assumption of the first method
is that the relaxed airway radii are concentric circles. The author's equations were re-derived
to verify their conclusions. Therefore, the relaxed internal area is
K= (3-16>
An
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The relaxed external area is
Atr = Afr+WA (3.17)
External relaxed perimeter turns out to be
Per=2^r (3.18)
These equations are used to provide an equation of Per as a function of P; and WA by
substituting Equation 3.16 and 3.17 into Equation 3.18. The resultant is
Per=^P?+4x-WA (3.19)
The percent of airway smooth muscle shortening is calculated by
PMS =
(P -P^
er ec
V rer J
xlOO (3.20)
The second method graphed relationships between P- and P^ for the relaxed set of
airways (theophylline treated). On another graph the different PMS isopleths were made
from the relaxed airway and plotted on the graph. Data points from the contracted airway of
Pec and PiC were then graphed on the same graph as the relaxed PMS isopleths. On both
figures there is also a line that reflects results from the calculated method 1 that is
represented by a dashed line.
The results for the contraction of airway dimensions show that there is no difference
between the relaxed and contracted relationships of the square-root of WA versus Pi. This
also alludes to WA being independent of ASM shortening. From the relationships, 4 groups
were made, separated by Pi size and region (membranous and cartilaginous). The contracted
data shows that Ai, Pe, and Ae were all smaller than the relaxed state which makes sense.
The results from AMS shortening show slight differences between method 1 and
method 2. The differences occur because of inexact airway cross-section match-ups. The
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overall consensus from the analysis summarizes that over a range of AMS shortening, P; and
WA are constant in relaxed and contracted states. Furthermore James et al. (1988) states that
these relationships can be used to accurately predict airway geometry in various states as well
as ASM shortening.
James et al. (1989) further promoted the former conclusion about internal perimeter
and wall area being constant in relaxed and constricted states to calculate the representative
relaxed airway of a constricted airway. Again values of Pi, Pe, Ae, and A; were measured
with the addition of wall area and different wall area components. The wall components
were epithelium, submucosa, and muscle. General inspection of the tabulated results gives
approximately a factor of 2-3 increase in wall thickening due to asthma. The same equations
of the last article were used to construct the relaxed airway.
Wiggs et al. (1990) developed a model based onMoreno et al. (1986) and James et al.
(1988 & 1989) conclusions about airway narrowing and applied it to calculating resistance of
the airway. This model employed symmetric and asymmetric TB values for use in predicting
resistance. The symmetric lung dimensions were based on Wiebel (1963), where the
asymmetric lung data were based on articles by Horsfield et al. (1971) and Raabe et al.
(1976). The symmetric method is of importance for current research. In Weibel (1963), the
airway dimensions were at a 75% maximally inflated lung situation; therefore to produce
airway dimensions for normal respiratory ventilation, the airways required scaling. The
dimensions were modified using an equation of Lambert (1982), Equation 3.21, which
tailored the dimensions to simulate dimensions at FRC volume.
-N
A =1.0-(l.0-an.0-% (3.21)
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where a and N are constants for each generation of the TB, P0 is the pressure from the
experiments morphological measurements, P is the desired pressure, and A is a fractional
quantity of current area of the airway over the area at TLC.
By use of the equation of Pedley et al. (1970), Equation 3.22, and the known
diameters and cross-sectional areas of the airways from Wiebel, the associated pulmonary
pressure drop and resistance of the TB can be accounted for. The equation had the form of
z=4{Reif <3'22)
where C is an experimental constant (-1.85), Re is the Reynolds number, d is the airway
diameter, and 1 is the length of the airway. The transforming equations were classical fluid
dynamic equations based on rigid, smooth cylinders with no heat transfer. Airway smooth
muscle contraction and shortening as described before in previous articles is an important
characteristic to add in disease. Wiggs et al. (1990) utilizes the equations fromMoreno et al.
(1986) Equation 3.14 is transformed into
K =M-ms-nicf[Ki*)- (3-23)
y \ Tt ) 71
and the definition of proportion of the cross-section that is wall area is
WA
PW = (3.24)
WA + Air
The variables are the same as expressed before in previous articles. PW is the proportion of
the wall and relies on information of airway wall data and luminal area (A*) of the entire
range of airway generations. Wiggs et al. (1990) used the data from James et al. (1988)
where they measured wall area data in autopsied people who died of chronic lung disease.
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The data was expressed by a regression equation of the relationship square-root of wall area
versus perimeter of the lumen border. An example of the equation is as follows:
JWA{mm2) = 0.076277 + 0.9658 1 Pt {mm) (3.25)
The criterion for use of this equation is that the perimeter of the lumen border must be scaled
up to the inflated state at TLC. The main conclusion from James et al. (1988) was that
internal perimeter of the airway stays constant throughout airway modification. Use of their
relationships, for example Equation 3.25, is based on the airway being fully inflated so that
the airway resembles a complete circle. The original Weibel is at the 75% inflated state of
TLC. Wiggs et al. (1990) inflated and deflated airways by the pressure-area relationships of
Lambert (1982). Inflation and deflation of the airways was based on three defined pressures
representing the experimental and/or assumed conditions. The pressures were 8 cmH20 for
Healthy-Weibel conditions, -30 cmH20 for 100% TLC and 5 cmH20 for FRC volume
pressure. In summary, Wiggs et al. (1990) inflated the airways to 30 cmH20 and found what
the diameters increased to, then used the diameters in the Pi calculation to findWA. Next, as
discussed a little later, Wiggs et al. (1990) deflated the diameters to FRC (5 cmH20) using
the pressure-area scaling equations to adjust for FRC volume to find the parameter dv.
Wiggs et al. (1990) also accounted for shortening of the muscle by using the basic
expression from Woolcock et al. (1986) that produces the proportion that muscle has
shortened relative to its starting length. The expression is:
]Qa+p\ogl0{dose)
dose response =
i + lQa+/}lo$io(dose)
(3-26)
where a and /? are constants that shift the S-shaped dose curve. The expression was modified
to:
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PMS = K '
( in" >\10
1 + 10*
( \c\a \
1-
10
xPMS. (3.27)
1 + 10"
where or and 0 in the analysis were -1.9 and 1.2, respectively, PMSn is assumed (0-40%)
and PMS is calculated for a particular dose. For this particular article the values for PMSn
and PMS were 20% and 16%, respectively. Values of PMC for Weibel generations were as
follows: 0 to 1: 0.33, 2: 0.66, and 3 to 23: 1 based on the data collected from autopsied lungs.
The contracted internal diameter after some amount of smooth muscle shortening was
represented by:
D. =
rD2
WA
4 lOOfl"
[{l-PMSxPMC)2-PW (3.28)
where Dv is a volume corrected relaxed diameter based on equations of Lambert (1982).
Wiggs et al. (1990) made use of a spreadsheet to program the relevant equations to produce
the corrected constricted diameter and related resistance for each generation.
Wiggs et al. (1992) uses the theory from Wiggs et al. (1990) with the exception that
Wiggs et al. (1992) uses collected data of wall area and internal perimeters and established
linear relationship between the two variables for asthma and COPD patient situations from
James et al. (1989) rather than James et al. (1988). The equations for COPD and asthma are
listed in Table 3.28. The contracted internal diameter values are given below in Table 3.29.
Table 3.28 - Relationship between square-root of wall area vs. internal perimeter, Wiggs et al. (1992)
Subject Type
Surgical Control
Surgical Obstructed (COPD)
Autopsy Control
Autopsy Asthmatic
Intercept
0.1043
0.1425
0.0548
0.0618
Slope
0.0958
0.1013
0.1032
0.1482
IT
0.83
0.79
0.92
0.94
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Table 3.29 - Results of contracted diameter for asthma, Wiggs et al. (1992)
Generation Weibel 1963 Contracted Internal Diameter (cm) Res. ofGen. (cmH20/L/s)
0 1.8 1.340 .268
1 1.221 0.909 .283
2 0.828 0.501 .684
3 0.562 0.250 2.47
4 0.445 0.197 2.92
5 0.351 0.154 2.51
6 0.281 0.122 2.06
7 0.227 0.098 1.62
8 0.186 0.079 1.22
9 0.154 0.065 .886
10 0.130 0.054 .615
11 0.110 0.045 .410
12 0.095 0.038 .300
13 0.083 0.032 .240
14 0.073 0.028 .185
15 0.065 0.024 .136
16 0.059 0.021 .096
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Chapter 4 - DepositionModel
4.1 Trumpet Model: Transport and Deposition of Particles
The model to be used for particle deposition predictions was originally developed for stable,
neutral, monodisperse particles (Taulbee and Yu, 1975; Yu, 1978; Yu and Diu, 1983) and
later altered to include coagulation, hygroscopic growth and particle-particle interaction or
cloud behavior by Robinson and Yu (2001) and Broday & Robinson (2003). The deposition
model treats the airways as a one-dimensional distributed system in which the airway depth
or the generation number is used as an independent variable. Transport and deposition of
inhaled particles will be determined by integrating the general dynamic equation over the
cross-sectional area of the respiratory airways, yielding the average rate of concentration
change per unit airway length. Assuming uniform airway expansion and a uniform velocity
profile, and neglecting axial diffusion, the transport equation in the direction of flow x, along
the airways, takes the form Yu, (1978)
(4.1)
Hyg)
where Ai and A2 are, respectively, the summed cross-sectional areas of the airways and
alveoli at rest, /? is an expansion factor relating tidal volume to lung volume at rest, and rjk is
the deposition collection efficiency also in variable form as DCE, per unit airway length due
to the combined mechanisms of impaction, sedimentation, and diffusion. The third term in
Equation 4.1 represents loss by deposition on the airway surfaces per unit length, which can
be written as
AA+a2)^ = -v^-l,+AA +A) dt +Coog dt
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Lk = Vnkrjk (4.2)
The DCE equations for impaction, sedimentation, and diffusion are as follows.
Impaction equations are used from Zhang et al. (1997) and shown in Equations (4.3a-d)
11* = 0.000654 exp 55.7
fstc
V * J
\
ReV3-sinr?
(4.3a)
If StC./2is<0.04
V,l.k 0.19 -1.93 exp -9.5
StC.
.1.565 ^
ReV3-sinr9
If StC.12is > 0.04
TJ,.k = 0.000425exp 22.7
StC,
0.832~1\
(4.3b)
Re173
sin9,
(4.3c)
If StC /2 is < 0.07
V.l.k 0.19-0.194exp -3.28!(^r ReV3sin0 (4.3d)
If StC /2 is > 0.07
Cs is the slip correction factor, Re is Reynolds number, and 6Z is the bifurcation angle at
generation z. St is particle Stokes number,
st=^>
H-dz
(4.4)
where pp is particle density, dp is the diameter of the particle, u is average velocity, p is
viscosity of air, and dz is the diameter of the airway of the particular generation.
Sedimentation equation is from Pich (1972) and is represented by Equations (4.5a-b)
Vs.k=~
n
-if
4
sm \eVf.n-
J
(4.5a)
where
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=3UL
g z
&ru (4.5b)
where Ug is particle settling velocity, Lz is generation length, rz is generation radius, and u is
average airflow velocity.
The diffusion equation is from Ingham (1975) and is shown in Equation (4.6a-b)
Vo,k =l-4Z^exp(-AX)-fl-4^
"=1 An V =1 ^n
where /l is mean free path and Ad is
exp
8-VA, In
J_ J_ J_
(4.6a)
Ad =
wrT
(4.6b)
in which D* is particle diffusion coefficient and u is velocity,
The three DCE's are combined by the following sequence provided by Yu, Liu, and
Taulbee (1977). Diffusion and sedimentation DCE's are combined in the following
expression.
Is.D^ylVs+nl-ifJs-lDf (4.7)
Following the computation ofEquation 4.7, Impaction DCE's is then tied to the otherDCE's
through the computation ofEquation 4.8.
VTot=Vs+D+rii{l-Vs+D) (4.8)
Tfrot is applied to the concentration of particles as it progresses through the respiratory tract.
The last two terms in Equation 4.1 represent the dynamic particle size distribution due
to coagulation and hygroscopic growth, which will not be used in the current work. However
the dynamic model is complete and will be utilized in future work to predict drug delivery of
hygroscopic medications.
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Given an initial size distribution of particles entering the trachea, the size distribution
at each airway generation is determined by solving Equation 4.2 for each size range, using
the appropriate initial concentration and boundary conditions for each generation. The total
deposition is calculated by summing, Lk, from Equation 4.2 over all particle sizes and
generations for one breathing cycle,
23
Total Deposition = J J^TVn^dxrfr (4.9)
cycle 0 *
Regional depositions can be similarly determined by summing over generations 0-14 for the
TB region and generations 15-23 for the pulmonary region.
Important parameters of initial airway size distribution and breathing conditions are
required for the deposition code of Robinson (RIT), and Yu (SUNY Buffalo) to predict
particle deposition. The following analysis of the literature search data provides a set of
initial airway size distributions and breathing conditions for a disease condition and healthy
case for input into the deposition code.
4.2 Diseased Lung Morphometry Model
Asthma is generally classified into two groups, namely asymptomatic and symptomatic.
Asymptomatic is described by acute attacks of asthma when irritating conditions (stress,
allergy, weather, exercise, etc.) stimulate the reflex of the airway, whereas symptomatic
asthma conditions are a daily part of the individual's life and encompass ailments of
abnormal breathlessness, wheezing, mucous production, and heavy use of a bronchodilator,
to list a few. The research will focus on symptomatic asthma and simulate deposition within
a generic, derived symptomatic asthmatics airway. The articles of symptomatic asthma are
as follows: Raw PFT data was obtained from (Tobin, 1983 and Siekmeier et al., 1994) and
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morphometry modification studies (Dunnill et al., 1969; Hossain, 1973; Sabonya, 1984;
James et al., 1989; and Saetta et al., 1991). This literature involves patients or autopsied
lungs of the symptomatic asthma type. The symptomatic asthma conditions for the airways
were simulated by 2 different methods, namely percentage of the airway cross-section that is
wall area rather than lumen cross-sectional area, Section 4.2.1, and resistance based on PFT
and fluid flow theory, Section 4.2.2.
4.2.1 Diseased Model based on PW
PW is the percentage of the airway cross-section that is wall area and is an important variable
that can be used to modify geometry to simulate an asthmatic airway system. Using and
building upon the assumptions, theory, and data from literature, on modifications in airway
wall components in asthma as compared to healthy subjects (previously discussed in Chapter
3), the procedure for modifying airway dimensions of healthy normal airways to that of
diseased is discussed and developed in the following paragraphs.
4.2.1.1 Theory ofDiseasedModel based on PW
Starting data is the set of internal luminal diameters (dz) of healthy individuals given by
Weibel (1963). The relationship of Pi to WA from James et al. (1988) was a necessity to use
but requires that the airway cross-section is completely circular. This condition relates to a
TLC of 100%. The Weibel diameters were recorded at 75% TLC. Therefore within the
internal perimeter equation, Equation 4.10, the Weibel diameters are transformed into larger
diameters that approximate 100% TLC by multiplying by 4/3.
Pi =d---n (4.10)z 3
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Wiggs et al. (1990) utilizes equations between internal perimeter, Pi, and wall area,
WA, from James et al. (1988). In the article by James et al. (1988) the authors demonstrate
that both internal perimeter and wall area of the airways are constant throughout various
states of healthy and diseased subjects. The equation of interest from Wiggs et al. (1990) is
the equation that relates internal perimeter and wall area for a healthy subject given by,
*JWA(mm) = 0.1 16883 + 0.80380xPi(cm) (4.11)
therefore Equation 4.1 1 modifies Pi values and wall area values are obtained.
Wall area, WA, is simply the area from the lumen wall to the outer layer of smooth
muscle in the airway. The parameter PW, is the percentage of the airway that is wall area
and the equation is simply
WA/
PW= /10
j2 (4.12)
WA/ + ^l_/100
4
where the nd^/4 term represents the lumen cross-sectional area; the dz are the Weibel
diameters. PW is calculated for the healthy values, PWH, and is the parameter that is altered
for disease since it relates to the percentage of the airway that is wall area. Upon disease the
percentage of the airway that is wall area will increase, therefore the cross-sectional area
percentage will decrease and the internal diameters of the airways will decrease. The
following paragraphs show the determination of a factor that is multiplied against the value
ofPWh to obtain a diseased percentage of the airway that is wall area, PWD.
James et al. (1989) compiled a list of different wall area components of the airways of
healthy and asthmatic individuals. From autopsied lung airways, the main wall components
that exhibited abnormalization were epithelium, submucosa/connective tissue, and muscle,
see Figure 4.1. The regions that wall components were recorded were split by generations 0-
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1, 2-3, 4-1 1, and 12-16 due to approximating the internal perimeters within the article. Table
4.1a shows the areas of different wall components collected in their analysis for healthy
individuals. Table 4.1b shows the area of different wall components collected in their
analysis for asthmatic individuals.
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Figure 4.1 - Cross-section of an airway wall, DesJardins (1988)
Table 4.1a - Area of different wall components of healthy individuals from James et al. (1989)
Normal
Cartilaginous Membranous
For airways with >
1 0 mm Pi, areamm2
For airways with <
1 0 mm Pi, areamm2
For airways with > 2
mm Pi, areamm2
For airways with < 2
mm Pi, areamm2
Epithelium 0.56 0.18 0.069 0.018
Submucosa/conn. tissue 0.71 0.20 0.049 0.010
Muscle 0.46 0.14 0.051 0.014
Total 1.73 0.52 0.169 0.0420
Table 4.1b - Area of different wall components of asthmatic individuals from James et al. (1989)
Asthmatic
Cartilaginous Membranous
For airways with >
1 0 mm Pi, areamm2
For airways with <
10 mm Pi, areamm2
For airways with > 2
mm Pi, areamm2
For airways with < 2
mm Pi, areamm2
Epithelium 0.88 0.46 0.156 0.030
Submucosa/conn. tissue 1.35 0.73 0.135 0.020
Muscle 1.57 0.67 0.152 0.015
Total 3.8 1.86 0.443 0.065
In this work there is an assumption that the percent of epithelium, submuscosa, and
muscle is constant in disease and healthy region. Each component of Table 4.1a for the
particular generation is represented as a proportion by dividing by the total wall component
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area. This gives a fraction of that particular wall component in terms of the total area of all
the wall components. So it is a baseline fraction of healthy wall area components. Each
healthy wall area component needs to be altered by the asthmatic case. Therefore the
asthmatic data in Table 4.1b (ie. for the James case) is divided by the data in Table 4.1a.
This results in a factor that boosts the given wall area components of the normal healthy wall
area components individually, see Table 4.2 (ie. for the James case). Adding up all the
percentages of increase in wall area components gives the total percentage factor that wall
area of the cross-section is increased due to symptomatic asthma for that given generation
and article. This will allow the import of different wall component alterations from
asthmatic morphology articles collected into the deposition model. An illustration of this
procedure for each article is below. The outcome of the summation will be the factor that is
applied to PWh-
For James et al. (1989), Table 4.2 is the calculated factor increases in wall area
component from asthma conditions. The table is simply Table 4.1b divided by 4.1a.
Table 4.2 - Factor change from healthy individuals in wall area components for James et al. (1989)
Generation Epithelium Conn. Tissue/Sub Mucosa Muscle
Cart. >10 mm 0-1 1.57 1.90 3.50
Cart. <10mm 2-3 2.55 3.65 4.75
Non-cart > 2 mm 4-11 2.26 2.75 3
Non-cart < 2 mm 12-16 1.67 2 0
Therefore factors for the particular generation are as follows:
F0_1=1.57
F2_3 = 2.55
F4_u=2.26-
^12-16=1-67
0.56
1.73
'0.18
,0.52
+ 1.90'
J
+ 3.65
0.71
.l-73y
0.20^
+ 3.50
J
0.069
0.169
+ 2.75
r 0.018
0.0420
+ 2-
0.52.
("0.049^1
\0.169j
'
0.010
. 0.0420
+ 4.75'
0.46
.1.73,
f0.14x
= 2.22
+ 3'
+ 0-
J
0.051
0.169
3.57
= 2.63
/ 0.014
0.0420,
= 1.19
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The same procedure occurs for Dunnill et al. (1969). Dunnill et al. (1969) did not
have all the detail that James et al. (1989) had in terms of specific wall area components of
asthma due to it being an independent article from the exact subject matter of James et al.
(1989). The same occurs for the remaining articles in this section, specifically Sabonya
(1984) and Hossain (1973). The values Dunnill et al. (1969) did provide were values for sub
mucosa/connective tissue and muscle for generations 2-3 for normal and asthmatic. The
values of asthmatic were divided by the normal values in the data table to come up with a
factor, ie. for muscle normals had 4.6% while asthmatics had 11.9% which results in a factor
of 2.59. The remaining generations and wall components were filled with James et al. (1989)
values from Table 4.2. This is because James et al. (1989) has all of the data on airway wall
components and should be applied to fill in the voids of the other articles lack of information.
The compilation of values for factor that is multiplied against the percentage of healthy wall
area component is shown in Table 4.3 and the resulting factor is shown in the following
calculations.
Table 4.3 - Factor change from healthy in wall area components for Dunnill et al. (1969), (t) indicates a
value adopted from James et al. (1989) data
Generation Epithelium Conn. Tissue/Sub Mucosa Muscle
Cart. >10mm 0-1 1.57+ 1.90f 3.50'
Cart. <10 mm 2-3 2.55' 0.76 2.59
Non-cart > 2 mm 4-11 2.26+ 2.75' 3+
Non-cart < 2 mm 12-16 1.67f T 0+
Therefore factors for the particular generation are as follows:
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Fo_,=1.57
F2_3=2.55
F*- 2.26
^2-16 =1.67-
2.22
= 1.87
= 2.63
= 1.19
The only parameter that could be used for Sabonya (1984) was the wall area
component - muscle wall area for generations 2-3. The other parameters as mentioned above
the absent values are filled in with factors from James et al. (1989) Table 4.2 values to arrive
at values in Table 4.4.
Table 4.4 - Factor change from healthy in wall area components for Sabonya et al. (1984), (t) indicates a
value adopted from James et al. (1989) data
Generation Epithelium Conn. Tissue/Sub Mucosa Muscle
0-1 1.57* 1.90* 3.50*
2-3 2.55* 3.65* 1.5
4-11 2.26* 2.75* 3*
12-16 1.67* r 0*
Therefore factors for the particular generation are as follows:
^o-i=l-57
2-3
2.55'
0.56]J
'Olif
v0.52,
+ 1.90
+ 3.65
0.71
1.73,
'0.20'
,0.52
+ 3.50.
+ 1.50-
0.46 ^
.1.73,
'0.14'
,0.52
2.22
2.69
F4_n=2.26
^2-16=1-67
0.069
0.169
+ 2.75
0.018 "\
+ 2-
(0.049
U-169
0.010
+ 3-
+ 0-
0.051
0.169
= 2.63
0.014 \
= 1.19
v
0.0420J ' " U.0420J ' " ^0.0420.
Similarly to Sabonya (1984), Hossain (1973) provides only a muscle wall area component for
generations 2-3.
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Table 4.5 - Factor change from healthy in wall area components for Hossain et al. (1973), (t) indicates a
value adopted from James et al. (1989) data
Generation
0-1
2-3
4-11
12-16
Epithelium
1.57*
2.55*
2.26*
1.67*
Conn. Tissue/Sub Mucosa
1.90*
3.65*
2.75*
Muscle
3.50*
3.0
3*
0*
Therefore factors for the particular generation are as follows:
F0_,=1.57
F2_3=2.55.
F4_u=2.26-
^12-16=l-67-
0.56^
.1-73;
"0.18^
v0.52
+ 1.90-
^0.71^
+ 3.65.
vl-73,
0.20
0.52
+ 3.50
+ 3.0
0.46
vl.73,
0.14N
0.52.
= 2.22
= 3.09
0.069^
^0.169;
f 0.018
v 0.0420
+ 2.75
A
+ 2-
0.049
v0.169
0.010
+ 3.
+ 0-
0.051
0.169,
0.014
2.63
= 1.19
0.0420 ) {0.0420 ,
The factors, F#_#, for the specific generations and article are multiplied against PWH to give
the value of PWD.
PWD = PWH-F#_# (4.13)
Finally from Wiggs et al. (1990) he presents an equation which can calculate a contracted
internal diameter (Dc) based on volume corrected diameters that scale diameters to FRC
volume (Dv), wall area (WA), smooth muscle shortening (PMS) which is the percentage of
airway cross-section that is wall area and for disease, proportion of the airway wall
circumference occupied by muscle (PMC), and the (PW), see Equation 3.28. Three
modifications were made to Equation 3.28. Two modifications pertained to the inflating and
deflating equation from Lambert (1982) and one dealt with capturing the modifications of
PW from disease. The first modification, as discussed earlier, was that the Healthy-Weibel
diameter was transformed to 100% TLC by taking the Healthy-Weibel diameter and
multiplying it by 4/3 for every generation. This diameter was used to calculate P, and
116
subsequently WA due to being a diameter based on scaling to 100% TLC which would yield
a completely circular airway. Second modification was that the variable Dv, which
represents the deflated airway diameter at FRC volume, was just the Healthy-Weibel
diameter, dz. In the deposition code, there is already a function that scales to FRC based on
two different scaling factors, discussed later in the text. Therefore, do is calculated but
further processed, as a last step, to represent the diameter at FRC. The third modification to
Equation 3.28 is PWD is used instead of PWH to encompass the modifications to the wall
components from asthma. Equation 4. 14 is the resultant,
d, =2-
'
'
dt WA A
+ -
v 4 WOnj
[(l - PMS x PMC)1 - PWD ] (4. 14)
Note: In Wiggs et al. (1990) the authors publish the above equation without the factor of 2 applied.
Upon derivation it is found that the factor of 2 is needed and in a subsequent article Wiggs et al. (1992)
publishes results using the corrected equation with a factor of 2 in it but not the corrected equation itself.
Wall area in Equation 4.14 is the same original number forWA due to the synopsis of
James et al. (1988) stated earlier. The observed smooth muscle shortening values are taken
from Okazawa et al. in Wiggs et al. (1992), which states that the PMS observed was 28
14% and said that they rarely observed shortening exceeding 40%. The values can be
toggled from 10%-40%, we found the change from toggling to be very small. For this
analysis 20% is used and also corresponds to the value that Wiggs et al. (1990) used. Wiggs
et al. (1990) article discusses the parameter of obtained proportion of muscle in the
circumference of the airway, PMC. The numbers were taken from studies of autopsied
lungs. Wiggs et al. (1990) used 0.33 for trachea and right/left main bronchi (Gen. 0 and 1),
0.66 for lobar bronchi (Gen. 3), and 1 for the remaining airways (Gen 4-16).
Included in this section, but is not related to the equation and procedure above, is the
article from Saetta et al. (1991). The article by Saetta et al. (1991) is related to the airway
117
cross-section by providing a percentage that the lumen was occluded in asthmatics and
healthy subjects. The lumen occlusion from Saetta et al. (1991) was stated as 16% for
healthy subjects and 55% for asthmatics. To account for the Saetta et al. (1991) alteration,
Weibel diameters for 0-16 were multiplied by 16/55 or 0.291 to generate the contracted
lumen diameter for Saetta,
A A I6d=d7c z 55 (4.15)
4.2.1.2 Results ofDiseasedModel based on PWf
Figure 4.2 shows the summary data of the analysis based upon PW and lumen occlusion of
Saetta et al. (1991) compared to Healthy-Weibel based on Weibel morphology.
Figure 4.2 - Diameters based on PW and lumen occlusion ofSaetta et al. (1991), for generations 0-14
Important note, from here until the end of the document, data sets will be noted in figure legends and
text boxes as the first author of the article, ie. Saetta et al. (1991) will be referred to as just Saetta
The data exhibits the correct trend for asthmatic type symptoms, where the diameters are
decreased due to lumen blockage or muscle shortening. Notice that the added data for
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generations 2-3 of Dunnill et al. (1969), Sabonya (1984), and Hossain (1973) does deviate
from the James et al. (1989) data. Capturing of this effect will be discussed later in the text.
Also notice the impact that Saetta et al. (1991) influenced airway diameters has by
multiplying the Weibel (1963) values by 16/55. The data based on Saetta et al. (1991) is
roughly half the data influenced by James et al. (1989).
Figure 4.3 shows the resulting modified cumulative airway lung volume for
generations 0-16, determined by assuming a cylindrical tube volume calculation for each
generation. Cross-sectional area, from the modified diameters, length of the airway, and
number of airways from Weibel were used in the computation of cumulative volume.
Length, in this analysis, is assumed to stay constant throughout the disease modifications,
using the original values published by Weibel (1963). This plot in essence has the same
trend, Healthy-Weibel, James, then Saetta, as Figure 4.2 due to the volume being based off of
diameter solely. The remaining parameters are the same for each data set.
In Figure 4.4, the cumulative airway volume is shown for generations 15-23. There is
not much volume in generations 0-16 compared to 17-23. Diameters are larger for
generations 0-16 but there are many more airways for generations 17-23. The figure shows
the data sets to be nearly equal to one another. This is correct for this state of the analysis
due to the modifications of Section 4.2.1.1 only being applied to the generations 0-14. The
final cumulative volume for the disease models is less than 4800 mL compared to 4800 mL
forWeibel cumulative volume. Tables of values for diameter, length and cumulative airway
volume are also provided in Appendix C. Note: that the addition of Dunnill, Sabonya, and
Hossain do not contribute much on a volume basis.
119
a>
E
200
180
160
140
120
> 100
a>
~ 80
JS
| 60
O 40
Healthy-Weibel James
James with Dunnill James with Sabonya
James with Hossain Saetta
James
James with Dunnill
James with Sabonya
James with Hossain
l""l""l""l""l""l""l" "I
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Generation
Figure 43 - Cumulative airway volume for articles based on PW and lumen occlusion of Saetta et al.
(1991) for generations 0-16
6000
5000
| 4000
> 3000
>
| 2000i
O 1000
16
* Healthy-Weibel
- James
James with Dunnill
- James with Sabonya
James with Hossain
Saetta
17 18
James
James with Dunnill
James with Sabonya
James with Hossain
19 20
Generation
21 22 23
Figure 4.4 - Cumulative volume for articles based on PW and lumen occlusion of Saetta et al. (1991) for
generations 16-23
120
4.2.2 Diseased LungMorphometryModel based on Resistance
In Chapter 3, Figure 3.10f resistance of the airway values were collected and plotted. The
normal and asthmatic Raw data is averaged and used in the following sequence for
modification of the airways by resistance. Through use of fluid flow theory and values of
resistance obtained from PFT, there is the ability to generate modified dimensions of the
different generations in asthma using resistance.
4.2.2.1 Theory ofDiseasedModel based on Resistance
Flow rate in a given airway represented by a cylinder,
nAPd4
V= (4.16)
12%/jL
where AP is pressure drop across the airway, dz is airway diameter, L is airway length and p
is viscosity of the air. Resistance in a given airway, Raw (analogous to R=V/I where R is
electrical resistance, V is voltage drop, and I is current ) is
*~=^- (4-17)
This can be applied to Healthy-Weibel model. In Weibel, generation numbers, z, from 0 to
23 and 2Z represents the number of airways of radius r in each generation. Let V be the flow
rate through generation 0. The flow rate in each subsequent Healthy-Weibel generation is
then reduced by 2Z. So resistance in generation with
2Z
airway, is given by,
R =-&- (4.18)
There is an additional term in Equation 4.18, namely the 1/2Z. The reason for this additional
term is to account for the increasing number of airways as the air progresses along the TB.
The increase in the number of airways counteracts the decrease in diameter of the TB,
121
meaning resistance is based upon cross-sectional area of the given passageway. Fundamental
fluid theory states that as an airway decreases in diameter there will be more of a resistance
of airflow. This is not the case when there are a number of small airways in parallel. The
cross-sectional areas of the small airways are combined thus providing less restriction to flow
than the large single or medium sized airways. Correspondingly, resistance should decrease
as the aerosol travels further in the TB. Combining Equation 4.16 with Equation 4.18 gives,
SLju
R., , = (4.19)aw'z Ynr*
Weibel (1963) airway lumen diameters are inserted into Equation 4.19 for each
generation to produce the resistance, RaWiZ of the generation to flow in healthy airways. Each
Raw,z is then normalized by the total resistance of all 23 generations to arrive at a relative
resistance, RRaw,z of each generation given by
K
23
^LRaw,z
nn
_
aw.z
KKaw.z ~ "2 (4.20)
which allows the ability to apply resistance values of asthmatics measured in experiments
without having to match parameters. Resistance values from pulmonary function tests, PFT,
were collected from several articles and are shown in Table 4.6. Values in Table 4.6 are
analogous to 2_,Q Rawz in Equation 4.20.
Table 4.6 - PFT resistance values of asthmatic individuals (Siekmeier et al., 1994; Tobin et al., 1983), see
also Figure 3.10f
Variable Value Unit
Raw,c_min 0.471 cmH20s/L
Raw,c_max 0.517 cmHiOs/L
Raw,c_avg 0.494 cmHzO-s/L
The 3 values, min, max, and average of the data collected, are multiplied with the RRaw>z
values to produce 3 sets of asthma-corrected resistance values, labeled Raw,c_min, Rawc_max,
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and RaW>c_avg. A graph of the RaW,z from Equation 4.19 and the asthma corrected resistance
values is shown in Figure 4.5. In summary, the total Raw,c_(min, max, avg.) values from
asthmatics were used to determine the resistance in each generation by assuming that the
relative resistance (RRaW,z) distribution among the airways remains constant between healthy
and asthmatics.
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Figure 4.5 - Resistance in the airway as a function of generation for min, max, and average resistance
models compared to Healthy-Weibel
With the 3 new asthma-corrected resistance data sets, rearranging ofEquation 4.19 is made
into 4.21 to derive the asthma-modified diameter sets. The contracted airway diameter (dc) is
given by,
d=2
( 1 SLp
i
^4
2Z
n Rawc (min,max, avg.)
(4.21)
Table 4.7 shows the example procedure to determine the asthma corrected diameter, dc, for
the PFT maximum resistance value for 3 generations.
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Raw.c_max 0.517 cmHOs/L
- -
Gen
**-aw,z
(poise/cm3)
**aw,z
(cmH20-s/L) RRuw,z Ra.zjnax,n
</cfor
max
0 0.00859 0.00876 0.0505 0.0261 1.363
1 0.00806 0.008247 0.0475 0.0246 0.924
2 0.00752 0.00767 0.0443 0.0229 0.629
4.2.2.2 Results ofDiseasedModel based on Resistance
Diameter results for the min, max, and average values of resistance are displayed in Figure
4.6. Also included in the figure are Healthy-Weibel results for a baseline. The diameters of
max and min resistance data sets vary from the average resistance value by 1 .20% and 1 . 1 3%
while percent difference from Healthy-Weibel data set is an average of23.4%.
Healthy-Weibel
Minimum Resistance
-'-Maximum Resistance
Average Resistance
i 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Generations
Figure 4.6 -Diameter for min, max, and average resistance models compared to Healthy-Weibel
The cumulative lung volumes for max and min resistance values vary from the average
resistance value by < 2.41% and < 2.25% respectively see Figure 4.7a-b. The percent
difference from Healthy-Weibel is a consistent 41% for generations 0-16 and 30% (averaged)
for 17-23.
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Figure 4.7a - Cumulative volume plot for min, max, and average resistance models compared to Healthy-
Weibel for generations 0-16
Figures 4.6 and 4.7a-b demonstrate the reason for the average value of resistance to be used
rather than include the maximum and minimum resistance values for computer model runs.
The graphs indicated that the range of resistance has negligible effect on diameter and
cumulative volume and therefore, an average of the reported resistance values can be used in
themodel.
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Figure 4.7b - Cumulative volume plot for min, max, and average resistance models compared to Healthy-
Weibel for generations 16-23
4.2.3 Compare Modified Geometry
Section 4.2.3 is meant to display the final charts that depict the entire modified diameter and
cumulative volume sets. Figure 4.8a shows a comparison of diameters for asthma for each
model for generation 0-16. No modifications were made to diameters 17-23. Figures 4.8b
and 4.8c show a comparison ofthe cumulative volume for each model in generation 0-16 and
17-23 respectively.
From these graphs it can be seen that Saettamodel gives largest decrease in diameter.
Resistance model diameters are larger than those based on physiology/autopsy after
generation 1. And finally, the maximum cumulative volume is given by James model (4628
mL) compared to 4800 mL Weibel, while the lowest cumulative volume is the min resistance
model (4042 mL). Both of the diseased volumes falls within the range of FRC reported in
the PFT test literature (3800-5200 mL).
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Figure 4.8a - Diameter plot ofHealthy-Weibel compared to disease models for generations 0-16
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23
These are the diameters that have only experienced part of the asthma modeling
process. The second part of the asthma modeling process deals with adjusting the geometry
by the functional reserve capacity, FRC, to account for the larger volume in generations 17-
23 in asthmatic patients compared to their Healthy-Weibel counterparts, Section 4.3.
4.3 Scaling ofDiameter, Length, and Volume by FRC
The scaling of diameter, length, and volume of the generations 17-23 is based upon the
gathered PFT results of FRC for asthmatics. FRC for asthmatics is larger than the normal
FRC of a healthy individual as shown in the Figure 3.1 Of. The FRC PFT values depicted in
Figure 3.1Ofwere acquired from the articles ofSiekmeier et al. (1994) and Tobin (1983) and
presented in the form ofniinimum, average, and maximum value, 3800, 4500 and 5200 mL,
respectively. The scaling occurs in generations 1 7-23 due to the support from literature that
the pulmonary region is the region most influenced by a larger volume due to the primary
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reason of gas trapping. DesJardins (1998) notes that in an obstructive disease, such as
asthma, the airways are smaller than normal subjects in diameter. Upon inhale air is allowed
to enter into the pulmonary region for gas exchange but upon exhale the airways act like a
one-way valve and actually trap air within the alveoli of the pulmonary region. This effect is
why obstructive subjects have larger TLC, FRC, and RV. In addition to the scaling to
generations 17-23, mentioned before is the scaling of generations 0-16 by the factor of
3200/4800 mL. This is done so that a resulting comparison to the Healthy-Weibel can be
made. Scaling process details are provided in the next section.
4.3.1 Reasoning for Scaling Diameter, Length, and Volume by FRC
In the Trumpet Model deposition code (Yu, 1978; Robinson and Yu, 2001), the Weibel
(1963) geometry values are scaled to reduce the FRC from 4800 mL to a value of 3200 mL,
that of a healthy normal. Recall that the Weibel geometry values are representation of a lung
inflation state of 75% TLC. The data is modified from TLC to FRC because the FRC is an
equilibrium point in the respiratory cycle, meaning the tendency for the lungs to collapse
inwards is balanced by the tendency for the chest to expand outward (outward pull of the
thoracic cage). Therefore it is a point where the geometry is at a base point or static point,
meaning there is no dynamic change in the airway geometry which makes it a great reference
point.
FRC is altered in asthma due to airway contraction and shutting, Barnes et al. (2002).
The airways tighten as previously shown in the asthma geometry for the generations 0-16.
Air is able to enter the generations due to inhalation of air expanding the diameters of the
airways, but upon exhale that air is presented with a one-way valve type situation, therefore
the air is trapped and FRC, RV and TLC is enlarged.
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Reducing the diameter resulted in FRC values, (see Table 4.8), that were smaller than
Healthy-Weibel unsealed and larger than Healthy-Weibel scaled. These FRC's were within
the range measured from PFT. A scaling factor was calculated and used to alter diameter,
length and volume so that a model for each FRC could be obtained. For the asthma the data
is multiplied by either of 2 factors corresponding to generations 0-16 or 17-23. For
generations 0-16 the data is multiplied by the Weibel factor ofF = 3200/4800 mL to adjust to
the balance FRC point (this is also done for Healthy-Weibel model). For generations 17-23,
the procedure starts by calculating the remaining volume, Vrem, of the scaled volume data set
using Equation 4.22. The scaled volume set simply means the summation of the volume for
each generation (0-16) that is modified by the 3200/4800 mL factor. So Vrem is found from,
16
I
z=0
Vrem = (3800, 4500, or 5200) - JT Vz (scaled) (4.22)
where 3800 mL, 4500 mL, and 5200 mL are the target FRC values for the diseased model.
Vrem is the volume needed to equal the target FRC. The next step is to sum the unsealed
volume (airways and alveoli) of the generations 17-23. Vrem divided by the summation of the
unsealed volume for generations 17-23 is the factor that is applied to the unsealed volume
data values, Equation 4.23.
Fd =3
^ (4.23)
y\Vz(unscaled)
z=n
Table 4.8 shows the different scaling factors for FRC.
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Table 4.8 - Scaling factors ofFRC, where NA means the variable is not calculated for that particular
data set
Model*
23
IX mL
z=0
(unsealed)
mL
Scaling
Target
FRC
16
z=0
mL
(scaled)
vT rem)
mL
Weibel
Scaling
Factor,
F,
0-16
23
z=16
mL
(unsealed)
Diseased
Scaling
Factor, Fd
16-23
Weibel 4,800 3,200 82.28 NA 0.667 NA 0.667
James 4,628
3,800
52.86
3,747.1
0.667 4,549.7
0.82
4,500 4,447.1 0.97
5,200 5,147.1 1.13
Saetta 4,564
3,800
9.88
3,790.1
0.667 4,549.7
0.82
4,500 4,490.1 0.98
5,200 5,190.1 1.13
Resistance
Avg.
4,064
3,800
68.50
3,731.2
0.667 3,960.8
0.94
4,500 4,431.2 1.12
5,200 5,131.2 1.29
Disease
Average
4,419
3,800
43.75
3,756.2
0.667 4,353.4
0.85
4,500 4,456.2 1.01
5,200 5,156.2 1.16
The diseased geometry was further modified by Equations 4.24-4.26 to produce scaled
diameters, ds, lengths, ls, and volumes, vs, for each generation, using the following equations:
ds = d {/cY (4.24)
Is=L(kY
v,=v(*-)
(4.25)
(4.26)
where K is used for the scaling factors F and Fd used for generations 0-16 and 17-23,
respectively.
4.3.2 Results of Scaling Diameter, Length, and Volume by FRC
Input of asthmatic disease modification into the deposition computer model is accomplished
by the diameter, length, and volumes presented before the scaling by FRC, namely Section
4.2.3. Within the code, the arrays of diameter, length, and volume are scaled by FRC in the
manner described in Section 4.3. This scaled data of diameter, length, and volume is what is
entered and analyzed in the conservation equations and that ultimately predict the deposition
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results. The figures that show this scaled data are presented below in the following manner.
For diameter, length, and volume there is an overall plot of the data for generation 0-23 at the
average FRC of 4500 mL. Following each of the overall plots, except for length, are half-
generation plots 0-16 that represent the data for 3800, 4500, and 5200 mL all on the same
plot. Note the data sets for generations 0-16 for the different FRC values are all scaled by the
factor 3200/4800 mL this is why they are plotted in the same figure. The half-generation
plots of 17-23 are distinct and are presented for diameter, length, and volume for each
individual FRC. Also, included in Figure 4.9 are the diameters reported from Wiggs et al.
(1992).
Figures 4.9, 4.10, and 4.11 show the results of the scaled diameters of Healthy-
Weibel compared to the various disease models. From Figure 4.9 it is clear that
modifications of the diameters are much more pronounced in generations 0-16 than 17-23.
Resistance data is the largest set in terms of diameter per generation of the disease
modification sets after generation 1, while Saetta is the least. Important to note that Disease-
Average is an average of the data sets James, Resistance-Average, and Saetta. Also included
for just generation 2 and 3 were the other data sets (James/Dunnill, James/Sabonya, and
James/Hossain) to represent and include these data sets would introduce. Wiggs et al. (1992)
data is also displayed amongst the other data sets. James and Wiggs data show that there is
hardly a scaling of diameter for the first couple of generations. This is due PMC value
reflecting that there is cartilage in those early generations, so constriction is limited.
Although the FRC with which Wiggs et al. (1992) scaled to is not known, the data provides a
sanity check knowing that the data from Wiggs et al. (1992) is approximately similar to
James.
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Figure 4.9 - Scaled diameter, FRC 4500 mL and generations 0-23
From Figure 4.10 the average percent decrease of Resistance-Average, James, Saetta, and
Disease-Average diameter data for generations 0-16 from Healthy-Weibel data are 23.4%,
41.8%, 70.9%, and 44.7% respectively.
Figures 4.11-4.13 show the difference in diameters for generations 17-23 for 3800
mL, 4500 mL, and 5200 mL, respectively. Resistance model diameters are smaller than
Healthy-Weibel for 3800 mL through 5200 mL. The diameters for this generation range are
Healthy-Weibel values that have the second factor, Fd (as mentioned before), applied to it.
Therefore James and Saetta diameter values for generation 17-23 will be above the Healthy-
Weibel data because the FRC is increased compared to Healthy-Weibel. As for the
resistance data sets that are below the Healthy-Weibel values, this is due to the method by
which the diameters were modified by resistance. The resistance PFT values were
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representative of a total resistance of the airways, meaning not segregating by regions of
generations 0-16 and 17-23. Therefore the diameters in generations 17-23 were scaled down
to a point where the second factor which enlarges the diameter to account for the FRC is not
large enough to surpass the diameters of Healthy-Weibel. Also the Disease-Average
diameter data becomes larger from Healthy-Weibel as the FRC volume increases.
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Figure 4.10 - Scaled diameter (valid for FRC 3800, 4500, and 5200 mL) generations 0-16
The diameter change for this region (17-23) is small with a AD of ~ .02 of a
centimeter. Percent differences for this region are also small compared to generations 0-16.
Table 4.9 shows the percent differences for 3800, 4500, and 5200 mL from Healthy-Weibel
for the different data sets.
134
Tahle 4.9 - Diameter percent differences from Healthv-Weibel for generations 17-23
FRC Volume, mL James & Saetta Resistance-Average Disease-Average
3800 + 7.2% - 14.1% + 0.3%
4500 + 13.4% -9.1% + 6.2%
5200 + 19.1% - 4.5% + 11.4%
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Figure 4.11 - Scaled diameter, FRC 3800 mL, and generations 17-23
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Figure 4.12 - Scaled diameter, FRC 4500 mL, and generations 17-23
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Figure 4.13 - Scaled diameter, FRC 5200 mL, and generations 17-23
Figure 4.14 shows the scaled length sets for the generations 0-23 for FRC of 4500
mL. The length results are uneventful for generations 0-16 due to every set ofmodification
data having the Healthy-Weibel length values, where the lengths deviate from each other is
in generations17-23 through scaling for FRC volume. There is a faint change in the data at
generations 17-23, with respect to FRC as shown in Figures 4.15, 4.16, and 4.17 for FRC
values of3800, 4500, and 5200 mL, respectively.
For each value ofFRC, the diseased lengths are all above Healthy-Weibel data, which
is a different trend as compared to the diameter plots of this region explained before. This
difference can be attributed to the fact that all the lengths started as Healthy-Weibel lengths.
The adjustment is an increase in volume; hence as there is progression to higher FRC
volumes with asthma, there is an increase in length for the modification data compared to
Healthy-Weibel. Since the Resistance models had the largest Fd, these lengths were largest,
followed by Disease-Average model, Saettamodel, and James model respectively.
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Figure 4.14 - Scaled length, FRC 4500 mL and generations 0-23
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Figure 4.15 - Scaled length, FRC 3800 mL, generations 17-23
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Figure 4.16 - Scaled length, FRC 4500 mL and generations 17-23
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Figure 4.17 - Scaled length, FRC 5200 mL and generations 17-23
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Figure 4.18 shows the results for the scaling ofvolume for generations 0-23 and with
an FRC of4500 mL. This plot provides insight into how the volume rapidly becomes larger
as airways increase in number and decrease in diameter. The disease modification sets from
this macroscopic view seem to have hardly a difference amongst them and become
disconnected from the Healthy-Weibel as the generations advance. Figure 4.18 shows the
Healthy-Weibel volume data set to be larger for generations 0-18 than the disease
modification sets and visa versa for generations 19-23.
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Figure 4.18 - Scaled volume, FRC 4500 mL and generations 0-23
Figure 4.19 depicts the cumulative scaled volume for generations 0-16 and is very
representative of the trend in the diameter plots discussed previously due to the volume being
derived from the diameter. There is a difference though from the diameter plots due to the
Equations 4.17 and 4.19. For the diameter equation, 4.17, the factor is to the 1/3 power
multiplied by the unsealed diameter while for the volume it is just the volume times the
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factor. Healthy-Weibel is limited after generation 16 by having to scale to 3200 FRC while,
for this case, the modification sets are scaling to the larger FRC of 3800, 4500, or 5200 mL
for the generations 17-23. For the generations of 0-16 the percent smaller of Disease-
Average from Healthy-Weibel is on the order ofa 59.8%.
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Figure 4.19 - Scaled volume, FRC 3800, 4500, 5200 mL, generations 0-16
Figure 4.20, 4.21, and 4.22 shows the modification data sets cumulative volumes for
the plots of FRC's 3800, 4500, and 5200 mL, respectively surpassing the Healthy-Weibel
sets. For Figures 4.20, 4.21, and 4.22, the Healthy-Weibel cumulative volume is surpassed
by the modification data at generations 20, 19, and 18, respectively. This is due to a lag in
the modification data sets in accumulating volume. The Healthy-Weibel data collected more
volume in generations 0-16 due to the larger diameter present, thus it takes a few generations
for the modification data to surpass the Healthy-Weibel. Percent difference detects this and is
not constant throughout the remaining generations.
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Figure 4.20 - Scaled volume, FRC 3800 mL and generations 16-23
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The percent difference between Healthy-Weibel and the modification sets begins to get
smaller until the modification data sets exceed the volume ofHealthy-Weibel, from there the
percent difference increases of the modification set from Healthy-Weibel. Overall the trend
is simply that as the FRC gets larger, there is a larger difference in volume for generations
where modification data is greater than Healthy-Weibel to generation 23.
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Figure 4.22 - Scaled volume, FRC 5200 mL and generations 16-23
4.4 Summary ofDiseased Models
Three disease morphometry data models were developed for the case of asymptomatic
asthma. They were based on measurements of asthmatic wall structure alterations of
theoretical lumen occlusion (James, Dunnill, Sabonya, and Hossain); actual lumen occlusion
measurement in asthmatics (Saetta) and PFT airway resistance measurements for asthmatics.
Modifications to James model for generations 2 and 3 using Dunnill, Sabonya, and Hossain
data produced negligible variation in diameter. This consistency adds credibility to the
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modifications and allows the models (Dunnill, Sabonya, and Hossain) to be represented by
James model and also the inclusion of the factors into Disease-Average data set for the
generations of 2-3. The range of data for airway resistance found in the literature was tested
and found to produce less than 2% difference, which is small compared to the difference
from Healthy-Weibel. Therefore the Resistance model can be based on the average value of
.494 cmH2Os/L. The FRC's of 3800 mL, 4500 mL, and 5200 mL, found in literature from
asthma PFT's, were tested and found to demonstrate a small deviation from the 4500 mL
case. Therefore, 4500 mL was chosen to be representative of the FRC for asthma.
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Chapter 5 - Results
5.1 Model Parameters
The deposition program will be run for the diseased model and Healthy-Weibel model
breathing conditions shown in Table 5.1a. The Healthy-Weibel model breathing conditions
are from ICRP, (1994). For the diseased models, breathing parameters from Tobin (1983)
and Lougheed et al. (1993) were found in literature. Lougheed et al. (1993) will be
employed as model input for a symptomatic asthmatic person, as shown in Table 5.1a, due to
the data being collected while the patient was in a sitting position. Tobin (1983) refers to
data that was taken in a supine position and the effect of the supine position is not a goal in
this analysis. For comparison the Normal-PFT subject values listed in Table 5.1a are from
the PFT data collected in Figures 3.10a-f, for healthy subjects.
Table 5.1a - Summary of model inputs of breathing parameters, '(James, Saetta, Resistance Average, and
Disease-Average)
Frequency
(Breaths/min)
Tidal Volume
(ml)
Inhalation
Time (s)
Pause
Time (s)
Exhalation
Time (s)
Healthy-Weibel 13.7 500 1.91 0.2 2.26
Disease Models 15.0 600 1.82 0.2 2.61
Normal-PFT 14.6 500 1.6 0.2 2.50
Table 5.1b shows the runs that were performed for this analysis. Each data set was
run with particle sizes 0.05, 0.1, 0.3, 0.6, 1, 2.5, 5, and 10 pm which represent a large number
of industrial and environmental particles refer to Figure 1.5, Chapter 1. FRC values ran were
3200 mL for Healthy-Weibel and 3800, 4500, and 5200 mL for disease models. The
Disease-Average set was created by averaging the geometry in each generation from James,
Saetta, and Resistance-Average models with the addition of Sabonya, Dunnill, and Hossain
factors applied to generations 2-3. The concentration of particles used was 2.86E+9 particles
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cm3
and the particle density was 1 g/cm3. The following sections provide the results of
running the deposition computer model for the various disease modification sets and
Healthy-Weibel data. Relationships of total, regional, and local deposition with respect to
particle size are presented. Data plots for unsealed and scaled modification data are also
accessible in Chapter 3.
Table 5.1b - Asthmatic geometry models, *Only have diameter data
Run Set Data Set Breathing
Condition
Location ofData Set in Appendix C
Unsealed Scaled
Dia., Length, and
Volume Data
Dia., Length, and Volume Data
3200 mL
1 Healthy-Weibel Healthy TableB.l Tabled
3800 mL 4500 mL 5200mL
2 James Disease Table B.
2*
Table C.2 Table C.6 Table C.10
3 Saetta Disease Table B.
6*
Table C.3 Table C.7 Table C. 11
4
Average
Resistance
Disease Table
B.8*
Table C.4 Table C.8 Table C. 12
5 Disease-Average Disease Table B.9 Table C.5 Table C.9 Table C. 13
5.2 Total Deposition
The runs of Table 5.1b were completed and analyzed, and at first glimpse there was some
redundancy in the data. Total deposition for the different FRC values did not fluctuate
greatly for the different FRC's (see Table D.l in Appendix D), therefore streamlining the
runs could be performed to aid in speed and clarity of the output. Table 5.2 shows that for a
particle size of 2.5 pm, at most the percent difference of 3800 mL and 5200 mL is
approximately 3% (and under) different from 4500 mL. Therefore 4500 mL results are taken
as an estimate of an FRC gain in asthma and the following plots will be representative of this.
In Figure 5.1, the disease data sets show a noticeable overall increase in deposition
from normal Healthy-Weibel values.
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Table 5.2 - Sample of total deposition output and percent difference of FRC values 3800 mL and 5200
mL from 4500 mL for particle size 2.5 pm
FRC
mL
Disease-Average
Model
% Difference
Resis.-Average
Model
% Difference
Saetta
Model
% Difference
James
Model
% Difference
3800 0.12% 0.02% 0.16% 0.07%
5200 1.04% 1.20% -0.11% 0.83%
From the modification data collected and synthesized in Chapter 3, it is apparent that the
effectiveness of particle deposition correlates highly with a change in the geometry of the
airways and breathing patterns. Figure 5.1 shows that the Resistance-Average disease data set
has the largest total deposition percent for particle sizes 0.05 to 0.3 pm, while for greater than
0.3 pm up to 10 pm, Saetta data is the largest.
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Figure 5.1 - Total Deposition versus Particle Size at 4500 mL
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James, Disease-Average and Resistance-Average total
deposition data hover in the same
vicinity until 2.5 pmwhere James and
Disease-Average pull away from Resistance-Average.
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Also, Saetta data is comparable to the other data sets until 0.6 pm where the deposition
percent is a lot greater than the other data sets, for example the average percent difference for
generations 1-2.5 pm of Saetta from Disease-Average is 74%. The compilation of data sets
represented by Disease-Average values have an average percent difference from Healthy-
Weibel values by 21.6% at 4500 mL FRC values over the entire range of particle sizes.
Also displayed in Figure 5.1 is the deposition of particles with and without the mouth
effects included. Mouth deposition is a separate function within the computer code that adds
a factor of deposition that would be expected from the mouth and oral region. Mouth
deposition boosts total deposition percentage by roughly 45% on average for Healthy-Weibel
and 44% on average for Disease-Average for particle sizes 5.0 pm and larger. For 2.5 pm
particles and less there is not a noticeable difference due to the addition of mouth deposition.
Mouth deposition slightly increases total deposition percentage by roughly 3.9% on average
for Healthy-Weibel and 3.0% on average for Disease-Average for particle sizes 2.5 pm and
less.
All the original data sets had no intermediate model run between 2 and 7 pm
particles. Added model runs between 2 and 7 pm were made following the desire to find a
correlation between max particle size and largest total deposition. Table 5.3 shows the
particle size resulting in the maximum total deposition for each of the data sets.
Table 5.3 - Particle size for peak total deposition
Data Set 3200 mL 4500mL
James - 4.2 Jim
Saetta - 2.8 Jim
Average-Resistance - 5.7 [xm
Disease-Average - 4.5 \im
Healthy-Weibel 6.6 urn -
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5.3 Regional Deposition
Presented in Figure 5.2 is the plot of regional deposition percent versus particle size. The
plot displays deposition for the mouth, TB, and pulmonary regions of the respiratory system
Total deposition is a combination ofthe regional deposition plots; as a result, the plot is more
of a refined look at regional contributions toward deposition. The results for each region are
discussed in the following paragraphs.
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Figure 5.2 - Regional deposition versus particle size FRC 4500 mL
For mouth deposition the trend was fairly constant and equal between the Disease-
Average and Healthy-Weibel data sets for particle sizes up to 2.5 pm After 2.5 pm the
percent differences between Healthy-Weibel and Disease-Average data show that Disease-
Average mouth deposition has a steady positive delta over Healthy-Weibel mouth deposition
data. This is due to primarily to disease breathing conditions that cause a larger flow rate in
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the disease model, including larger frequency and tidal volume. The average percent
increase of Disease-Average mouth deposition over Healthy-Weibel is an average of 30.5%
for particle size 5.0 pm and larger. As particle size gets larger so does the amount of mouth
deposition and early TB airway deposition, which is directly related to the inertial impaction
mechanism. At a particle size of 10 pm the mouth deposition values ofDisease-Average and
Healthy-Weibel are in the 30-40% deposition bracket.
For the TB region, Saetta deposition data has the largest TB deposition of all the data
sets for all particle sizes. The Saetta data quickly pulls away from the other data sets at 0.6
pm. This shows the impact that scaling the TB airway diameters by 16/55 has on TB
deposition. It is a good indication that Saetta should have very small deposition results in the
pulmonary region. Resistance-Average TB deposition data values are the smallest out of the
disease data sets. Disease-Average modification data is on average, over the interval 0.05-1
pm, 5.8% larger in value than Healthy-Weibel data. For 2.5 pm particles and larger the
Disease-Average data is larger than the Healthy-Weibel data. The increase percent
differences of Disease-Average over Healthy-Weibel data, for particle size 2.5, 5, and 10 pm
are 59.7%, 135.9%, and 24.5%, respectively, for an average difference of 73.4% in the TB
region.
The pulmonary deposition plot, upon first inspection, shows that there is fluctuation
of pulmonary deposition totals in the data sets due to particles being deposited early in the
TB region. For particle sizes 0.05-1.0 pm, the order for the largest pulmonary deposition per
particle size are Resistance-Average, Disease-Average, Saetta, James then Healthy-Weibel.
For particle size 1.0 pm and larger, Saetta pulmonary deposition values die-out due to the
large TB deposition at 1.0 pm, James and Disease-Average pulmonary deposition decreases
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at 2.5 pm and lower. Resistance-Average remains to be the largest until 5 pm where
Healthy-Weibel surpasses the Resistance-Average pulmonary deposition data.
5.4 Local Deposition
Local deposition shows the deposition percent in each generation. Figures 5.3 and 5.4 are
two plots of deposition percent versus generation and particle size for Healthy-Weibel and
Disease-Average data at an FRC of 4500 mL. Note, the scales of the two plots are of equal
value due for ease in viewing. Also, the local deposition results of James (Figure 5.7), Saetta
(Figure 5.8), and Resistance-Average (Figure 5.9) are shown.
Comparing Figure 5.3 to Figure 5.4, there is a definite distinction in the deposition
percent location and particle size. The Disease-Average plot (Figure 5.4) shows that for a
particle size range of 4.6-10 pm, there is a considerable amount of deposition in the lower
airways of the TB region compared to the Healthy-Weibel plot (Figure 5.3). The Healthy-
Weibel plot shows a steady increase in deposition percent as the particles progress through
the airways with the highest percentages occurring in the pulmonary region. Figures 5.5 and
5.6 provide a comparison of Disease-Average and Healthy-Weibel for small and large
particle sizes, respectively. For the particle sizes 2.5 pm and less, the deposition pattern of
the Disease-Average data set resembles Healthy-Weibel (Figure 5.6), while for 5 pm and
greater there is a clear difference in deposition percent.
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Figure 53 - Deposition percent versus generation and particle size for Healthy-Weibel
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Figure 5.4 - Deposition percent versus generation and particle size for Disease-Average
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Figure 5.5 - Local deposition comparison for Disease-Average versus Healthy-Weibel with larger particle
sizes
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Figure 5.6 - Local deposition comparison for Disease-Average versus Healthy-Weibel with smaller
particle sizes
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Figures 5.7-5.9 show the remaining data set's local deposition patterns for different
particle sizes and generations. James (Figure 5.7) and Disease-Average (Figure 5.4) are very
similar with deposition percent peaking at -33%. Saetta (Figure 5.8) provides a large
deposition percent of particles than the rest of the data sets within the lower airways have a
maximum value of around 52%. Figure 5.8 shows that the airway geometry is tightened so
much that 2.5 pm particles show impaction in the lower airways much to the effect that 5 pm
particles and greater have. Finally, Resistance-Average (Figure 5.9) is the least in terms of
early generation deposition percent and shows a peak ofaround 12%.
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Figure 5.7 - Deposition percent versus generation and particle size for James
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Figure 5.8 - Deposition percent versus generation and particle size for Saetta
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Figure 5.9 - Deposition percent versus generation and particle size for Resistance-Average
Note for Figures 5.3, 5.4, and 5.7-5.9 it is evident that there is zero deposition for
generations 21-23. For the deposition to be non-zero, the tidal volume must be large enough
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to reach that deep. The model is an analytical model based on the conservation ofmass. One
could say that the deposition by generation in the pulmonary region given by the model is an
approximation based on the total deposition predicted in each airway. So the deposition in a
given generation is an estimation and it is assumed that mixing from the lower generations is
taking place to provide deposition there even though the program did not predict it.
In summary of the total, regional, and local deposition plots it is clear that deposition
is greater within a person with symptomatic asthma especially with larger size particles. The
next section presents plots of the deposition collection efficiencies, DCE, that were output
concurrently with the deposition results. The DCE's provide information on which particular
deposition mechanism was active for a given particle size and generation.
5.5 Effect ofDeposition Collection Efficiencies
Deposition collection efficiencies were computed from the runs for the breathing conditions
and particle sizes of the analysis. The code allows for the DCE to be output for all
generations and in separated categories of diffusion, sedimentation, impaction and total
combined collection efficiencies, which are plotted in Figures 5.10-5.13, respectively. Also
included in the output of each deposition run were the inhalation velocity per generation and
the particle residence time per generation. Following this introduction the results of the
DCE, inhalation velocity, and particle residence time per generation are presented.
5.5.1 Diffusion
In Figure 5.10 diffusion collection efficiency is shown for every generation and particle size
for the two data sets of Disease-Average and Healthy-Weibel. From the figure there are
several results to point out such as, diffusion deposition collection efficiency has its
maximum efficiency of approximately 33% at the last generation, Healthy-Weibel data has
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more of diffusion DCE than Disease-Average, and that the general trend of the diffusion
DCE is that the collection efficiency decreases with increasing particle size. The trends can
be explained by the diffusion parameter presented in Chapter 3, Equation 3.5b,
A -A4
ur
(3.5b)
where Dk is the particle diffusion coefficient and u, Lz and rz are velocity, length of the
airway and radius ofthe airway, respectively.
When comparing Disease-Average and Healthy-Weibel, the parameter Dk will be the
same for both sets as well as the lengths of airways, since Dk is a function of particle size.
Also, Lz changes only slightly for the disease case (see Figure 4.12 in Chapter 4). Therefore
the denominator ofEquation 3.5b is the only part that will experience a difference between
the data sets.
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Figure 5.10 - Diffusion deposition collection efficiency, Values on the right-hand side correspond to
particle size and are indicating general region of data sets for the particular particle size
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Figure 5.11 shows the velocity plot upon inhale per generation for Disease-Average
and Healthy-Weibel and Figure 5.12 presents the particle residence time per generation. The
velocity plot shows that particle flow travels faster through the Disease-Average airways as
compared to Healthy-Weibel mainly due to the constriction in airway diameter, which
increases velocity and has a larger tidal volume. Particle residence time per generation is
shown in Figure 5.13. Overall the values for particle residence time per generation and for
each data set are essentially the same. A closer look shows that Healthy-Weibel has a larger
particle residence time for each generation. This can be directly related to the velocity plot
of Figure 5.12 by the rate at which the flow is passing through each generation. Healthy-
Weibel had a slower velocity than Disease-Average for every generation thus a larger
particle residence time.
Getting back to Equation 3.5b, the velocity for Disease-Average is larger than
Healthy-Weibel and is the dominant term in Equation 3.5b for the difference between the
data sets. Since velocity is obtained by squaring the radius due to cross-sectional area being
involved in the calculation, it is the variable that has the most change. Therefore with larger
velocities the parameter in Equation 3.5b (Ad) decreases. This is why there is a small
diffusion DCE percentage in the early generations due to the large difference in velocity of
the data sets. For the diffusion DCE decreasing with increasing particle size this is a function
of the parameter Dk. Dk is directly multiplied by Lz/(urz) and Dk is a parameter that decreases
for increasing particle size therefore the effect of Dk is present in Figure 5.10 for both data
sets.
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5.5.2 Sedimentation
Figure 5.13 shows a plot of the deposition collection efficiency from sedimentation. The
sedimentation DCE main parameter is similar in structure to the equation for diffusion DCE
parameter but differs in the trends that are produced. The sedimentation DCE from Chapter
3, Equation 3.4b, is driven by the parameter e, which is
3^4
%ru
s =- (3.4b)
where Ug is the particle settling velocity, Lz is the length of the airway, rz is the radius of the
airway and u is the average velocity of the airflow. Upon inspection there is similarity
between the sedimentation DCE and the diffusion DCE parameter. The numerator of the
equation is the same for both data sets and the terms for radius and velocity in the
denominator are subject to change.
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Figure 5.11 - Inhalation velocity per generation
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Figure 5.13 - Sedimentation deposition collection efficiency
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The same discussion is applied for the trends realized by Figure 5.13. Sedimentation DCE
increases with increasing particle size due to the particle settling velocity variable. This
variable directly increases with increasing particle size. Maximum DCE is achieved at the
last generation, Healthy-Weibel data has more sedimentation DCE than Disease-Average for
each particle size, and sedimentation DCE increases with increasing particle size. Maximum
DCE is achieved at the last generation due to the radius being in the denominator and the
velocity of the last generation being very small. Both data sets rapidly decrease in radius as
the generation increases therefore enlarging the parameter 8. Healthy-Weibel data has more
sedimentation DCE than Disease-Average for each particle size due to the same trend as that
found with diffusion, where the velocity of Disease-Average is larger than Healthy-Weibel,
which makes the parameter E smaller for Disease-Average the airway radius effect is small
compared to the velocity effect on e.
5.5.3 Impaction
In Figure 5.14 the impaction DCE is displayed for the results of Disease-Average and
Healthy-Weibel data sets. The impaction DCE the output obtained produces significant
DCE's for the lower generations and large particle sizes of the Disease-Average data set.
Impaction DCE is driven by the Stokes number, Equation 3.3c.
C,pnd2nu
St=
s p " (3.3c)
judz
pp is the particle density, dp is the diameter of the particle, u is the velocity, Cs the slip
correction factor, p is the dynamic viscosity and dz is the generation diameter. Viewing
Figure 5.14 Healthy-Weibel geometry and flow conditions do not produce effective
conditions for impaction DCE, while the Disease-Average geometry for 5 pm and 10 pm
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seem to flourish. This affect can be attributed to the numerator of Equation 3.3c, namely u
and dz in the denominator. As noted before velocity is the most dynamic variable for all of
the DCE's. For impaction, velocity is in the numerator as well as the particle diameter
squared. Velocity for the Disease-Average case is very large compared to Healthy-Weibel
for the beginning airways since u is larger and dz is smaller compared to Healthy-Weibel, this
is why there is a large impaction DCE for Disease-Average. The variable dp is constant
between the data sets but shows that the larger particles will have a larger Stokes number.
Also the slip-correction variable increases with increasing particle size.
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Figure 5.14 - Impaction deposition collection efficiency
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5.5.4 Combined Mechanisms
Recall that for each particle size the DCE's of diffusion, sedimentation, and impaction are
combined through Equation 3.6 and 3.7
Vs+d =
hl+vl-ils-Vo)2
(3-6)
1m=1s+D+Vi^-Vs+D) (3-7)
where rjs, nD, and rjj are the efficiency for sedimentation, diffusion and impaction,
respectively. Figure 5.15 is the net plot of combining the DCE's.
The total result is very clear from this figure that the largest deposition collection
efficiency occurs with Disease-Average with larger size particles 5 and 10 pm. The most
effective DCE's for Disease-Average are impaction in the early TB generations and
sedimentation in the pulmonary region, while for Healthy-Weibel it is just sedimentation in
the pulmonary region. It is obvious that the impaction DCE is the dominant mechanism that
differentiates symptomatic asthma from healthy subjects. The DCE's provide a sanity check
for the result of the previous section that the largest deposition is occurring in Disease-
Average with large particle sizes 5 and 10 pm. Notice that for the large generations .05 pm
particle size has larger combined DCE than .1, 1, .3, and .6 pm. This is a result of the
diffusion DCE being dominant for particle size less than .6 pm, decreasing as particle size
reaches .6 pm. At .6 pm sedimentation starts increasing while diffusion is phased out.
Sedimentation rules for later generations and increasing particle size.
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Figure 5.15 - Combined deposition collection efficiency
5.6 Comparison of Published Deposition Data versus Model Runs
Results
From Appendix A, experimental results of total deposition percent for Asthmatic patients
were extracted and compared to the results from the Disease-Average model. Table 5.4
shows the articles and parameters used for comparison. Notice that there was information
missing in most of the articles, therefore Table 5.5 shows the assumptions that were made to
compensate for the missing data.
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Table 5.4 - Experimental particle deposition parameters for Asthma, * Does not state in the article
Article
Concentration
of Particles,
(particles/cm3)
Particle
Size (pm),
density
(g/cm3)
Frequency,
(Breaths/
Minute)
Tidal
Volume,
(ml)
Ti(s) Pause (s) Te(s)
Lippmann
etal. (1970)
* 1-14, 1.0 14 700-1200 * * *
Svartengren
etal. (1990)
* 3.6,2.13 12 500 * 1-2 *
Siekmeier
et al. (1994)
* 0.8 * * * * *
Kim&
Kang
(1997)
104
1.0 30 500
Inhale =
exhale
0
Inhale =
exhale
Table 5.5 - Deposition code runs of the experimental/assumpt
the run
tion parameters for Asthma, * Assumption for
Article
Concentration of
Particles,
(particles/cm3)
Particle
Size
(pm),
density
(g/cm3)
Frequency,
(Breaths/
minute)
Tidal Volume,
(ml) Tt (%)
Pause
(%) Te (%)
Lippmann et
al. (1970)
2.59e+9* 1.5*, 1.0 14 700* & 1200* 43.5* 5* 51.5*
2.59e+9* 2.2*, 1.0 14 700* & 1200* 43.5* 5* 51.5*
2.59e+9* 4.5*, 1.0 14 700* & 1200* 43.5* 5* 51.5*
Svartengren
etal. (1990)
2.59e+9* 3.6,2.13 12 500 43.5* 5* 51.5*
Siekmeier et
al. (1994)
2.59e+9* 0.8, 1.0 15* 600* 43.5* 5* 51.5*
Kim&
Kang (1997)
104 1.0, 1.0 30 500 50* 0 50*
The results of the runs are given in the order listed in Table 5.3. Each of these articles
have already been given synopsizes in Chapter 2, but a discussion about how the deposition
results were interpreted will also be included as an introduction to the results to regain
insight.
Lippmann et al. (1971) performed a multitude of deposition tests using particles that
were tagged with gamma emitting isotopes. The study included healthy people who do and
do not smoke, bronchitics, and asthmatics. The data in Table 5.5 only pertains to the
experiment data of the asthmatic patient. Particle sizes for all the subjects ranged from 1-14
pm. There was only one individual who was considered asthmatic. The authors collected
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deposition results for the head, trachea, TB, and alveoli regions and presented the data in a
form of percent of percent collected. Therefore, the deposition of the regions added to
approximately 100%. Also, the data was presented by means of a 3-way graph, deposition %
on the y-axis, particle diameter on the Xi axis, and the parameter p-d2-V on axis x2. The
parameter represented on axis x2 is an impaction parameter; looking at the units indicates that
the output of the parameter is force. This parameter was explained to be a normalizing agent
for the large number of trials the author's performed and was used to normalize every data
point to an airflow of 30 L/min for inspiration.
The output for the experimental results was in terms of 3 approximate particle sizes:
1.5, 2.2, and 4.5 pm due to visual inspection of the graphs. Also, extracting tidal volume
from the article for the asthmatic patient was not clear. The authors stated 700-1200 ml but a
specific tidal volume was not correlated to the deposition data. Hence there were two runs of
Vt 700 and 1200 mL for each particle performed to acquire the result for the given tidal
volume. A summary table is provided in Table 5.6 with the results noted in the article as
well as the results from the computer model run. The computer model results for tracheal
region are within the TB results.
Overall the values used to simulate Lippmann et al. (1971) did not correlate that well
and can be contributed to not having the exact data to model this case. The only close set of
deposition region percentages occurred at the large particle size of 4.5 pm where both
experimental and model generated results show a high regional deposition percent in the TB.
Svartengren et al. (1990) had patients, 10 asthmatics ofwhich 5 were ex-smokers and
the other 5 never smoked, inhale Teflon particles that were radio labeled to find what time
step the deposition data could be collected before the clearance mechanisms altered the total
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deposition significantly. Svartengren et al. (1990) had patients inhale Teflon particles that
were radiolabeled in pursuit to find what time step the deposition data could be collected
before the clearance mechanisms altered the total deposition significantly.
Table 5.6 - Deposition comparisons for the run ofLippmann et al. (1971), 'Values are taken from visual
inspection
Author
Particle
Size,
pm
Location
Experimental
Deposition
Result %*
Tidal
Volume,
ml
Disease-AverageModel
Total %
Percent of
Total %
Lippmann
etal.
(1971)
1.5
Head 5
700
0.23 1
Tracheal 5
6.78 24.7
TB 35
Pulmonary 50 20.48 74.5
1200
0.21 1
9.71 30.3
22.09 69.0
2.2
Head 10
700
0.17 0.3
Tracheal 7
14.31 30.9
TB 73
Pulmonary 25 31.86 68.8
1200
3.06 5.3
26.49 45.8
28.23 48.9
4.5
Head 0
700
15.56 17.4
Tracheal 0 60.05 67.3
TB 84
Pulmonary 14 13.60 15.2
1200
23.13 24.2
69.51 72.7
2.94 3.1
Gamma counts of the head, neck, lungs, and stomach were taken to capture the total
deposition in the study. In Chapter 2, Table 2.3, it shows the total deposition results of the
healthy and asthmatic case, but for this section the value is in the asthmatic experimental
total deposition case versus the modeled. Table 5.7 shows the comparison of results for
Svartengren et al. (1990) with the model prediction. The results show that the model's
166
prediction for the breathing parameters selected corresponded very well with the
experimental result of Svartengren et al. (1990) even though the authors provide a reasonable
tolerance on the total deposition collected of 12%.
Table 5.7 - Deposition comparisons for the run ofSvartengren et al. (1990)
Comparison
Svartengren et al. (1990)
Disease-Average Model
Deposition Result
83 + 12% total deposition
86.2% total deposition
73.2% without mouth deposition contribution
Siekmeier et al. (1994) states that the purpose of the study was to assess the influence
asthma has on convective gas transport, but instead the article is satisfactory in just providing
the results without much discussion. One of the plots contained within the results section
deals with deposition percent per depth of lung in cm . Below in Table 5.8 are the results for
the average deposition for 10 asthmatics and the computer model's prediction. The downfall
for this particular comparison was that the only information from Siekmeier was the particle
size at which the experiment was run (0.8 pm); therefore assumptions that relate to the
default condition were applied to simulate the experiment.
Table 5.8 - Deposition comparisons for the run of Siekmeier (1994)
Comparison Deposition Result
Siekmeier et al. (1994) 30% total deposition at 800
cmj
Disease-Average Model
13.2% total deposition
13.6% total deposition including
mouth deposition
Kim & Kang (1997) presented deposition results in attempts to show that there is
more deposition of inhaled particles for a subject experiencing an obstructive disease
symptom compared to a healthy subject. The particles of interest were that of particulate
pollutants that would produce a risk factor to people with respiratory ailments. The method
of deposition calculation was analyzing the input and output of particles by means of a
collapsible bag and the particle size was 1 pm. The deposition fraction was calculated by
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(inhaled - exhaled) / inhaled. The results of Kim & Kang for the average of 5 asthmatics as
well as the computermodel are depicted in Table 5.9.
Table 5.9 - Deposition comparisons for the run ofKim & Kang (1997)
Comparison Deposition Result
Kim & Kang (1997) 22% Deposition Fraction
Disease-AverageModel
9.9% Deposition Fraction,
10.2% with mouth deposition
In summary, four experimental deposition studies from the literature were compared
to the asthmatic deposition model. Svartengren et al. (1990) data closely agreed with the
computational model. Lippmann et al. (1970) deposition plots were ambiguous and key
parameters of particle size, frequency, among others were assumed. Siekmeier et al. (1994)
and Kim and Kang (1997) reported a larger total deposition, by a factor of approximately
two, than the computer model result. In each case a high-level of confidence could not be
achieved in comparing the data from experimental to theoretical since critical breathing
parameter data was assumed.
5.7 Conclusion
The computer model runs of Table 5.1b were very telling in terms of differentiating
asthmatics from healthy individuals. The runs provided information on total, regional, and
local deposition as well as information on the different deposition mechanisms impact
throughout the generations. The synopsis is that Disease-Average model predictions for total
deposition is on average 21.6% larger than Healthy-Weibel, which is found to be directly
related to the impaction DCE that is activated in early generations of TB airways with small
caliber compared to Healthy-Weibel due to the velocity of airflow through the airways.
TB and pulmonary deposition plots showed that the disease model data sets were
collecting more deposition percent than Healthy-Weibel for the
same region due to the
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impaction mechanism. Healthly-Weibel and the disease models deposition percentage
remained steady through the pulmonary region due to both data sets having nearly the same
sedimentation and diffusion deposition mechanism efficiencies.
Experimental deposition data for asthmatics compared to the corresponding computer
model runs turned out to be a fraction off of the model runs for the primary reason of not
having great inputs into the code. Though, one of the article's total deposition results did
match the computer model run within a close tolerance, Svartengren et al. (1990). The topic
of experimental deposition data will be further discussed in the following chapter of
recommendations and conclusions in order to expose what is needed to provide accurate
modeling.
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Chapter 6 - Perspective and FutureWork
6.1 Summary
The goal of this research was to provide foundation for the development of a diseased
module that would use the already existing and proven particle deposition code from Dr.
Robinson. Chapter 1 was mainly focused on introducing the reader to the human respiratory
system and aerosol particles. The respiratory components, regions, and function were
described in detail as well as how the system is portrayed in literature (Weibel, 1963) by
quantitative morphological measurements. In addition, a sampling of pulmonary function
test methods were explained to fully describe how quantitative data is extracted from
experiments to diagnose patients. Finally, a description of aerosol particles and their
deposition methods were presented.
Chapter 2 provides a synopsis of lung ailments that can affect an individual. The goal
was to filter the various disorders into separate categories based on similar characteristics of
how it affects the patient. Also, this chapter can be useful in providing a reference for the
different terms that may arise when reading the journal article summaries. Six main groups
of lung diseases were referenced that most lung ailments could fall under: Obstructive,
Resistive, Vascular, Environmental, Neoplastic and Infectious. West (1998) and Farzan &
Farzan (1997) were of great aid in this endeavor.
Chapter 3 compiles the literature gathered pertaining to actual experimental
deposition data from COPD and asthmatic patients, theoretical disease deposition models,
diseased experimental breathing parameters, morphological modifications (airway narrowing
and/or alveolar degeneration) from asthma and COPD, elasticity studies, and background on
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models that can predict airway narrowing based on disease. This chapter provides basis for
development of a disease module from the quantitative and qualitative results from literature.
Chapter 4 constructs the disease module based on the literature investigation of
chapter 3. The executive decision to make the module based off of asthmatic data was made,
due to the lack of morphological data of COPD; although Segal et al. (2002) does provide
quite a case for a COPD computer model. Asthmatic modifications were applied to the
Healthy-Weibel geometry by two different methods, proportion of the airway cross-section
that is wall area (PW) and resistance of the airways (Raw). James, Saetta, Resistance-
Average, and Disease-Average modification sets arose from the two methods. The
modification sets were then exposed to another method of representing asthma by an
increased FRC compared to a normal individual. The output of this chapter directly feeds
into Dr. Robinson's code to predict the deposition of a range of particles within in this
diseased lung.
Finally Chapter 5 summarized the results of running the code with the asthmatic
modification data sets. Results were presented in terms of total, regional, and local
deposition fractions for the complete cycle of a breath. Also presented was the involvement
of the different deposition mechanisms in capturing the particles traveling through the
airways. The deposition mechanisms were sedimentation, diffusion, and impaction as well
as the combination deposition collection efficiency results from all of the deposition
mechanisms.
6.2 Conclusion
In conclusion, it can be verified from the produced results that the asthmatic deposition
model created from the morphological data from literature is a useful and computationally
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cheap tool in predicting the probability of the deposition of different sized particles and
where the particles will deposit within the lungs. Incorporated in this model are data
acquired from literature on the size of different airway wall components, breathing
parameters, and volumes within an asthmatic person as compared to normal. The created
disease geometric data sets all exhibit the general qualitative trends presented in literature, in
a quantitative manner. Namely, decrease in diameter of the airway in the front generations
due to inflammation of the airway wall components as well as mucus buildup and an inflated
volume in the later generations'characteristic of air trapping.
The model predicts that there is generally more total deposition in a symptomatic
asthmatic person for the span of particle run. On average, using Disease-Average as the
nominal deposition data set, the total deposition is 21.6% larger than Healthy-Weibel. The
peak total deposition for the data sets occurred between 2.5 pm and 6 pm. The regional
deposition shows that the asthma disease data sets are very active in collecting deposition,
within the TB region, for larger particles 1 pm and beyond. The pulmonary region shows
Disease-Average deposition larger than Healthy-Weibel up until particle size of 2.5 pm, for
the larger sizes Healthy-Weibel is greater than the disease sets. Regional deposition further
dissects the results and shows that the main difference in the deposition characteristics for
asthma and healthy runs was for the asthmatic data sets the deposition was larger in the front
generations with larger particles 2.5 - 6 pm, where the healthy case had nil results. Below
those sizes of particles, the deposition results are comparable to Healthy. By use of
examining the deposition collection efficiencies it was shown that the deviation is due to a
larger deposition by the impaction mechanism. The theoretical results of this experiment
correspond very well with intuition. The constriction of the airways due to an attack or
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constant irritant is characterized in literature to reside in the TB generation as well as the
alveolar region trapping gas due to collapsed airways and distended alveoli. These generated
data sets mimic the asthmatic conditions of a constricted TB and an expanded pulmonary
region.
The results of this model were compared to experimental data from four articles. For
the articles compared, assumptions were made for most of the inputs into the deposition code
but inputs that the article provided were used accordingly. The predicted results for
Svartengren et al. (1990) inputs were approximately 3% different from the experimental
results given in the article. Deposition results for Siekmeier et al. (1994) and Kim & Kang
(1997) the results were a factor of two off the experimental. While Lippmann et al. (1971)
conditions showed generally closeness in relative magnitudes within regions to the
experimental data. For example, Lippmann et al. (1971) experimental results show 5%, 5%,
35%, and 50% for head, tracheal, TB, and pulmonary regions, theoretical shows 1%, 33%,
and 66%. Simply more of the deposition is predicted to occur in the pulmonary regions for
both models.
6.3 Future Direction
The reader should take away from this body of literature that there are obvious gaps in
literature for collecting rich modification data for disease conditions as well as there are
ways, that may be out of reach now, that could predict the whole situation with predicting
deposition of particles in disease. This modification data is vague and inconsistent for the
most part. Also there are few deposition models that take on the challenge to model different
disease conditions.
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Finlay et al. (2000), whose roots are of mechanical engineering background, shares
some of the gaps in deposition modeling in disease. In their article they call for a model
which would include the following information: specific dimensions of lung geometry,
regional deposition data, better information of the mouth and throat region in terms of
filtering, resistance and geometry, time dependent breathing flow rates during aerosol
exposures, and properties of the inhaled aerosol as a function of time during the breath.
If more time were available, time would be spent incorporating the relationships that
Ebina et al. (1990) researched relating muscular thickness in an asthmatic airway wall to the
radius of the airway and/or working with an actual pulmonary & respiratory diseases MD to
aid in setting up deposition experiments where better data based off known inputs could be
acquired.
In my opinion, the future of deposition of inhaled particles in the lung (healthy and/or
diseased) lies not only in computational fluid dynamics (CFD) but also accurate system
dynamic models of the airways undergoing respiration. As of right now, the CFD gurus have
only been able to model some of the conductive airways, i.e. generation 0-3 through 7. The
problems of CFD modeling of the lung are computational expense
(223
generations) and
accurate meshing schemes. Some models have been symmetric models, while some have
been geometry derived from lung casts. The geometry derived from lung casts is the trophy
among models due to being an exact replica, but if further generations can be expressed using
a symmetric model, than that should be the first step.
Dynamic system models of healthy and diseased lung mechanics should be also
incorporated with the CFD models. CFD will only deal with flow progressing through a
series of rigid tubes. The rigid tubes will be exact if taken from a lung cast, but will not
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accurately reflect the changes in airway geometry among inspiration and expiration. As
noted in Chapter 1 the CFD would represent a non-elastic resistance to work of breathing.
Recall that 65% of total resistance of airflow moving through the respiratory system is elastic
related, the rigid tube resistance only accounts for 80% of the 35% remaining for total
resistance to airflow.
Overall, this work gives an accurate prediction of total, regional, and local deposition
of particles within a healthy and asthmatic individual. The conditions of this computer
model should be taken as an approximate case based on concluded assumptions and results
from the investigator and literature. This model has a place in future deposition in the way
that it can predict results from a computationally inexpensive method and could be refined in
the future with iterations of the lumped CFD and dynamic system model.
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Appendix A
Experimental Deposition Data for Diseased
Lung
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Appendix B
Modified Diameter Data Sets
Table B.l - Weibel diameter, length, and volume
Generation
z
Number per Generation
n(z)
Diameter
d(z)
cm
Length
Kz)
cm
Total Volume V(z)
cm3
0 1 1.8 12.0 30.50
1 2 1.22 4.76 11.25
2 4 0.83 1.90 3.97
3 8 0.56 0.76 1.52
4 16 0.45 1.27 3.46
5 32 0.35 1.07 3.30
6 64 0.28 0.90 3.53
7 128 0.23 0.76 3.85
8 256 0.186 0.64 4.45
9 512 0.154 0.54 5.17
10 1,024 0.130 0.46 6.21
11 2,048 0.109 0.39 7.56
12 4,096 0.095 0.33 9.82
13 8,192 0.082 0.27 12.45
14 16,384 0.074 0.23 16.40
15 32,768 0.066 0.20 21.70
16 65,536 0.060 0.165 29.70
17 131,072 0.054 0.141 41.80
18 262,144 0.050 0.117 61.10
19 524,288 0.047 0.099 93.20
20 1 ,048,576 0.045 0.083 139.50
21 2,097,152 0.043 0.070 224.30
22 4,194,304 0.041 0.059 350.00
23 8,388,608 0.041 0.050 591.00
Table B.2 - James calculated diameter change
James PAIS 0.2
Gen Dia (em) Pi (cm) WAH PWH PW0 PMC { DiaMod
1.4740 1.8 7.540 38.160 0.130 0289 033
1 1.22 5.110 17347 0.132 0294 033 0396
2 033 3.477 8.477 0.135 0.483 0.666 0.462
3 0.56 2.346 4.010 0.1 40 0.499 0227
4 0.45 1 .885 2.663 0.143 0377 0250
5 0.35 1.466 1.678 0.1 48 0390 0.190
6 0.28 1.173 1.123 0.154 0.405 0.148
7 0.23 0.963 0.794 0.161 0.421 0.117
8 0.186 0.779 0.552 0.169 0.443 0390
9 0.154 0.645 0.404 0.178 0.468 0.071
10 0.13 0.545 0.308 0.1 88 0.494 0355
11 0.109 0.457 0.234 0.201 0327 0341
12 0.095 0.398 0.191 0.212 0253 0367
13 0.082 0.343 0.154 0226 0270 0.057
14 0.074 0.310 0.134 0238 0283 0.051
15 0.066 0.276 0.115 0252 0300 0.044
16 0.06 0.251 0.102 0265 0315 0.040
17 0.054 0.226 0.089 0280 . - ;
18 0.05 0.209 0.081 0293 - - j
19 0.047 0.197 0.076 0.304 ! - \
20 0.045 0.188 0.072 0.312 j - -
21 0.043 0.180 0.068 0.320 > - \
22 0.041 0.172 0.065 0.330 . - I
23 0X141 0.172 0.065 0330 - - I
Table B.3 - - Dunnill calculated diameter change
Dunnill
Gen Dia fcm) Pi (cm) WA PWU PW PMC j DiaMod
0 1.8 7.540 38.160 0.130 0289 0.33 1 .474
1 1.22 5.110 17.847 0.132 0294 0.33 0396
2 0.83 3.477 8.477 0.135 0.254 0.666 0.630
3 0.56 2.346 4.010 0.140 0262 0.371
4 0.45 ! 1 .885 2363 0.143 0.377 0250
5 0.35 1 .466 1378 0.148 0390 0.1 90
6 0.28 1.173 1.123 0.154 0.405 0.148
7 0.23 0.963 0.794 0.161 0.421 0.117
8 0.186 0.779 0552 0.169 0.443 0.090
9 0.154 0.645 0.404 0.178 0.468 0.071
10 0.13 0.545 0.308 0.188 0.494 0.055
11 0.109 0.457 0234 0201 0.527 0.041
12 0395 0.398 0.191 0.212 0253 0.067
13 0382 0.343 0.154 0226 0.270 0.057
14 0374 0.310 0.134 0.238 0.283 0.051
15 0366 0.276 0.115 0252 0.300 0.044
16 0.06 0.251 0.102 0265 0.315 ; 0.040
17 0354 0.226 0.089 0280 - - !
18 0.05 0.209 0.081 0293 ! - j
19 0347 0.197 0.076 0.304 ! - -
20 0.045 0.188 0.072 0312 I - \
21 0343 0.180 0.068 0320 ; - \
22 0341 0.172 0.065 0330 -
---'- - {- ~ -
23 0341 I 0.172 0.065 0330 -
Table B.4 - Sabonya calculated diameter change
Sabonya 1
Gen Dia (em) Pi (em) WAH PWH PWB PMC DiaMod
0 1.8 7.540 38.160 0.130 0.289 0.33 1.474
1 122 5.110 17.847 0.132 0.294 0.33 0396
2 0.83 3.477 8.477 0.135 0.364 0.666 0555
3 056 2.346 4.010 0.140 0377 1 0.310
4 0.45 1 .885 2.663 0.143 0.377 1 0.250
5 0.35 1 .466 1.678 0.148 0390 1 0.190
6 028 1.173 1.123 0.154 0.405 1 0.148
7 023 0.963 0.794 0.161 0.421 1 0.117
8 0.186 0.779 0.552 0.169 0.443 1 0.090
9 0.154 0.645 0.404 0.178 0.468 1 0.071
10 0.13 0.545 0.306 0.188 0.494 1 0355
11 0.109 0.457 0.234 0201 0.527 1 0.041
12 0.095 0.398 0.191 0212 0.253 1 0367
13 0.082 0.343 0.154 0.226 0270 1 0.057
14 0374 0.310 0.134 0.238 0283 1 0.051
15 0.066 0.276 0.115 0.252 0.300 1 0.044
16 0.06 0.251 0.102 0.265 0.315 1 0.040
17 0.054 0.226 0.089 0280 ! - I - -
18 0.05 0209 0.081 0.293 ! - -
19 0.047 0.197 0.076 0.304 ! - ! - -
20 0.045 0.188 0.072 0.312 ! - -
21 0.043 0.180 0.068 0.320 j - -
22 0.041 0.172 0.065 0.330 - - -
23 0.041 I 0.172 0.065 0.330 ! - -
Table B.5 - Hossain calculated diameter change
Hossain !
Geff Dia (em) Pi (em) WAH PWh PWD PMC DiaMod
0 1.8 7540 38.1 60 0.130 0.289 033 1.474
1 122 5.110 17347 0.132 0294 033 0.996
2 0.83 3.477 8.477 0.135 0.417 0.666 0.516
3 056 2346 4.010 0.140 0.431 0276
4 0.45 1.885 2.663 0.143 0.377 0.250
5 0.35 1.466 1.678 0.148 0.390 0.190
6 0.28 1.173 1.123 0.154 0.405 1 0.148
7 023 0.963 0.794 0.161 0.421 1 0.117
8 0.186 0.779 0.552 0.169 0.443 1 0390
9 0.154 0.645 0.404 0.176 0.468 1 0.071
10 0.13 0545 0.308 0.188 0.494 1 0.055
11 0.109 0.457 0.234 0.201 0527 1 0.041
12 0.095 0.398 0.191 0.212 0.253 1 0.067
13 0.082 0.343 0.154 0.226 0.270 1 0.057
14 0374 0310 0.134 0.238 0.283 0.051
15 0.066 0.276 0.115 0.252 0300 0.044
16 0.06 0.251 0.102 0.265 0.315 1 0.040
17 0.054 0226 0.089 0.280 -
-
18 035 0.209 0381 0.293 -
- -
19 0347 0.197 0.076 0.304 -
- -
20 0.045 0.188 0.072 0.312 -
- -
21 0.043 0.180 0.068 0.320 - -
-
22 0.041 0.172 0.065 0.330 - -
-
23 0.041 0.172 0.065 0.330 - - " I
Table B.6 - Saetta calculated diameter change
Saetta
Gen Dia (cm) SAE Dia
0 1.8 0.524
1 1.22 0.355
2 0.83 0.241
3 0.56 0.163
4 0.45 0.131
5 0.35 0.102
6 0.28 0.081
7 0.23 0.067
8 0.186 0.054
9 0.154 0.045
10 0.13 0.038
11 0.109 0.032
12 0.095 0.028
13 0.082 0.024
14 0.074 0.022
15 0.066 0.019
16 0.06 0.017 |
Table B.7 - Wiggs et al. (1992) published diameters
Generation
Contracted Internal
Diameter (cm)
0 1.340
1 0.909
2 0.501
3 0.250
4 0.197
5 0.154
6 0.122
7 0.098
8 0.079
9 0.065
10 0.054
11 0.045
12 0.038
13 0.032
14 0.028
15 0.024
16 0.021
Table B.8 - Constricted diameters and volume per generation based on resistance
Minimum Resistance Maximum Resistance Average Resistance
Diameter (cm)
Volume,
Airway +
Alveoli, (mL)
Diameter (cm)
Volume,
Airway +
Alveoli, (mL)
Diameter (cm)
Volume,
Airway +
Alveoli, (mL)
1.363 17.512 1.395 18.347 1.379 17.915
0.924 6.382 0.946 6.686 0.934 6.529
0.629 2.358 0.643 2.471 0.636 2.412
0.424 0.859 0.434 0.900 0.429 0.879
0.341 1.853 0.349 1.942 0.345 1.896
0.265 1.889 0.271 1.979 0.268 1.933
0.212 2.034 0.217 2.131 0.214 2.081
0.174 2.318 0.178 2.428 0.176 2.371
0.141 2.553 0.144 2.675 0.142 2.612
0.117 2.953 0.119 3.094 0.118 3.021
0.098 3.586 0.101 3.757 0.100 3.668
0.083 4.274 0.084 4.478 0.083 4.373
0.072 5.494 0.074 5.757 0.073 5.621
0.062 6.699 0.064 7.018 0.063 6.853
0.056 9.294 0.057 9.738 0.057 9.508
0.050 12.858 0.051 13.471 0.051 13.154
0.045 17.534 0.047 18.370 0.046 17.937
0.041 31.131 0.042 32.289 0.041 31 .690
0.038 56.493 0.039 58.140 0.038 57.288
0.036 117.514 0.036 119.977 0.036 118.703
0.034 298.973 0.035 302.759 0.034 300.799
0.033 561.432 0.033 567.263 0.033 564.245
0.031 1065.714 0.032 1074.651 0.031 1070.027
0.031 1810.760 0.032 1825.906 0.031 1818.068
ZVol. 4042.467 ZVol. 4086.226 ZVol. 4063.582
Table B.9 - Constricted diameters ofDisease-Average
Generation Diameter,
cm
Length,
cm
Volume per
Generation
cm3
0 1.125 12 13.658
1 0.762 4.76 4.964
2 0.507 1.9 1.346
3 0.296 0.76 0.417
4 0.242 1.27 1.054
5 0.187 1.07 1.060
6 0.148 0.9 1.122
7 0.120 0.76 1.255
8 0.096 0.64 1.347
9 0.078 0.54 1.512
10 0.064 0.46 1.774
11 0.052 0.39 2.020
12 0.056 0.33 3.714
13 0.048 0.27 4.477
14 0.043 0.23 6.155
15 0.038 0.2 8.414
16 0.034 0.165 1 1 .341
17 0.050 0.141 43.353
18 0.046 0.117 73.882
19 0.043 0.099 143.516
20 0.041 0.083 338.940
21 0.040 0.07 622.988
22 0.038 0.059 1160.053
23 0.038 0.05 1970.655
Appendix C
Scaled Diameter Data Sets
Table C.l - Weibel diameter, length, and volume scaled to FRC 3200 mL
Generation Scaled Diameter, cm Scaled Length, cm Scaled Volume, cm3
0 1.572 10.482 20.330
1 1.066 4.158 7.499
2 0.725 1.660 2.646
3 0.489 0.664 1.013
4 0.393 1.109 2.306
5 0.306 0.935 2.200
6 0.245 0.786 2.353
7 0.201 0.664 2.566
8 0.163 0.559 2.966
9 0.135 0.472 3.446
10 0.114 0.402 4.139
11 0.095 0.341 5.039
12 0.083 0.288 6.546
13 0.072 0.236 8.299
14 0.065 0.201 10.932
15 0.058 0.175 14.464
16 0.052 0.144 19.797
17 0.047 0.123 32.434
18 0.044 0.102 55.363
19 0.041 0.087 106.031
20 0.039 0.073 239.358
21 0.038 0.061 442.249
22 0.036 0.052 818.774
23 0.036 0.044 1389.249
Table C.2 - Scaled diameter, length, and volume for James - FRC 3800 mL
Generation Scaled Diameter, cm Scaled Length, cm Scaled Volume, cm3
0 1.287 10.482 13.647
1 0.870 4.158 4.947
2 0.404 1.660 0.851
3 0.198 0.664 0.163
4 0.218 1.109 0.662
5 0.166 0.935 0.645
6 0.129 0.786 0.657
7 0.103 0.664 0.702
8 0.079 0.559 0.702
9 0.062 0.472 0.720
10 0.048 0.402 0.750
11 0.036 0.341 0.705
12 0.058 0.288 3.139
13 0.050 0.236 3.726
14 0.044 0.201 5.057
15 0.039 0.175 6.793
16 0.035 0.144 8.997
17 0.051 0.132 40.508
18 0.047 0.110 67.683
19 0.044 0.093 128.419
20 0.042 0.078 294.860
21 0.040 0.066 537.287
22 0.038 0.055 992.500
23 0.038 0.047 1685.880
Table C3 - Scaled diameter, length, and volume for Saetta - FRC 3800 mL
Generation Scaled Diameter, cm Scaled Length, cm Scaled Volume,
cm3
0 0.457 10.482 1.723
1 0.310 4.158 0.628
2 0.211 1.660 0.232
3 0.142 0.664 0.084
4 0.114 1.109 0.182
5 0.089 0.935 0.186
6 0.071 0.786 0.200
7 0.058 0.664 0.228
8 0.047 0.559 0.251
9 0.039 0.472 0.291
10 0.033 0.402 0.353
11 0.028 0.341 0.420
12 0.024 0.288 0.540
13 0.021 0.236 0.659
14 0.019 0.201 0.914
15 0.017 0.175 1.265
16 0.015 0.144 1.725
17 0.051 0.133 40.973
18 0.047 0.110 68.460
19 0.044 0.093 129.892
20 0.042 0.078 298.242
21 0.040 0.066 543.450
22 0.039 0.056 1003.884
23 0.039 0.047 1705.218
e C.4 - Scaled diameter, length, and volume for average resistance - FRC 380I
Generation Scaled Diameter, cm Scaled Length, cm Scaled Volume, cm3
0 1.204 10.482 11.941
1 0.816 4.158 4.352
2 0.555 1.660 1.608
3 0.375 0.664 0.586
4 0.301 1.109 1.264
5 0.234 0.935 1.288
6 0.187 0.786 1.387
7 0.154 0.664 1.581
8 0.124 0.559 1.741
9 0.103 0.472 2.014
10 0.087 0.402 2.445
11 0.073 0.341 2.915
12 0.064 0.288 3.747
13 0.055 0.236 4.568
14 0.050 0.201 6.338
15 0.044 0.175 8.768
16 0.040 0.144 11.956
17 0.041 0.138 29.855
18 0.038 0.115 53.971
19 0.035 0.097 111.830
20 0.034 0.081 283.384
21 0.032 0.069 531.577
22 0.031 0.058 1008.076
23 0.031 0.049 1712.809
Table C.5 - Scaled diameter, length, and volume for Disease-Average - FRC 3800 mL
Generation Scaled Diameter, cm Scaled Length, cm Scaled Volume, cm3
0 0.983 10.482 9.104
1 0.666 4.158 3.309
2 0.443 1.660 0.897
3 0.259 0.664 0.278
4 0.211 1.109 0.703
5 0.163 0.935 0.706
6 0.129 0.786 0.748
7 0.105 0.664 0.837
8 0.084 0.559 0.898
9 0.068 0.472 1.008
10 0.056 0.402 1.183
11 0.045 0.341 1.347
12 0.049 0.288 2.475
13 0.042 0.236 2.984
14 0.038 0.201 4.103
15 0.033 0.175 5.608
16 0.030 0.144 7.559
17 0.047 0.134 37.406
18 0.044 0.111 63.748
19 0.041 0.094 123.831
20 0.039 0.079 292.450
21 0.038 0.067 537.536
22 0.036 0.056 1000.934
23 0.036 0.048 1700.349
Table C.6 - Scaled diameter, length, and volume for James - FRC 4500 mL
Generation Scaled Diameter, cm Scaled Length, cm Scaled Volume, cm3
0 1.287 10.482 13.647
1 0.870 4.158 4.947
2 0.404 1.660 0.851
3 0.198 0.664 0.163
4 0.218 1.109 0.662
5 0.166 0.935 0.645
6 0.129 0.786 0.657
7 0.103 0.664 0.702
8 0.079 0.559 0.702
9 0.062 0.472 0.720
10 0.048 0.402 0.750
11 0.036 0.341 0.705
12 0.058 0.288 3.139
13 0.050 0.236 3.726
14 0.044 0.201 5.057
15 0.039 0.175 6.793
16 0.035 0.144 8.997
17 0.054 0.140 48.076
18 0.050 0.116 80.327
19 0.047 0.098 152.409
20 0.045 0.082 349.943
21 0.043 0.069 637.657
22 0.041 0.059 1177.908
23 0.041 0.050 2000.818
Table C.7 - Scaled diameter, length, and volume for Saetta - FRC 4500 mL
Generation Scaled Diameter, cm Scaled Length, cm Scaled Volume,
cm3
0 0.457 10.482 1.723
1 0.310 4.158 0.628
2 0.211 1.660 0.232
3 0.142 0.664 0.084
4 0.114 1.109 0.182
5 0.089 0.935 0.186
6 0.071 0.786 0.200
7 0.058 0.664 0.228
8 0.047 0.559 0.251
9 0.039 0.472 0.291
10 0.033 0.402 0.353
11 0.028 0.341 0.420
12 0.024 0.288 0.540
13 0.021 0.236 0.659
14 0.019 0.201 0.914
15 0.017 0.175 1.265
16 0.015 0.144 1.725
17 0.054 0.140 48.540
18 0.050 0.116 81.104
19 0.047 0.099 153.882
20 0.045 0.083 353.325
21 0.043 0.070 643.820
22 0.041 0.059 1189.292
23 0.041 0.050 2020.155
e C.8 - Scaled diameter, length, and volume for average resistance - FRC 450I
Generation Scaled Diameter, cm Scaled Length, cm Scaled Volume, cm3
0 1.204 10.482 11.941
1 0.816 4.158 4.352
2 0.555 1.660 1.608
3 0.375 0.664 0.586
4 0.301 1.109 1.264
5 0.234 0.935 1.288
6 0.187 0.786 1.387
7 0.154 0.664 1.581
8 0.124 0.559 1.741
9 0.103 0.472 2.014
10 0.087 0.402 2.445
11 0.073 0.341 2.915
12 0.064 0.288 3.747
13 0.055 0.236 4.568
14 0.050 0.201 6.338
15 0.044 0.175 8.768
16 0.040 0.144 11.956
17 0.043 0.146 35.456
18 0.040 0.121 64.096
19 0.037 0.103 132.809
20 0.036 0.086 336.545
21 0.034 0.073 631.297
22 0.033 0.061 1197.183
23 0.033 0.052 2034.118
Table C.9 - Scaled diameter, length, and volume for Disease-Average - FRC 4500 mL
Generation Scaled Diameter, cm Scaled Length, cm Scaled Volume, cm3
0 0.983 10.482 9.104
1 0.666 4.158 3.309
2 0.443 1.660 0.897
3 0.259 0.664 0.278
4 0.211 1.109 0.703
5 0.163 0.935 0.706
6 0.129 0.786 0.748
7 0.105 0.664 0.837
8 0.084 0.559 0.898
9 0.068 0.472 1.008
10 0.056 0.402 1.183
11 0.045 0.341 1.347
12 0.049 0.288 2.475
13 0.042 0.236 2.984
14 0.038 0.201 4.103
15 0.033 0.175 5.608
16 0.030 0.144 7.559
17 0.050 0.142 44.377
18 0.046 0.118 75.628
19 0.044 0.100 146.907
20 0.042 0.084 346.949
21 0.040 0.071 637.708
22 0.038 0.059 1187.463
23 0.038 0.050 2017.220
Table CIO - Scaled diameter, length, and volume for James - FRC 5200 mL
Generation Scaled Diameter, cm Scaled Length, cm Scaled Volume, cm3
0 1.287 10.482 13.647
1 0.870 4.158 4.947
2 0.404 1.660 0.851
3 0.198 0.664 0.163
4 0.218 1.109 0.662
5 0.166 0.935 0.645
6 0.129 0.786 0.657
7 0.103 0.664 0.702
8 0.079 0.559 0.702
9 0.062 0.472 0.720
10 0.048 0.402 0.750
11 0.036 0.341 0.705
12 0.058 0.288 3.139
13 0.050 0.236 3.726
14 0.044 0.201 5.057
15 0.039 0.175 6.793
16 0.035 0.144 8.997
17 0.056 0.147 55.643
18 0.052 0.122 92.971
19 0.049 0.103 176.399
20 0.047 0.086 405.025
21 0.045 0.073 738.028
22 0.043 0.061 1363.316
23 0.043 0.052 2315.756
Table C.ll - Scaled diameter, length, and volume for Saetta - FRC 5200 mL
Generation Scaled Diameter, cm Scaled Length, cm Scaled Volume, cm3
0 0.457 10.482 1.723
1 0.310 4.158 0.628
2 0.211 1.660 0.232
3 0.142 0.664 0.084
4 0.114 1.109 0.182
5 0.089 0.935 0.186
6 0.071 0.786 0.200
7 0.058 0.664 0.228
8 0.047 0.559 0.251
9 0.039 0.472 0.291
10 0.033 0.402 0.353
11 0.028 0.341 0.420
12 0.024 0.288 0.540
13 0.021 0.236 0.659
14 0.019 0.201 0.914
15 0.017 0.175 1.265
16 0.015 0.144 1.725
17 0.056 0.147 56.108
18 0.052 0.122 93.747
19 0.049 0.103 177.872
20 0.047 0.087 408.407
21 0.045 0.073 744.191
22 0.043 0.062 1374.701
23 0.043 0.052 2335.093
Table C.12 - Scaled diameter, length, and volume for average resistance - FRC 5200 mL
Generation Scaled Diameter, cm Scaled Length, cm Scaled Volume, cm3
0 1.204 10.482 11.941
1 0.816 4.158 4.352
2 0.555 1.660 1.608
3 0.375 0.664 0.586
4 0.301 1.109 1.264
5 0.234 0.935 1.288
6 0.187 0.786 1.387
7 0.154 0.664 1.581
8 0.124 0.559 1.741
9 0.103 0.472 2.014
10 0.087 0.402 2.445
11 0.073 0.341 2.915
12 0.064 0.288 3.747
13 0.055 0.236 4.568
14 0.050 0.201 6.338
15 0.044 0.175 8.768
16 0.040 0.144 1 1 .956
17 0.045 0.154 41 .056
18 0.042 0.128 74.220
19 0.039 0.108 153.787
20 0.038 0.090 389.705
21 0.036 0.076 731.017
22 0.034 0.064 1386.290
23 0.034 0.055 2355.427
Table C.13 - Scaled diameter, length, and volume for Disease-Average - FRC 5200 mL
Generation Scaled Diameter, cm Scaled Length, cm Scaled Volume,
cm3
0 0.983 10.482 9.104
1 0.666 4.158 3.309
2 0.443 1.660 0.897
3 0.259 0.664 0.278
4 0.211 1.109 0.703
5 0.163 0.935 0.706
6 0.129 0.786 0.748
7 0.105 0.664 0.837
8 0.084 0.559 0.898
9 0.068 0.472 1.008
10 0.056 0.402 1.183
11 0.045 0.341 1.347
12 0.049 0.288 2.475
13 0.042 0.236 2.984
14 0.038 0.201 4.103
15 0.033 0.175 5.608
16 0.030 0.144 7.559
17 0.053 0.149 51.348
18 0.049 0.124 87.508
19 0.046 0.105 169.984
20 0.044 0.088 401.449
21 0.042 0.074 737.881
22 0.040 0.062 1373.993
23 0.040 0.053 2334.090
Appendix D
Deposition Results for Different Disease
Model
0.05 u.m
FRC Disease-Average Resistance-Average Saetta James
3.8 55.24 56.16 56.25 52.01
4.5 54.11 55.13 55.10 50.78
5.2 52.80 53.96 53.77 49.44
0.1 urn
FRC Disease-Average Resistance-Average Saetta James
3.8 34.59 35.70 35.35 32.28
4.5 33.76 34.94 34.51 31.38
5.2 32.80 34.06 33.53 30.40
0.3 Lim
FRC Disease-Average Resistance-Average Saetta James
3.8 16.04 16.61 17.09 14.93
4.5 15.63 16.22 16.69 14.50
5.2 15.17 15.78 16.23 14.03
0.6 urn
FRC Disease-Average Resistance-Average Saetta James
3.8 12.23 12.41 15.14 11.50
4.5 12.03 12.24 15.02 11.28
5.2 11.77 12.00 14.81 10.98
1 Lim
FRC Disease-Average Resistance-Average Saetta James
3.8 15.92 15.87 27.65 15.25
4.5 15.89 15.90 28.03 15.13
5.2 15.66 15.73 28.15 14.80
2.5 Lim
FRC Disease-Average Resistance-Average Saetta James
3.8 51.66 47.65 90.99 55.70
4.5 51.72 47.66 91.14 55.74
5.2 51.18 47.11 91.24 55.28
5 jam
FRC Disease-Average Resistance-Average Saetta James
3.8 71.98 65.21 81.47 72.63
4.5 71.81 64.24 81.48 72.65
5.2 71.66 63.38 81.49 72.66
10 Lim
FRC Disease-Average Resistance-Average Saetta James
3.8 58.25 56.04 62.30 58.62
4.5 58.32 56.08 62.30 58.74
5.2 58.37 56.10 62.31 58.83
